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ABSTRACT
The menopause is associated with a deficiency of reproductive hormones, and accompanied by a
significant loss of bone mass. This bone loss is accelerated within the first five years post-menopause.
Muscle strength at this time would have important clinical implications for correcting imbalance and
preventing falls. The aim of the studies within this thesis were to 1) determine the rate and time course
of force loss of the quadriceps muscle group over 12 months in three groups of women with varying
hormonal status 2) establish the role of oestrogen in this weakness and 3) investigate the effectiveness of
hormone replacement therapy (HRT) in maintaining muscle function.
The reliability of an isokinetic dynamometer and a strain gauge assembly was examined initially to
determine the inherent variability of muscle function assessment. Strength of the knee extensors
measured on the isokinetic dynamometer was deemed reliable in middle-aged women, although at 1.05
rad/s more practice trials were needed to attain peak torque. Measurements of the knee flexors were
highly variable. Maximal voluntary isometric contractions were repeatable using the strain gauge
system, for both the knee extensors and first dorsal interosseus (FOI) muscle. There was greater
variability in force production generated from electrically stimulated contractions.
Maximal strength of the knee extensors declined by 9.3±4.6 and I0.3±3.1% (mean±SE) for dynamic
(1.05 radls) and isometric strength respectively over 9 months in hypoestrogenic post-menopausal
women. There were no changes at higher angular velocities, or for handgrip strength. These results
support the role of reproductive hormones in influencing force production, which is further endorsed by
the observation that females on HRT did not experience a reduction in strength over this time. The force
loss was significant only when the post-menopausal and HRT group were compared (p<0.05). The post-
menopausal group were within I to 3 years past the menopause, the time period in which bone loss is
rapid. This rapid loss of strength would therefore be expected to level out, similarly to bone.
The menopause is an oestrogen-deficient and progesterone-deficient endocrinopathy. It is not possible to
identify which hormone, if not both, is responsible for these observed changes in strength. To explore
the relationship between acute changes in oestrogen and progesterone and strength, maximal force
production of the quadriceps and first dorsal interosseus (FOI) was measured across the menstrual cycle.
Maximal strength of the quadriceps was lowest prior to the surge in luteinizing hormone (LH) and
reached its peak mid-luteal, a difference of 12.6±4.3% (mean±SE). These changes were significantly
different (p<O.OS). From these results, there does not appear to be a role of unopposed oestrogen
influencing force production but the pattern of strength changes implicates progesterone. There were no
corresponding fluctuations in strength of the FOI, which remained relatively stable across the menstrual
cycle. The contractility and fatigue resistance of the quadriceps did not differ significantly between any
phase (p>O.OS).The difficulty in isolating oestrogen during the menstrual cycle does not render this a
good model to assess its effects upon force production. Maximal strength and fatiguability of the FDI
were examined in young women undergoing in vitro fertilisation (IVF) treatment when acute, massive
changes in oestrogen are induced. There were no differences in muscle function of the FDI when
assessed under very low or high oestrogen changes (p>O.05). The independent effects of oestrogen upon
muscle function were not demonstrated here.
Hormone replacement therapy is the most efficacious treatment for preventing menopausally-related
bone loss. The results from the longitudinal study suggest that HRT confers protection against muscle
weakness as a consequence of ovarian failure. Whether HRT maintains or restores strength was
examined in the FDI of post-menopausal women (n=9). The oestrogen only and oestrogen-progestogen
phases were compared with baseline measurements. A positive change in strength was observed,
although this did not reach significance (p<O.1). The increase in strength (15.2±20.6%) between
baseline and the oestrogen-progestogen phase of HRT corroborates the involvement of progesterone in
determining muscle function.
The findings suggest that the menopause is associated with a loss of strength, prevented by the
administration of HRT. Oestrogen alone does not influence force production, although progesterone is
impli~!ed. This has important ramifications in hysterectomised women who are prescribed preparations
contammg oestrogen only.
.
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CHAPT£RONE
INJTRODUCTION
1.1. INTRODUCTION
Osteoporosis (brittle bone disease) is a contemporary disease which causes extreme
morbidity and mortality in post-menopausal women. Statistics from the National
Osteoporosis Society (1995) estimate that by 80 years of age, approximately 40-50%
of women will have developed osteoporosis, and one woman in eight will have
sustained a fracture. This places considerable strain on health care costs. Whilst
osteoporosis also affects men, it is far more prevalent in their females counterparts
since oestrogen deficiency is the single most significant factor in postmenopausal
osteoporosis (Riggs et al., 1982). Bone loss begins to accelerate immediatelyafter the
menopause at a rate of 1 to 7% per annum depending on skeletal site (Krolner and
Nielson, 1982; Lindsay et al., 1976). Hormone replacement therapy (HRT) is the most
.J
efficacious treatment for preventing osteoporosis (Aitken et al., 1973) and also
protects against the risk of cardiovascular disease (Paganini et al., 1988). This
treatment is most effective when taken before or shortly after menopause at a time
when bone loss is accelerated (Riggs and Melton, 1986).
A loss of bone mass after the menopause is accompanied by a loss of force per cross-
sectional area (force/CSA) of skeletal muscle. A significant reduction in specific force
of the adductor pollicis muscle (AP) has been reported in women around 50 years of
age, coinciding with the menopause (Phillips et al., 1993b), implicating an additional
role of reproductive hormones in regulating muscle function. This has previously been
indicated by Winner et al. (1989) who found a greater incidence of falling in
perimenopausalwomen.
Muscle strength is positively related with functional activities such as walking speed
and stair climbing ability and is negatively related to the incidence of hip fractures
(Aniansson et al., 1983). Muscle weakness and fatigue will therefore impair the ability
to undertake everyday activities. Muscle weakness is more pronounced in the
proximal, lower limb muscles, predisposing postmenopausal women to the risk of
falling and sustaining fractures (Wickham et al., 1989). Since muscle strength is
compromised in females suffering from osteoporosis (Rutherford and Jones, 1992) this
1
poses a major health problem in vulnerable females. Impaired functioning of a muscle
group such as the quadriceps, which has an important role in performing activities of
daily living will have significant clinical implications in the ageing population. Given
that the specific force of the AP muscle is lower in hypoestrogenic post-menopausal
women, other muscles may be similarly affected. The sites at most risk from
osteoporotic fractures are the hip, wrist and spine, and therefore there is a need to
investigate the effect of hypoestrogenialhypoprogesteronia on the strength of muscles
associated with these areas.
Specific muscle force is greater in post-menopausal women taking hormone
replacement therapy compared to age-matched controls (phillips et aI., 1993b).
Understanding the onset and rate of a reduction in muscle strength associated with the
menopause is therefore a requisite for the administration of HRT. How reproductive
hormones mediate their effects on muscle is currently unknown, and it is still highly
speculative which hormone - oestrogen or progesterone - is responsible for
preserving strength. There are tenuous suggestions from studies of the endogenous
fluctuations during the menstrual cycle that oestrogen is responsible for increases in
strength of the AP muscle (Phillips et aI., 1996), although findings of a negative
correlation between oestrogen and hand grip strength (Bassey et al., 1995) conflict
with these reports. If progesterone is implicated, this would have significant clinical
consequences in hysterectomised post-menopausal women. A progestogen component
is added to HRT preparations to reduced endometrial hyperplasia in females with an
intact uterus and thus treatment for this group of women may need to be revised.
The purpose of this thesis will be to investigate the effects of reproductive hormones
on muscle strength in middle-aged women. The rate of strength loss of multiple muscle
groups, the quadriceps and handgrip, will be assessed longitudinally between three
groups of menopausal and post-menopausal females of varying hormonal status. Other
models will be employed to determine the possible mechanisms and hormone
responsible for strength changes. From these findings, it is hoped that the hormonal
milieu within which a loss of muscle function occurs will be elucidated, so that
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preventative measures can be enforced in the growing population of post-menopausal
females.
1.2. AIMS AND OBJECTIVES
The investigation of the effects of reproductive hormones on muscle function will be
undertaken through the following aims:-
1) Determine the rate offorce loss of the quadriceps and palmer flexors in
menopausal and post-menopausal women.
2) a) Compare the effects of acute changes in reproductive hormones on muscle
strength of a large muscle group, the quadriceps, and a small muscle, the first
dorsal interosseus (FDI).
b) Assess the effects of acute changes in reproductive hormones on contractile
properties of the quadriceps.
3) a) Investigate the role of oestrogen in influencing strength changes in young
women
b) Examine the role of oestrogen on the fatigue resistance of the FDI.
4) a) Examine the efficacy of hormone replacement therapy (HRT) as a
prophylaxis to muscle weakness
b) Establish the effects ofHRT on the contractile properties of the FDI.
These primary aims cannot be fulfilled until a series of methodological steps have been
taken. These are concerned with the assessment of reliability of the equipment and
protocols employed in the experimental studies:
i) Establish the day-to-day reliability of the LIDO Active'" isokinetic dynamometer
across a range of increasing angular velocities.
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ii) Determine the reliability of performance of leg and handgrip strength in middle-
aged women.
iii)Quantify inherent variability of measuring maximal voluntary contraction (MVC)
of the quadriceps and FDI using a strain gauge system.
iv)Assess the reliability and repeatability of electrically stimulated contractions of the
quadriceps.
v) Establish the reliability of the hand dynamometer used to measure maximal
strength and electrically stimulated contractions of the first dorsal interosseus
(FDI) muscle.
..
Fulfillment of these aims will elucidate the hormonal milieu in which muscle weakness
occurs and the role ofHRT in preventing the reduction in the force generating capacity
of skeletal muscle. The effects of hormonal status on volitional and electrically
stimulated contractions will also be determined.
The following means will be employed in fulfilling these aims:
1) Employment of the LIDO Active" dynamometer to measure isometric and
concentric strength isokinetically across a range of increasing angular velocities.
2) Application of the electrical stimulator to: a) confirm maximal activation of muscle
b) electrically stimulate muscle at increasing frequencies and c) induce fatigue.
3) Utilise a strain gauge system for measurements of volitional and electrically
stimulated isometric contractions.
4) Construction and use of the hand dynamometer to assess muscle function of the first
dorsal interosseus muscle with use of the electrical stimulator.
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REVI£W OF THE
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2.0. REVIEW OF THE LITERATURE
Over the past decade, there has been an increase in the participation of wome~ in
sports and regular exercise programmes. As a consequence of this, much scientific
interest has focused on both the females' responses to exercise and the effects of
exercise on reproductivefunctioning.
The increase in longevity of women in contemporary society compared to theirfemale
counterparts earlier this century is probably due to an enhanced quality of life, aand
women now tend to live one third of their life in the infertile, post-menopausal period.
The health implications of the menopause and loss of reproductive hormones are a
growing concern since hormonally related insidious diseases are associated with
increased morbidity and mortality. These are offset with the availability of hormone
replacement therapy (HRT). Although there is much concern over its 'safety',
research is ongoing to reduce the side effects and enhance the therapeutic role of
HRT.
To understand these issuesfully, this chapter willprovide a theoretical background of
the regulation and functions of the female reproductive system, focusing on
endocrinological changes during the menstrual cycle and menopause.
2.1. THEORECTICAL BACKGROUND OF THE HUMAN REPRODUCTIVE
SYSTEM. FROM MENARCHE TO MENOPAUSE.
2.1.1. Endocrinology of the human female menstrual cycle
The onset of reproductive function, termed menarche, is reported to occur between
the 10th and 16th year in 95% of European girls (Abraham, 1978). Reproductive
cycles begin at pubery when the hypothalamic pulse generator is activated. Stimulation
of the hypothalamic-pituitary-ovarian axis initiates the first menstrual flow. From
menarche to the end of reproductive life, menopause, a series of coordinated events
occur within the ovaries and endometrium called the menstrual cycle. These events are
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controlled by a finely tuned interaction of hormones, regulated by the brain. An
interrelationship between the hypothalamus, anterior pituitary, and the ovaries lead to
the periodic maturation and extrusion of the ovum (egg) from the ovary, which is then
transported to the fallopian tubes to be fertilised. Meanwhile, the endometrium
undergoes histological changes in preparation for the fertilised egg.
The normal menstrual cycle established after puberty averages 28 days, although most
cycles range between 23-35 days. The cycle can be divided into four phases: day 1 of
the cycle is the onset of menstruation, which lasts 4-5 days; follicular phase of the
ovary corresponds to the proliferative of the endometrium; ovulation, which lasts
about 36 hours and the luteal phase which corresponds to the secretory phase of the
endometrium. The hypothalamus and pituitary gland control timing within a menstrual
cycle, but the ovary regulates its phases and duration as ovarian steroids exert
"negative" and ''positive'' feedback effects on the hypothalamus. Variability in cycle
length of women is determined by the duration of the follicular phase. The luteal phase
is usually constant, lasting 14 days (Vollman, 1977), but it may be shortened in highly
trained females athletes (prior et al., 1982).
2.1.1.1. Structure and function of the ovary
The function of the ovary is to nurture the growth and development of an ovum in
preparation for ovulation and subsequent fertilisation. The activities within the ovary
are cyclical and involve a complex process of steroid synthesis, negative and positive
feedback signals and interaction with exogenous hormones. A morphological account
of the ovary will be given to assist in the understanding of the events ofthe menstrual
cycle.
2.1.1.1.2. Morphology of the ovary and follicular development
The ovary consists of three regions, the outer cortex, inner medulla and hilum. The
cortex contains the functional units of the ovaries, i.e. the follicles, in different states of
development and occupy the main body of the ovary. The medulla forms the stromal
cells and the hilum yields the entry point of the nerves and blood vessels (Fig. 2.1.1).
Fig. 1.1.1. Microscopic view of the human ovary. From Ojeda, 1992, pp.135.
At birth. each ovary contains up to one million follicles, each one enclosing a primary
oocyte. The oocyte is surrounded by a flattened layer of epithelial cells separated by
the basal lamina. This is the primordial follicle. Several layers of cuboidal granulosa
cells evolve from these stromal cells to form the primary follicle. During the early part
of the menstrual cycle, 20 to 25 primary follicles begin to produce low levels of
oestrogen.
Around day 5 of the menstrual cycle, a cohort of these follicles develop into secondary
follicles, characterised by concentric layers of granulosa cells and the cultivation of
outer theca cells, separated by the basal lamina. A glycoprotein band is formed
between the oocyte and granulosa cells called the zona pellucida. Thecal cells
differentiate into theca intema and theca extema layers; theca intema become cuboidal
and fill with lipid droplets, indicative of steroidogenesis. The granulosa cells secrete
follicular fluid containing steroids, pituitary hormones -luteinzing hormone (LH) and
follicle stimulating hormone (FSH) - and local growth factors which fill the follicular
cavity or antrum, forcing the oocyte to the edge of the follicle. As the oocyte is
displaced, it becomes surrounded by granulosa cells called the cumulus oophorus (Fig.
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2.1.2}. These follicles become antral or graafian follicles and reach a diameter of 5
mm (Ojeda, 1992).
Fig. 2.1.2. Schematic representation of the development of an ovarian follicle. From Ojeda, 1992,
pp.145.
Growing antral follicles need gonadotropins to reach their ovulatory size. Of the
selection of follicles which have progressed beyond the antral stage, only one
"dominant" follicle reaches ovulation. The LH surge usually occurs after the leading
follicle exceeds 16 mm (Edwards and Brody, 1995). Under the influence of LH, the
oocyte matures and ovulation occurs 36 to 40 hours later. Following the expulsion of
the oocyte, the collapsed follicle is reorganised to form the corpus luteum. Granulosa
and thecal cells are 'luteinized', and fibroblasts and capillaries invade. If fertilisation
does not occur, the corpus luteum remains functional for 13 to 14 days and then
undergoes luteolysis. Endocrine function is lost rapidly and the corpus luteum is
replaced by scar tissue called the corpus albicans (Ojeda, 1992).
2.1.1.2. Hypothalamic 'neural' and pituitary control
Reproductive function is regulated by two peptide hormones, called the gonadotropins,
secreted from the anterior pituitary gland. Follicle stimulating hormone (FSH)
stimulates follicular maturation and production of oestrogen. Luteinizing hormone
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(LH) is responsible for ovulation, luteinization and ovarian steroidogenesis. Prior
primingwith FSH is essential for LH to exert its effects (Shearman, 1986). Prolactin is
also released, although its physiological role in ovarian control is unclear (Shearman,
1986).The gonadotropins, particularlyLH, are released into the bloodstream every 60-
90 minutes in a pulsatile manner. This is called a "circhoral" rhythm. If this pulse
frequency declines oestrogen output becomes low and inconsistent (Edwards and
Brody, 1995) and ovarian folliclesfail to develop.
The release of these hormones are, in turn, regulated by a pulsatile secretion of
gonadotropin releasing hormone (GnRH) from the arcuate nucleus of the
hypothalamus.The frequency of release of this decapeptide is suppressed by increasing
progesterone concentrations produced by the ovary, and stimulated by the mid-cycle
rise in oestrogen, preceding the increase in serumLH (Miyake et al., 1983).
2.1.1.3. Ovarian control
Oestrogen and progesterone are the two principal ovarian steroid hormones which
regulate events within the ovary. These sex hormones are under the control of the
gonadotropins. The formation of oestradiol is dependent upon both LH and FSH,
whereas the synthesis of progesterone is enhanced by LH alone. The secretion of
progesterone however, can be stimulated by both gonadotropins. Oestrogen and
progesterone exert "negative" and ''positive'' feedback mechanismson both the GnRH
pulse generator and on the secretion of FSH and LH from anterior pituitary. This is
shown in Fig. 2.1.3.
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Fig. 2.1.3. Interaction of hypothalamic-pituitary-ovarian axis and regulation of steroid hormones
oestrogen and progesterone.
2.1.1.4. Follicular (proliferative) phase
The onset of the menstrual flow is considered as the first day of the cycle. A reduction
in oestrogen and progesterone causes a sloughing off, or shedding of the structural
functionalis layer of the endometrial lining along with small amounts of blood ,..,40 ml
from supporting blood vessels, which lasts 4 to 5 days. The negative feedback of
oestrogen on gonadotropin release is relieved and FSH levels begin to rise. Under the
influence of FSH, the ovarian cycle is initiated with the development of the primary
follicles. It has been suggested that activin, the ovarian FSH-releasing protein, has a
physiological role in the maintenance ofFSH secretion (Ojeda, 1992).
The developing follicles produce increasing levels of oestrogen which is more
pronounced with the maturation of antral follicles late in the follicular phase. This is
facilitated by the increased sensitivity of the follicle to FSH by the oestrogen it
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synthesises (Richards and Midgley, 1976). The secretion ofFSH declines in response
to high oestrogen concentrations and inhibin. Inhibin is a peptide hormone secreted by
the ovary which exerts selective inhibitory control over the secretion of FSH. The
production of inhibin is stimulated by FSH itself (Ojeda, 1992). The inhibition of LH
by low oestrogen concentrations during the early follicular phase is relieved at high
oestrogen levels in the late follicular phase. In the presence of an oestogenic milieu, the
endometrium undergoes ''proliferative'' histological changes (Shangold, 1988).
Progesterone and 17 a-hydroxyprogesterone levels remain unchanged until the
ovulatory phase (Ojeda, 1992).
2.1.1.5. Mid-cycle dynamics
The mid-cycle hormonal events involve a complex relationship between gonadotropins
LH and FSH, and the sex hormones oestradiol (E2) and progesterone (Fig. 2.1.4). The
pre-ovulatory elevation of E2 characterising the ovulatory phase, triggers a surge in
gonadrotropins. A rapid rise in LH and a less pronounced increase in FSH are elicited
from the positive feedback of E2 on the pituitary. The gonadotropin surge lasts
approximately 24 hours and is induced only if the oestradiol threshold exceeds 250
pg/ml for longer than 36 hours (Edwards and Brody, 1995) (This surge is in concert
with the dominant follicle reaching> 16 mm). The peak in LH is denoted as day 0 in
the diagram (Fig. 2.1.4). As gonadotropins begin to rise, there is a concomitant
increase in 17a-hydroxyprogesterone (17-0H) and a smaller rise in testosterone and
androstendione.
Progesterone increases concomitantly with E2 prior to the LH surge. which is proposed
to act synergistically to induce the progressive increase in basal LH (Hoff et al., 1983).
This increase in progesterone has also been implicated in regulating the pre-ovulatory
gonadotropin surge in vitro. In the ovariectomized rat, oestradiol alone failed to
generate the full gonadotropin surge and progesterone was required to restore the
levels to the same magnitude and duration seen in the proestrus rat (Mann and
Barraclough, 1973). The rise in progesterone may also be responsible for the mid-cycle
elevation ofFSH.
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The rise in progesterone continues after the initiation of the LH surge, although this is
not accompanied by an increase in E2. Soon after the LH surge, E2 falls precipitously
(Fig. 2.1.4), despite increases in androstenedione and testosterone. This may be due to
the rapid rise in progesterone within the follicle inhibiting aromatase activity, resulting
in a decline in E2 formation (Hoff et al., 1983).
The most mature, dominant follicle, produces greater amounts of E2 than the growing
follicles and is most sensitive to gonadotropin stimulation. On selection of this follicle,
the other growing follicles undergo atresia. Oocyte maturation begins in response to
the LH surge and is mature at ovulation 10 to 12 hours later, 24 to 36 hours after the
E2 peak. Oestradiol and androgen levels have fallen at this time, although progesterone
increases further and 17a-hydroxyprogesterone remain elevated. At ovulation the
oocyte is expelled from the follicle and transported to the fallopian tubes in preparation
for fertilisation.
After ovulation, under the influence of LH the supporting cells of the follicle form the
corpus luteum (yellow body). The corpus luteum produces progesterone in significant
amounts (and E2 to a lesser extent) and influences secretory changes in the uterine
endometrium. If fertilisation does not occur, the corpus luteum degenerates within two
weeks, resulting in a sudden loss of progesterone. Withdrawal of progesterone and E2
initiates another menstrual flow. The events of the cycle are shown in Fig. 2.1.5.
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Fig. 2.1.4. Mean values (±SE) of LH, FSH, progesterone, oestradiol (£2) and 17-
hydroxyprogesterone (17aOH prog) in daily serum samples of 9 women during ovulatory menstrual
cycles. Days from mid-cycle LH surge (0). From Ojeda, 1992, pp. 150.
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Fig. 2.1.5. Menstrual and ovarian cycles with hypothalamic and anterior pituitary gland hormones.
From Tortora and Anagnostakos, 1989, pp. 902.
2.1.2. Biosynthesis of reproductive steroid hormones
Oestrogen and progesterone, like all steroid hormones, are derived from the precursor
cholesterol (chol = bile and steroes = solid), a 4-ring hydrocarbon molecule with a side
chain (Fig. 2.1.6). Cholesterol is transported to the ovary via the blood stream with
low-density lipoproteins (LDL), and is released from its LDL-receptor complex inside
the ovary through hydrolysis with lysosomes. Excess cholesterol is esterified and
stored in lipid droplets for later use.
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Fig. 2.1.6. Structure of cholesterol, a precursor to steroid synthesis.
Cholesterol (C 27) is initially converted to pregnenolone (C 21) through the sidechain
cleavage of the 6-carbon isocaproic acid molecule. This reaction occurs in the
mitochondria mediated by the cytochrome P-450. This is the rate limiting step of the
steroid biosynthetic pathway (Al-Azzawi, 1992). Pregnenolone is then converted into
progesterone or into 17 a-hydroxypregnenolone. These, in turn, can be metabolized to
17 a-hydroxyprogesterone (See Fig. 2.1.7).
Fig. 2.1.7. Biosynthetic pathway for the oestrogens. From Ojeda, 1992. pp 136.
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Further metabolism to androgens and oestrogens results in an additional reduction in
the number of carbons to C 19 of androgens and C 18 to oestrogens. Androstenedione
and testosterone are immediate precursors for the aromatisation of oestrogen
production. Luteinizing hormone is responsible for stimulating the production of
androgens used to synthesise oestrogens, and receptors are found on steroidogenic
cells of the stroma and thecal cells of the follicles. A gradual increase in plasma LH
levels promote the differentiation of thecal cells and induces the synthesis of 17,20-
lyase enzyme, increasing the availability of androgens for oestrogen biosynthesis.
Oestradiol is metabolized from testosterone in granulosa cells of antral follicles through
an FSH-mediated aromatisation enzyme complex (Fig. 2.1.8). Oestrone and oestriol
are synthesised from androstenedione. Progesterone is secreted by all steroidogenic
cells of the ovary regardless of their localisation.
A "two cell-two gonadotropin" hypothesis has been devised to explain the
gonadoptropic control of ovarian steroidogenesis. Under the influence of LH, thecal
cells produce androgens that upon diffusion to the granulosa cell compartment of the
follicle are converted to oestrogens via an FSH-supported aromatization reaction (Fig.
2.1.8).
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Fig. 2.1.8. Control of ovarian oestrogen, progesterone and androgen production by LH and FSH
Luteinizing hormone acts on thecal and granulosa cells. Follicle stimulating hormone acts on
granulosa cells only. From Ojeda, 1992. pp 139.
Oestradiol is the predominant oestrogen in women of reproductive age and exists in
equilibrium with oestrone ina ratio of 1:2 to 1:4. The ovary secretes oestradiol directly
into the bloodstream. After the menopause the main oestrogen, oestrone, is derived
from the peripheral conversion of androstenedione or oestradiol. Oestrone is further
metabolised in the liver to oestriol. More than 70% of circulating oestrogens are bound
to proteins in the blood stream, preferably albumin for which they have a low affinity,
or testosterone-binding globulin (TeBG) for which they have a high affinity. Since
oestrogens have a lower affinity for TeBG than testosterone, there are more circulating
oestrogens available to tissues. Only free steroids can be transported to their target
cells. Steroids are dissociated from their binding molecule at the target cells, and
allowed to enter the cell membrane to bind to high affinity, low capacity receptors
located in the cytoplasm. The steroid receptor complex migrates to the nucleus and
bind to a specific segment of deoxyribonucleic acid (DNA). This reaction modifies its
transcription and the synthesis of specific types of messenger ribonucleic acid (mRNA)
(Fig. 2.1.9).
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Fig. 2.1.9. Oestrogen-receptor complex: RC=cytopiasmic oestradiol 17f3 complex.
2.1.3. Oral contraceptives
The prevalence in the use of exogenous steroid hormones in women of reproductive
age is increasing. The principal use of steroid hormones are for contraceptive purposes,
although they are also used medically e.g. relieve dysmenorrhoea. There are reports
that a growing number of elite athletes take steroid hormones for cycle control or as a
form of hormonal replacement to ameliorate the effects of amenorrhoea on the skeletal
system (Shangold, 1988). The widespread use of oral contraceptives (OC) is
accompanied by a growing concern of the side-effects of the constituent steroid
hormones in these agents. There are further implications for the athlete of ~C's upon
exercise performance given the effects ofOC's on metabolic function (Lebrun, 1994).
Oral contraceptive agents operate by inhibiting gonadotropin-releasing factors from the
hypothalamus through a negative feedback effect, similarly to the mechanism of
endogenous hormones. Gonadotropin secretion is subsequently suppressed preventing
ovulation (Bingel and Benoit, 1973). Oral contraceptives provide a constant dosage of
synthetic hormones, in contrast to the cyclical fluctuations in naturally occurring
hormones. The dosage of current combined preparations are lower «35~ oestrogens
and < 1 mg progestins) compared to original formulations introduced in 1960 (Kaunitz
et al., 1995) in an attempt to minimise the risk of cardiovacular disease and other side
effects associated with high doses of the synthetic hormones (Baird and Glasier, 1993).
In monophasic ~C's, a constant dose of oestrogen and progestin is provided in each of
the 21 active tablets of the cycle pack. This is followed by seven pill-free days. The
development of phasic OC's to reduce the metabolic side-effects have lower overall
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monthly steroid dose. The dose of the progestin and/or the oestrogen is varied over the
pill cycle, thereby mimicking the physiological variation in endogenous hormones.
For the exogenous steroid hormones to exert their desired pharmacological effects,
these components must be converted to more potent synthetic derivatives. Current OC
formulations contain the metabolically active syntheticoestrogen ethinyloestradiol
derived from the addition of a 17-a ethinyl radical to oestradiol. Mestranol, the less
biologically active syntheticoestrogen, must be converted to ethinyloestradiol in the
liver before exerting its oestrogenic effects (Whitehead and Godfree, 1992) and must
therefore be administered in higher doses. Ethinyloestradiol is administered in low
doses of 20 to 35 ug and are now contained in all OC preparations. Progestins are
characterised according to the structure of the steroid from which they were derived.
Most progestins are derivatives of 19-nortestosterone (Bembem, 1993), subclassified
as gonanes or estranes (Crook et al., 1988). The progestational potency of gonanes are
ten fold higher, with greater androgenic effects than estranes. Progestins of a
progesterone derivative (17-a hydroxyprogesterone) are no longer available as a result
of its association with breast cancer in dogs (Daniel, 1970). Table 2.1.1. lists the
progestin components of current OC preparations.
Table 2.1.1. Oral contraceptive oestrogens andprogestins.
Oestrogens Ethiny loestradiol
19-Nortestosterone-related progestins Estranes
Norethisterone'"
Norethisterone acetate"
Noretynodrel
Lynestrenol
Ethynodiol diacetate
Gonanes
Levonorgestrel'"
Norgestimate'"
Gestodene'"
Desogestrel'?
a denotes the metabolically active steroid
b denotes new generation of progestins
• = progestins used by subjects in study 4.2
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The effects of ~C's are dependent upon the type and dose of progestins administered
(Bembem, 1993). Progestins may have androgenic, oestrogenic, antiandrogenic or
antioestrogenic activity. The balance of oestrogen and progestin components in a
specific preparation will also be important for determining their physiological effects.
The effects ofOC's on muscle strength will be discussed in section 2.2.
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2.1.4. The menopause and climacteric
Circamensal reproductive cycling is not a perpetual rhythm, but diminishes during
middle-age as a consequence of the ageing process. The cessation of menses due to
ovarian follicular failure is termed the menopause - the transition from a reproductive
to non-reproductive stage of life. This biological phenonemon is not an abrupt event
but may take up to 10 years for amenorrhoea to occur. A 12 month interval of
amenorrhoea is characteristic of the menopause (Khaw, 1992). Different terms are
used interchangeably to categorise the stages of endocrinological changes surrounding
the menopause. For the purpose of the thesis, the conventional terms pre-menopause,
peri-menopause and post-menopause will be used in reference to the following
definitions:
Pre-menopause: The stage of reproductive function prior to the climacteric.
Peri-menopause: Also called the climacteric, it may begin 5-10 years before
the menopause and is associated with the endocrinological,
biological and clinical features of approaching menopause,
and at least the first year after the menopause.
Post-menopause: Following the menopause, although it cannot be
determined until after a period of 12 months of spontaneous
amenorrhoea has occurred.
2.1.4.1. Epidemiology of the menopause
The increase in the female population over the past century (Fig. 2.1.10) is considered
to be the result of an increase in the number of births and a reduction in the mortality
rate. At present, the highest number of females in the population are aged between 16-
39 years, with proportions decreasing thereafter. The Office of Population Census and
Surveys (OPCS) predict this pattern to change by 2031 where the greatest population
21
of women will be aged 40-64 years. The increase in the older population is attributable
to the number of women surviving over 80 years. They have been predicted to
comprise 50% of the females population over the next 2-3 decades (Population trends
25, 1995).
Female Popu1ation in the UK
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Fig. 1.1.10. Thefemale population of the United Kingdom (UK) over 45 years, estimated into the next
century: From SOCIAL TRENDS 24, 1994. .
The current life expectancy of females in the UK is 79 years. This is estimated to
increase to 81 years by the year 2000. In contrast to the increase in longevity, age at
menopause has remained constant. The average age at menopause is 49.8 - 50.8 years
in developed countries (Khaw, 1992), and has not reported to have changed over the
past century (See Fig. 2.1.11). Women can therefore expect to live one third of their
lives in the postmenopausal state. Unlike menarche, age at menopause does not appear
to be affected by factors such as race, weight, skinfold thickness or socio-economic
status. Even oral contraceptive use, which acts by suppressing ovulation, and parity do
not delay menopause (Brambilla and McKinlay, 1989). However, smoking (McKinlay
et al., 1985) and possibly malnourishment (Scragg, 1973) accelerate the menopause by
1-2 years.
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Fig. 2.1.11. Average life expectancy and age at menopause in females from 1901-2001. From:
POPULATION TRENDS No 23, 1993. opes.
2.1.4.2. Aetiology of the menopause
The menopause is the result of a depletion of primordial follicles or oocytes in the
ovary and the consequent fall in oestrogen and progesterone secretion Since
pregnancy and oral contraceptive use do not influence menopausal age, it has been
suggested that these follicles are subject to a 'programmed cell death' (Al-Azzawi,
1992).
Throughout life, oocytes undergo growth, ovulation or atresia. Atresia is degenerative
process of the ootytes, characterised morphologically by the necrosis of the oocyte and
the granulosa cells. Prior to birth, at 24 weeks of gestation, there are about 7 million
oogonia contained within the primitive gonad. At birth, only about 2 million of these
mature into primary oocytes, the others degenerate and die. At puberty this is reduced
to around 400 000. The loss of follicles during reproductive life are not replaced, and
hence the continual ovulation and atresia exhausts the 'ovarian capital' .
Follicles decline exponentially throughout life at two different rates (Edwards, 1995).
As shown in Fig. 2.1.12, follicular loss up to 37 years of age is relatively slow until
follicular numbers reach 25 000. Follicles are subsequently lost at a rapid rate and at
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the menopausal transition, at around 51 years, the typical follicle number is 1 000
(Edwards and Brody, 1995).
Fig. 2.1.12. Biexponential model of declining follicle numbers in women aged between 0 and 51
years, showing a sharp decline in older ages. From Edwards and Brody, 1995, pp 165.
2.1.5. Endocrinology of the menopause
The progressive failure in ovarian function begins 5-10 years prior to the menopause.
Oestrogen and progesterone production decline due to depleting oocytes and an
increase in gonadotropin stimulation compensates for this ovarian unresponsiveness.
Oestradiol levels fall below a critical threshold and endometrial stimulation no longer
occurs, resulting in amenorrhoea. Endocrine changes are not restricted to reproductive
hormones. Other ovarian, pituitary and hypothalamic hormones such as inhibin,
prolactin and catecholoestrogens are involved.
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The following phases are characteristic of the endocrine changes at the climacteric:
• Hypothalamic pituitary hyperactivity - this starts 5-10 years before the menopause
and continues after the menopause
• Ovulatory and corpus luteum failure - starts 5-10 years before the menopause
• Ovarian follicular failure - begins at the menopause
These events will be clarified below.
2.1.5.1. Endocrine changes before the menopause
The change in ovarian function resulting in the menopause begins in utero where there
is a progressive decline in oocytes from 24 weeks of gestation. Whilst this continues
through reproductive life, ovulation only contributes to a small proportion of the loss.
As the number of follicles decrease, the oocytes that remain are those which are most
resistant to simulation by gonadotropins. Consequently, oestrogen levels begin to
decline in the older pre-menopausal women. Sherman et al. (1976) found that
oestradiol (the main oestrogen of reproductive age synthesized by the ovary)
concentrations are reduced in pre-menopausal women aged 46-56 years with regular
menstrual cycles compared with younger women at the same stage of the cycle. In
response to reduced oestradiol production, the negative feedback mechanism of the
hypothalamus and pituitary causes FSH levels to increase (Sherman et al., 1976). This
is the most characteristic feature of endocrine changes at the climacteric.
The hyperactivity of the hypothalamic-pituitary axis initially compensates for the
increasing resistance of follicles to gonadotropin stimulation. The rise in LH occurs
later and is less marked than that in FSH. This differential increase in FSH, compared
with LH, in older regularly menstruating women was first reported by Sherman and
Korenman (1975). They also postulated that a non-steroidal negative feedback factor
of FSH, called inhibin, is reduced leading up to the menopause, consequent to a
diminished number of follicles. Inhibin is found in ovarian follicular fluid and
considered a biological marker of ovarian function relating to the size of the ovarian
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follicular pool. Whilst oestradiol also regulates FSH, in isolation it is not sufficient to
account for gonadal feedback (Chetkowski et al., 1986).
As oestradiol levels continue to fall as a result of follicular deficiency, the menstrual
cycle shortens. Ovarian unresponsiveness becomes more marked and the cycle
lengthens, and becomes increasingly anovulatory. In conjuction with defective corpus
luteum formation, progesterone secretion is significantly reduced resulting in
unopposed oestrogen secretion. This may give rise to dysfunctional endometrial
bleeding, hyperplasia and carcinoma. Progesterone is the first hormone to become
deficient at the climacteric.
2.1.5.2. Endocrine changes at the menopause
The reduced follicular development results in inadequate oestrodiol secretion to
stimulate endometrial growth. Menstruation does not occur, and thus amenorrhoea
ensues. The cessation of menses marks a change from cyclical to continuous
hypothalamic, pituitary and ovarian function. The menopause is the last menstrual
period and is the only constant feature of the climacteric. The main steroid hormone
changes at the menopause are shown in Table 2.1.2.
Table 1.1.2. Circulating sex steroid hormones (plmo/) before and after natural menopause and
oophorectomy.
Oestrone Oestradiol Progesterone Testosterone Androstenedione
(E2) (E1) (P)
Premenopause
EF 25-50 25-75 200-400 1600-1750
LF 150-200 200-600 300-800 1850-2000
ML 70-100 100-300 100-500 300-600
oe+ 20-40 15-25 50 75-150 600-1500
Postmenopause
Natural 20-40 9-15 100-200 200-300 600-900
op: 20-40 9-15 100-200 100-150 500-800
EF=Early follicular
LF=Latefollicular
ML=Mid-luteal
OPt=Oophorectomy before menopause
oPt=Oophorectomy after menopause
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2.1.5.3. Endocrine changes after the menopause
An important hormonal marker of the menopause is serum FSH which increases 10-15
fold post-menopause, compared to levels found during the follicular phase in women of
reproductive age. Circulating LH levels only increase 3-5 fold in comparison. Both
gonadotropins reach a peak 2-3 years after the menopause (Chakravarti et al., 1976)
and then begin to decline until levels equivalent to those found prior to menopause are
reached 20-30 years later (Fig. 2.1.13.).
Fig. 2.1.13. Mean (±JSD) plasma FSH and LH values in pre-, peri- and post-menopausal women. FP
= follicular phase, PO = peak ovulatory value, LP = luteal phase. A and B are women still
menstruating with apparent symptoms. B are women complaining of vasomotor symptoms. (Yrs =
years). From Whitehead and Godfree, 1992, pp 9.
The main circulating oestrogen following the menopause is oestrone, synthesised from
the peripheral conversion of androstenedione. Aromatization of androstendione to
oestrone in adipose tissue accounts for 98% of the total oestrone production in post-
menopausal women. The plasma levels of both oestrone and oestradiol correlate with
body weight (Armstrong et al., 1996) and excess body fat post-menopausally (Judd et
al., 1976). Even though it appears that post-menopausal women are not totally
deficient in oestrogen, oestrone has only one tenth of the biological activity of
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oestradiol. Plasma oestradiol levels in the immediate post-menopausal period range lO-
15 u/ml, as compared with 25-27 u/ml and 20-600 ,.uml in the early follicular phase
and late follicular phase respectively in pre-menopausal women.
The ovary continues to secrete androgens - androstenedione, testosterone,
dehydroepiandrostenedione (DHA) and its sulphate (DHAS) - after the menopause.
Androstenedione is derived from the ovary (30%) and the adrenal cortex (70%). The
main proportion of testosterone is derived from the adrenal cortex (50%), then the
ovary (35%). Peripheral conversion of androstendione accounts for 15% of
testosterone produced (Fig. 2.1.14). Following bilateral oophorectomy, plasma
androstenedione and testosterone fall by 50% in both pre- and post-menopausal
women. Chakravarti et al. (1976) reported a 20% fall in concentrations of
androstenedione, oestrone and oestradiol within a year after the menopause. After 5
years, androstenedione increased and testosterone levels had fallen significantly.
Progesterone (P) and I7-hydroxyprogesterone (17 HOP) levels in post-menopausal
women are derived exclusively from the adrenal gland. They are suppressed by
dexamethasone and increased 50% by adrenocorticotropin releasing hormone (ACTH).
Bilateral oophorectomy does not affect progesterone concentrations.
Fig. 2.1.14. Diagrammatic representation of the source of oestrogens in post-menopausal
women. From Anderson, 1979.
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2.1.6. Physiological and pathological changes
Oestrogen exerts widespread effects on many tissues of the body, of both intra- and
extra ovarian origin. The decline in oestrogen prior to, and hypoestogenia at the
menopause are therefore associated with many physiological and pathological changes.
It is important to note that the climacteric is as much a progesterone deficiency as an
oestrogen deficiency syndrome. In addition to oestrogen, the effects of progesterone
and other endocrine changes will be addressed in this section.
The symptoms of the climacteric are classified from their time of onset and aetiology
and range from temporal, vasomotor disturbances to chronic and insiduous diseases
which result in physical and pathological changes that pose health hazards to middle-
aged women. These are listed in Table 2.1.3.
Table 2.1.3. Acute, intermediate and long-term symptoms associated with oestrogen deficiency.
From:Whithead and Godfree (1992).
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2.1.6.1. Acute responses (vasomotor symptoms)
Acute responses to the climacteric arise when menstruation is still ongoing. These
symptoms are characterised by vasomotor disturbances, manifest as sensations of heat
which travel from the face, neck and chest outwards. The 'hot flush' is associated with
sweats, palpitations, dizziness and fainting. Vasomotor symptoms affect approximately
75% of females during the climacteric (McKinlay and Jeffers, 1974; Studd et al.,
1990), 70% of of which are affected for 2 years, 25% for 5 years and 5% long-term
indefinitely.
The endocrine and physiological mechanisms responsible for flushes are not fully
understood. The occurrence and intensity of symptoms have not been correlated with
plasma E2 levels, although it has been postulated that the concentrations of 'free' E2
(those not bound to plasma protein) are involved. Some studies have shown that
episodic discharge of the gonadotropin LH is responsible for these symptoms (Casper,
1979; Tataryn et al., 1979). Meldrum et al. (1981) found that inhibiting LH secretion
does not mitigate the frequency or severity of symptoms, and thus some other
mechanism is involved which may originate from the hypothalamus.
Sweating often coincides with the onset of a hot flush. The sensation of a flush
precedes an initial increase in skin conductance and vasodilation ensues. A fall in core
temperature - up to 1°c - and a rise in peripheral skin temperature from 10 to 5°
have also been proposed (Tataryn et al., 1979). This suggests an initial change within
the central nervous system which includes an acute resetting of the thermoregulatory
centre. Cardiovascular changes have been detected, with a marked increase in heart
rate of up to 20 beats per minute (Silverman et aI., 1981), suggesting an increase in
sympathetic drive.
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2.1.6.2. Intermediate responses
Oestrogen has many regulatory functions on reproductive tissues and thus prolonged
oestrogen deficiency affects the reproductive tract. Indeed, within 3-4 years post-
menopause, atrophic vaginitis, vaginal dryness and dyspareunia will begin to cause
problems in 10-20% of the female population (Studd et al., 1990). At 5-8 years, 40-
50% will be inflicted with genital tract atrophy. Moreover, loss of collagen from the
skin and connective tissue may induce thinning and muscular aches and pains
respectively. Approximately 30% of collagen is lost during the first 5 years after
menopause.
2.1.6.3. Chronic responses
Long-term consequences of ovarian failure may have more serious implications on
health and quality of life in post-menopausal women. The incidence of cardiovascular
heart disease (CVD) and osteoporosis increase with age. These are two major causes
of morbidity, which have been suggested to be exacerbated by the menopause. Female
mortality due to diseases associated with hypoestrogenia across all ages show that
coronary disorders are the main cause of death (Mortality statistics, 1992, Fig.2.l.15.).
Female Mortality by Underlying Causes
Lung Breast Ovarian Fracture Fracture MI D-ID
CanCft Cencer CanCft (LL) (NF)
Nature of Death
Fig. 2.1.15. Female mortality (thousands) in England and Wales by underlying causes in 1992. LL =
lower limb; NF = neck of femur;MI = myocardialinfarction; IHD =ischaemic heart disease (MI and
IHD = cardiovascular disease). From Mortality Statistics: Cause. Series DH2 NoI9 OPCS.
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Mortality of different age categories for disorders associated with the menopause are
shown in Fig. 2.1.16. Despite an increase in the incidence of gynaecological and breast
cancer after the menopause (50 years plus), heart disease is accountable for
significantly more deaths. This is exacerbated with ageing.
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Fig. 1.1.16. Deaths in women from breast cancer, gynaecological cancer and heart disease in 1992.
From: Mortality Statistics: Cause. Series DH2 No19 OPCS.
2.1.6.3.1. Cardiovascular disease
Low oestrogen levels have been associated with the high incidence of cardiovascular
disease in post-menopausal women (Witteman et aI., 1989). The low mortality rate
associated with CVD in pre-menopausal females compared to males of the same age
support these suggestions, and figures from the British Heart Foundation show that
cardiovascular mortality is 2.7 times greater inmales than females below 55 years.
Oestrogen deficiency is believed to cause unfavourable changes in lipid metabolism,
including a decline in high density lipoproteins (HOL), an increase in low density
lipoproteins (LDL) and higher serum cholesterol levels from pre-menopausal controls
(Wahl et al., 1983). Hence, the protective role of oestrogens on the cardiovascular
system is reversed postmenopause. However, oestrogen status is not the only risk
factor of CVD. The confounding effects of hereditary predisposition, obesity,
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hypertension, diabetes mellitus, smoking, hyperlipidaemia, inactivity and stress causes
problems in isolating oestrogen status as a risk factor.
Whilst controlling for age and smoking, Colditz et a1. (1987) claimed that women aged
30-55 years who had undergone a natural menopause and had never taken oestrogen
replacement were not at an increased risk of CVD. Cross-cultural studies corroborate
these findings. Reduced absolute death rates ofCVD in Japanese women despite lower
oestrogen levels compared with caucasian women (Godsland et at, 1987) cannot be
explained by differences in oestrogen status. Colditz et al. (1987) did report that
women who had surgical removal of the ovaries (bilateral oophorectomy) with no
subsequent hormone replacement therapy, had an increased risk of CVD. Oestrogen
replacement in this group appeared to reduce the risk ofCVD (Colditz et al., 1987).
Many epidemiological studies have shown that the administration of oestrogen reduces
the incidence of CVD by 50-70% (Knopp, 1988). Furthermore, hormone replacement
therapy (HRT) also protects post-menopausal women against stroke (Paginini-Hill et
al., 1988), probably mediated through its changes in lipid metabolism Oestrogen
replacement causes a decrease in total cholesterol and LDL and an increase in HDL
(Wahl et al.,1983), reversing lipid profiles to pre-menopausal values. The effect of
oestrogen on triglycerides and LDL depends on the type and dose of oestrogen.
Oestradiol valerate used in many HRT preparations causes a fall in these lipids whereas
ethinyloestradiol, used in oral contraceptive preparations, increases the LDL and
triglycerides concentrations. In addition to the progestogen component, this explains
the increased risk of myocardial infarction and thromboembolic disease in
premenopausal women (Meade et al., 1980). Since many progestogens antagonise the
effect of oestrogen, to obtain optimal benefits from HRT women with an intact uterus
should be administered a progestagen of a pregnane derivative
A meta-analysis survey in post-menopausal oestrogen users and non-oestrogen users
suggests that this hormone is a significant (but not the only) protective factor against
CVD (Manson, 1992). However, the mechanism of the action of oestrogen is still
uncertain. In pubescent females, the large changes in oestrogen do not alter lipid ratios
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which has led researchers to focus on possible non-lipid mediated actions of oestrogens
(Bourne et al., 1990; Lieberman et al., 1994). Bourne et al. (1990) treated 10 post-
menopausal women with transdermal oestrogen (Estraderm") and sequential oral
norethisterone acetate. Using transvaginal ultrasound and pulse doppler, they found a
reduction in arterial impedance and vascular tone of the uterine artery. Lieberman et aI.
(1994) reported improvements in flow-mediated endothelium-dependent vasodilation
in post-menopausal women after 9 weeks of oestrogen replacement therapy.
Additonally, Padwick et al. (1989) may have elucidated a further mechanism. They
identified a protein related to the oestrogen receptor in smooth vessels and suggested
that oestrogen may affect arterial status through a conventional sex hormone-receptor
mechanism.
2.1.6.3.2. Skeletal changes
The loss of endogenous oestrogen at the menopause is known to disturb the
homeostatically maintained process of bone remodelling. The consequential changes in
skeletal intergrity can lead to a metabolic bone disease called osteoporosis. The
association between bone loss and the menopause was first recognised in 1941 by
Fuller Albright (Albright et al., 1941) and is now axiomatic (Lindsay et al., 1976;
Horsman et al., 1977; Lindsay et al., 1978b). Oestrogen deficiency has since become
established as the single most important factor in the aetiology of osteoporosis
(Stevenson et al., 1989).
Osteoporosis is the most common metabolic bone disorder in Western countries and is
becoming a serious, yet preventable public health problem. Osteoporosis is
characterised by a significant reduction in bone density per unit volume, leading to
increased susceptibility to fractures. Lifetime risk of fractures in women is greatest for
the vertabrae at 32%; risk of hip and Co lies' fracture is 16% and 15% respectively
(Compston, 1992).
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(i) Bone loss
The skeletal system is composed of cortical and trabecular bone. Compact plates of
cortical bone are located in the peripheral skeleton. Bones of the central or axial
skeleton consist of trabecular bone, a honeycomb of vertical and horizontal plates filled
with red marrow (Marcus, 1991). Age-related bone loss affects cortical and trabecular
bone in both sexes and may lead to "senile" osteoporosis (Riggs and Melton, 1986).
Women experience an accelerated loss of trabecular bone after the menopause at a rate
of 1-6% per annum (Morgan, 1973; Lindsay et al., 1976; Krolner and Nielson, 1982).
Trabecular bone is more metabolically active than cortical bone and is more responsive
to oestrogen deficiency. Common sites for fracture following the menopause are
therefore localised at the wrist, spine and hip. Studies reporting bone loss at different
skeletal sites are conflicting. In a longitudinal study of 139 healthy post-menopausal
women, bone loss of the lumbar spine occurred before the menopause which amounted
to half of overall bone loss, and was accelerated after the menopause at 1% per annum.
No significant change was found for the midradius (99% cortical bone) pre-
menopausally (Riggs et al., 1986). Krolner and Nielsen, (1982) did not report any
change in bone of the lumbar vertebrae before the menopause but documented a 6%
loss per annum after the menopause. Oestrogen deficiency has been shown to be a
major contributor to a reduction in bone density of the proximal femur (Stevenson et
al., 1989), although this hasn't been found in previous studies (Riggs and Melton,
1986). Rates of loss differ between cortical and trabecular bone, at different skeletal
sites (Riggs et al., 1981; Stevenson et al., 1987) although it is agreed that the spine is
the main site of disease in post-menopausal women (Riggs et al., 1982).
Fracture risk is dependent on two factors - peak bone mass and subsequent rate of
loss. Peak bone mass is attained by mid-thirties and is mainly under genetic control
(Lindsay et al., 1983). Lifestyle factors such as physical activity and diet, smoking,
excess caffeine and alcohol intake have also been implicated in the redution of bone
density (Stevenson et al., 1989). For instance, daily consumption of caffeine can reduce
BMD of the hip and spine if at least one glass of milk is not consumed each day
(Barrett-Connor et al., 1994). Maximising peak bone mass in adulthood is therefore
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important in preventing bone density falling below the critical threshold for fracture
risk in later life. Fig. 2.1.17 illustrates the effect of peak bone mass on fracture risk.
Fig. 2.1.17. Effect of bone mass on fracture risk. The upper broken line represents BMD in women
with a high peak bone mass who lose 20% of their bone density after the menopause. The lower line
represents bone density in women with low peak bone mass who only lose 10% of their bone density
post-menopausal/y, yet become osteoporotic. From Stevenson, 1990.
(ii) Bone mineral density and muscle strength
Bone mineral density is not only dependent on systemic (hormonal) factors.
Mechanical mechanisms are also in operation through external (gravity) and internal
(muscular contraction) forces. The adapatation of bone to the force placed upon it was
first recognised by Wolfe (1872 - Wolfe's law). It has since been recognised that
muscle is an important determinant of bone mass (Doyle et al., 1970; Carter and
Hayes, 1977; Zimmerman et al., 1990). Indeed, weight-bearing activities have been
shown to increase the load to bone although activities such as swimming, which do not
incorporate gravity stimulation, do not produce the same effect (Wolman, 1990). This
is further supported in changes following immobilisation, in which significant bone
losses of up to 1-2% per week in trabecular bone have been reported (Whedon, 1984).
Many assessments have been undertaken assessing muscle strength and bone density at
local sites. Exercise exerts a local effect on the skeleton, where greatest increases in
BMD occur at the site of maximum stress. A 30% difference in BMD of the playing
)
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arm compared to the non-playing arm has been reported in tennis players (Huddleston
et al., 1980) and is greater in the os ca1cis of runners (Williams et al., 1984).
Muscle strength has been implicated in predicting bone mineral density in post-
menopausal women (Snow-Harter et al., 1990; Kyllonen et al., 1991) at functionally-
related antomical sites (Pocock et al., 1989; Rutherford and Jones, 1992; Zimmerman
et al., 1990; Madsen et al., 1993). Correlations have been found between muscle
strength of the back and bone density of the vertebral bodies (Sinaki et al., 1986; Halle
et al., 1990) and quadriceps strength and BMD at the proximal tibial (Madsen et al.,
1993) and proximal femur (Pocock et al., 1989). According to Zimmerman et al.
(1990) muscle strength is not a predictor ofBMD, but may be a factor in determining
BMD. The association between muscle function and bone density is further
substantiated from findings of strength in osteoporotic patients. Muscle weakness is
more pronounced in senile osteoporotic sufferers compared to healthy age-matched
controls (Rutherford and Jones, 1992). Meena et al. (1973) revealed that osteoporotics
had lower bone mass of the proximal radius site, but they did not have smaller muscles.
However, the muscle weakness reported with osteoporosis may be independent of
muscle mass, similiarly to that reported by Rutherford and Jones (1992), and has the
same aetiology as the significant reduction in bone.
(iii) Pathogenesis of post-menopausal osteoporosis
Bone is a dynamic tissue and is constantly under repair through a process of
remodelling. Bone resorption is governed by osteoclasts and bone formation by
osleoblasts. This dynamic homeostatic process is regulated through the action of•
hormones and growth factors. A disruption in hormone balance may result in a
significant loss of bone (or an increase in bone mass). Oestrogen deficiency has been
implicated in increasing the rate of bone resorption through indirect influences on other
regulatory factors and/or direct effects on bone.
The mechanisms by which oestrogen alters bone turnover are still much debated,
although it has been suggested that oestrogen acts indirectly by affecting the secretion
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of parathyroid hormone (PTH). In hypo estrogenic post-menopausal women, reduced
calcitonin levels enhance bone resorption to stimulate increased serum calcium levels.
Parathyroid hormone is subsequently suppressed which reduces the synthesis of 1,25-
dihydroxyvitamin D3 (Compston,1992). Recent proposals have focused on the role of
the immune system. Oestrogens inhibit cytokines interleukin 1 (IL-l), IL-6 and tissue
necrosis factor (TNF), indicators of bone resorption. Cytokines also increase the
sensitivity of bone to resorptive effects of PTH (Arnaud, 1993). Evidence of a direct
effect of oestrogen on bone have been reported in in vitro studies. Eriksen (1988) and
Komm (1988) both found that oestrogens have specific receptors in osteoblasts and
therefore probably affect bone metabolism directly through a receptor-mediated
mechanism. Even though it is recognised that oestrogen deficiency is responsible for
increased bone resorption, the precise mechanisms need confirmation.
Whilst oestrogen has been reported the most important factor associated with bone
metabolism, the role of progesterone in bone remodelling has been questioned.
Considering the close relationship of both these hormones in the ovulatory cycle, it is
reasonable to assume that progesterone may be the 'other hormone' which balances
the activity of oestrogen in bone resorption. Indeed, in vitro studies have shown that
progesterone acts directly on bone by engaging osteoblast receptors (Eriksen et al.,
1988) and indirectly, by competing for glucocorticoid receptors on osteoblasts
(Feldman et al., 1975). Further evidence emanates from hormonal treatment and bone
markers. A reduction in calcium and hydroxyproline excretion, markers of bone
resorption, following oestrogen treatment (Gallagher and Nordin, 1975) has been
observed with progesterone treatment (Lobo et al., 1984). However, it has been
reported that progestagen combined with oestrogen has a different effect on bone
markers than oestrogen treatment alone. Christiansen et al. (1985) noted an increase in
osteocalcin and alkaline phosphatase after progestogen administration on days 13-22
of a 28-day oestrogen therapy, compared with oestrogen alone in which urinary
calcium and hydroxyproline excretion diminished. This would suggest that
progesterone and oestrogen combined are implicated in increased bone formation as
opposed to decreased bone resorption with oestogen therapy alone.
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(iv) Progesterone and bone mineral measurements
Preliminary findings have implicated progesterone in the changes of bone mineral
density. In a prospective study, Prior et al. (1989) measured BMD using single-energy
quantitative computed tomograpy (QCT) of 66 healthy pre-menopausal women during
one year. Changes in the menstrual cycle were monitored using basal body temperature
readings. The mean length of the luteal phase was positively correlated with percent
annual change in BMD of the vertebrae (thoracic 12 to lumbar 13). The authors have
suggested that anovulation, with subsequent low or absent progesterone, might explain
the low bone mass in peri-menopausal women.
Data assessing the effects of progesterone treatment on BMD are limited. Work from
animal studies has demonstrated an increase in femoral width and ashed mineral in
progestogen-treated rats (Lindsay et al., 1972; Aitken et al., 1978). In humans, Prior et
al. (1987) reported an increase in vertebral density with QCT in 11 post-menopausal
women treated with medroxyprogesterone for one year. Furthermore,
medroxyprogesterone administered cyclically to pre-menopausal women with
secondary amenorrhoea resulted in a significant increase in bone density in 3 women
taking 10 mg/month; for those who took less progestogen, there was evidence of a
dose-response relationship of bone changes. In clinical trials, Lee (1990) found that
bone density increased markedly with the administration of 'natural' progesterone
applied in a cream, which was greater than synthetic progestagens. In 67 post-
menopausal women, bone density increased by 10% in the first six to twelve months,
followed by an annual increase of 3 to 5%. Oestrogen slowed down bone loss, but no
increases were observed (Fig. 2.1.18.).
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Fig. 2.1.18. Bone mineral denisty changes with progesterone (P), oestrogen only (£1 ) or controls.
From Lee, 1990.
Osteoporosis can be prevented through different approaches, but needs to be
recognised from an early age so that attainment of peak bone mass can be optimised.
Exogenous oestrogens have proven to be the most efficacious treatment for preventing
osteoporosis (Albright et aI., 1941; Aitken et at, 1973; Stevenson et at, 1990) even if
given many years after the menopause (Quigley et aI., 1987) although treatment should
begin soon after ovarian failure. It has been recommended that duration of therapy
should last approximately 7 years after menopause (Felson et al., 1993).
2.1.7. Hormone replacement therapy
The use of oral contraceptives (OC) as a form of hormone replacement in
amenorrhoeic athletes has been mentioned previously in section 2.1.3. Hormone
replacement therapy (HRT) is the most efficacious treatment for menopausally-related
symptoms but differs to OC's in dose and composition. Another important difference is
the therapeutic application of HRT, formulated to produce a physiological, not a
pharmacological effect. Hormone replacement therapy replenishes the loss of
endogenous reproductive hormones as a consequence of the menopause or other
disorders associated with a hypoestrogenic and hypoprogesteronic state. There is
substantial evidence to suggest that hormone replacement therapy mitigates the acute
menopausal symptoms such as vasomotor disturbances (Hargrove et at, 1989) and
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confers protection against bone loss (Lindsay et al., 1976; Weiss et al., 1980; Felson et
al., 1993) and cardiovascular disease (Colditz et al., 1987; Paganini-Hill et al., 1988).
2.1.7.1. Formulations
The majority of HRT preparations contain an oestrogen and progestogen component.
The oestrogen component of HRT is not synthetic (i.e. not structurally dissimilar to
naturally occurring oestrogen) like ethinyloestradiol of OC formulations. Conjugated
equine oestrogens for example, most widely prescribed in HRT preparations in the U.K
(Whitehead and Godfree, 1992), comprise 50-65% oestrone sulphate with the
remainder constituting equine oestrogens which are structurally similar to oestrogens.
The oestrogen component of HRT is believed to be responsible for mitigating acute
vasomotor symptoms and reducing the risk of osteoporosis and cardiovascular disease.
Progestogens are only added to prevent endometrial hyperplasia caused by unopposed
oestrogen, and are therefore not routinely prescribed to hysterectomised women
(without an intact uterus) (Whitehead et al., 1990). Progestogens ofHRT preparations
are the same as those of OC formulations, and are mostly derived from the 19-
nortestosterone group. Progesterone is the precursor of many other steroids and thus
the admininstration of 'natural' progesterone results in its rapid metabolism. Very high
doses (200 mg) are needed to elicit an endometrical effect which has to be
administered twice daily (padwick et al., 1986) with accompanying sedative effects.
Synthetic progestogens may cause adverse side effects which may detract from the
benefits ofHRT. These side effects range from physical symptoms of breast tenderness
and bloating to anxiety, irritability and depression of a psychological origin
(Whitehead et al., 1990). Side effects are dose related, and depends on the type of
progestogen administered. Probably the most significant of these adverse effects are
the unfavourable changes in lipid profile. The beneficial effects of oestrogen are offset
with the addition of a progestogen which causes HDL to fall and LDL cholesterol to
increase (Ottoson et al., 1985; Siddle et al., 1990).
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Progestogens taken sequentially in combined preparations also induce a withdrawal
bleed which may be unacceptable in post-menopausal women. A gonadomimetic,
tribolone, has been developed to prevent withdrawal bleeding associated with
conventional HRT. Tribolone is a derivative of a C-19 nortestosterone compound
which possesses oestrogenic, progestogenic and androgenic properties (Ellerington et
al., 1992). Tribolone has been demonstrated to relieve vasomotor symptoms as
effectively as conjugated equine oestrogens and oestradiol valerate (Crona et al., 1988;
Volpe et al., 1986). Tribolone has been shown to be more effective in preventing bone
loss than a placebo (Lindsay et al., 1980) although comparisons with HRT
preparations have not been made. Their effects on lipid metabolism remain
inconclusive.
2. J. 7.2. Route of administration
The oral and transdermal routes for oestrogens and progestogens are the most popular
methods of administration. Other parenteral applications such as creams are also
advocated. The main disadvantage with oral administration of hormones is their
metabolism in the gastrointestinal tract and 'first pass' effect ofthe liver (Ellerington et
al., 1992). Oestradiol administered orally undergoes rapid conversion to oestrone in
the gut mucosa. Hence, all oestrogens prescribed orally are absorbed into the portal
venous system as oestrone, which passes through to the liver and is further metabolised
and inactivated. Between 30 to 90% of the administered dose is inactivated by the liver
prior to reaching the systemic circulation. Transdermal patches were developed to
overcome the hepatic first-pass effect. The efficacy of this method appears to equal
oral administration, with relief of hot flushes and maintenance of bone density (Haas et
al., 1988). There is little intermediate metabolism through the epidermis (Stumpf,
1990) and thus the initial dose of oestogen in oral preparations is higher than that of
the non-oral route. Progestogens are usually added sequentially in oral preparations,
mimicking the endogenous hormonal fluctuations during the menstrual cycle.
However, the adverse side effects of higher doses of progestogens in oral preparations,
and the unfavourable changes in the lipid profile, have prompted the development of
non-oral administration of the progestogen norethisterone acetate.
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2.2. MUSCLE FUNCTION
The endocrinology of the female reproductive system has been reviewed in the
previous section, so that reference throughtout the thesis to the hormonal status of
young and middle-aged women and the effects that reproductive hormones exert will
befully understood.
Thepurpose of this section is to review aspects of muscle function and to establish a
link with reproductive hormones. It is necessary at first to brief the reader of the
structure and characteristics of the skeletal muscle to clarify the mechanisms of the
actions of hormones.
2.2.1. Introduction
The ability to undertake any activity, from subliminal actions of blinking to strenuous
exercise, is possible through the functioning of the muscular system. A highly
specialised contractile machinery, skeletal muscle is characterised by its physical
location, histology and nervous mode of control (Tortora and Anagnostakos, 1990).
Cardiac (heart) tissue and smooth muscle (e.g. blood vessels) are under involuntary
control, whereas movement of skeletal muscle is voluntary.
Muscle is a responsive tissue, adapting to external stimuli to enhance its mechanical
and physiological functioning. Like many living tissues, muscle is not resistant to
disease. Muscle strength, the capacity to generate force, is impaired in diseases such as
myasthenia gravis, mytonia congenita and muscular dystrophy. The accompanying
sensations of weakness and fatigue result in diminshed capacity to undertake 'simple'
activities without undue strain. Muscle function is also compromised in the elderly and
muscular atrophy, localised in the proximal muscles of the lower limb, results in a
significant reduction in strength. This has important implications for enhancing the
functional capacity in the elderly population.
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Measuring indices of muscle function can determine the individual changes in strength
and identify weaknesses inmuscular performance. Much of the equipment used in the
past has been subject to measurement error and limited to select muscle groups.
Contemporary dynamometers allow the measurement of different muscle groups
during different contractions and through a wide range of movements. Information
derived from these tests provide more 'accurate' and realistic information, a sound
basis from which to study functional changes in the population.
2.2.2. Structure of skeletal muscle
Skeletal muscle is responsible for movement and support of the skeleton. The human
body contains over 215 pairs of skeletal muscle. For muscle to produce movement, the
individual muscle fibres must contract. Contraction is initiated through a complex
interaction originating from the higher centres of the brain, which relays messages
along the central nervous system (CNS), peripheral nerves to the neuromuscular
junction. This culminates in the transmission of electrical activity to muscle fibres for
contraction to occur (Tortora and Anagnostakaos, 1990).
Muscle is comprised of individual muscle cells called muscle fibres, which run along
the longitudinal axis of the muscle. They are enclosed in a plasma membrane called the
sarcolemma. Muscle fibres are arranged in bundles, and contain smaller subunits of
myofibrils. These are the contractile elements of skeletal muscle. Each myofibril
contains numerous sacromeres, the basic functional unit of a myofibril. They are
arranged along the myofibril and gives the muscle fibre a striated appearance (Billeter
and Hoppeler, 1992). The magnified striations represent dark (A bands) and light (I
bands) regions, occupied by contractile proteins myosin and actin filaments (Fig.
2.2.1.).
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Fig. 2.2.1_ A sacromere, the functional unit of the myofibril
Two thirds of skeletal proteins in each myofibril consist of myosin filaments. Myosin is
characterised by two intertwined strands termininating in globular heads. The
adenosine triphosphate CATP) cleaving site is located in the myosin head, where the
hydrolysis of ATP to adenosine diphosphate (ADP) provides energy for contraction.
When the myosin head interact with actin molecules, ATPase is activated several
hundred-fold (Fig. 2.2.2.).
Fig. 2.2.2: A molecule of myosin
Actin, a double helical strand, is attached to two other proteins, tropomyosin and
troponin. Tropomyosin is a long, rod-shaped protein spanning the length of seven actin
residues. The troporrin complex is carried on the tropomyosin and consists of globular
shaped troporrin C, troponin I and an elongated troponin T. Troponin C is the binding
site for calcium (Fig. 2.2.3).
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Fig. 2.2.3. An actin filament, composed of molecules of actin, tropomyosin and troponin
A system of membranous channels called the sarcoplasmic reticulum (SR) run
longitudinally to the myofibril, providing a storage site for calcium in preparation for
muscle contraction. The transverse tubules, which extend from the sarcolemma,
transports extracellular fluid to individual muscle fibres. Muscle fibres are innervated
by a motor neuron, which along with its axon and the fibres it supplies is collectively
called the motor unit (Billeter and Hoppeler, 1992).
Characteristics of motor units differ, and early reports of Ranvier demonstrated that
speed of contraction differed between muscles of the same individual (Ranvier, 1873:
cited by McComas and Thomas, 1968). The nomenclature of muscle fibres depends on
the different isoforms of the myosin. Three distinct isoforms have been identified,
which differ on the basis of ATPase activity. Using the needle biopsy technique
(Bergstrom, 1962) and histochemical staining, Peter et al. (1972) classified the fibres
types as slow twitch fibres (type I) which rely heavily on aerobic metabolism; fast
twitch-oxidative glycolytic (type IIa) have a moderate to high glycolyic activity with a
higher capacity for aerobic metabolism and fast twitch glycolytic fibres (type lIb) are
characterised by a high glycolytic capacity. Faster myosin heads split ATP about 600
times per second, double the speed of slower myosins (Billeter and Hoppeler, 1992). In
most everyday contractions, slow motor units (type I) are the first to be recruited.
Greater power output recruits fast (type II) fibres and fast glycolytic fibres (type lIb)
are preferentially activated in fast movements.
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2.2.3. Excitation-contraction coupling
Excitation-contraction coupling refers to the process by which the nerve signal results
in muscular movement. Nerve impulses travel along the axon at a speed of several
metres per second and activate the motor unit and all the fibres in innervates. The site
of signal transduction from the motor nerve to the muscle fibre's membrane is the
synapse. This is separated from the muscle membrane by a cleft or the neuromuscular
junction (NMJ). The arrival of a nerve impulse at the nerve's endings (motor end
plates) stimulates the release of a neurotransmitter, acetylcholine (ACH) , into the
synaptic cleft and binds to receptors on the muscle cell membrane. The binding of
ACH increases the permeability of sodium (Na+) and initiates depolarisation of the
postsynaptic muscle membrane generating an action potential. The action potential
travels across the sarcolemma and through the T tubules and the sarcoplasmic
reticulum (SR) to the interior of the muscle fibre. The electrical charge elicits the
release of large quantities of stored calcium ions from the SR into the myoplasm,
where they bind to troponin C on actin filaments.
2.2.3.1. Cross-bridge cycling
Muscle force is generated by the interaction of myosin heads with actin, which detach,
and slide further along the molecule - a process of cross-bridge cycling. Prior to the
binding of calcium, myosin heads are detached from actin, and adenosine triphosphate
(ATP) is bound in the head of myosin. The ATP is split into adenosine diphosphate
(ADP) plus phosphate (Pi) but is not released from the ATPase (adenosine
triphosphotase) site. The binding of calcium to troponin C on actin filaments causes a
conformational change in troponin C and subsequently troponin I, T and tropomyosin.
The myosin heads attach to the active sites of actin, forming cross-bridges and the
phosphate is released. This causes the head to tilt and pulls the actin filament towards
the middle of the sacromere. This is referred to as the 'power stroke' and is the main
regulatory step in cross-bridge cycling. After the 'power stroke' the cross-bridge is
detached from the thin filament when ATP binds to the myosin head and a new cycle
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begins. The muscle relaxes when calcium is actively removed and transported back to
the SR, another energy dependent action.
The four states during cross-bridge cycling have been proposed to exist as two bound
and two unbound states (Eisenberg et al., 1980). According to this model, the initial
crossbridge attachment is in a weakly-bound state. Phosphate release results in the
transition to a strongly-bound actin-myosin-ADP state. Pate and Cooke (1989) have
developed a mathematical model similar to that of Eisenberg et al.(1980), including a
state in which myosin binds weakly to actin prior to release of Pi. Under conditions of
high concentrations of Pi, the model predicts that tension decreases. Force is lowered
by altering the equilibrium between the two attached cross-bridge states (Pate and
Cooke, 1989).
2.2.4. Force-velocity relations
The strength of a muscle is determined by the amount of force it can generate. Muscle
can produce force whilst shortening, when it is static and during lengthening. The
contractile behaviour of muscle can be characterised by the force-velocity relation,
which describes the relationship between muscular tension and shortening velocity. The
inverse relationship existing between force or load and shortening velocity was first
demonstrated in situ in the early work ofFenn and Marsh (1935) and Hill (1938). Hill
devised a formula in which the force (F) and shortening velocity (V) represent a
hyperbola:
(F + a) (V +b) = (Fo + a) b
where Fois the force exerted in an isometric contraction, and a, b are constants.
At zero velocities, the muscle is contracting whilst the joint angle remains constant.
The myosin cross-bridges are formed and recycled, although the external force is too
great for actin filaments to be moved (Wilmore and Costill, 1994). This action is
termed isometric. The force-velocity relationship obtained from one joint angle for a
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single muscle during an isometric contraction may not necessarily apply to other joint
angles, since isometric force differs over a range of joint angles, as reviewed by Kulig
(1984).
When the force developed by a muscle is greater than the external load, the muscle will
shorten. During shortening or concentric contractions the thick (myosin) and thin
(actin) filaments overlap, thereby exerting a positive force. This has been described
above (section 2.3.2.1.). At increasing velocities, there is a non-linear decrease in force
due to a reduced number of attached cross-bridges. This is due to the shorter time in
which the myosin bridges are exposed to a potential binding site (Edman, 1992).
Maximum shortening velocities are produced under zero load with lowest force
production.
When the external load exceeds the isometric force Fo the muscle is stretched against
its external forces (GUlch, 1994). This eccentric action exerts negative force due the
lengthening of the muscle. It has been well documented that force increases with
velocity during "lengthening contractions" (Katz, 1939; Edman, 1988; Lombardi and
Piazzesi, 1990). Increases in velocity above the optimum length, however, do not
result in higher forces (Lombardi and Piazzesi, 1990). When muscle fibres are
overstretched, the actin and myosin filaments are pulled further apart, hence fewer
cross-bridges interact (Wilmore and Costill, 1994). The number of attached cross-
bridges increases by approximately 10% from isometric contractions (Lombardi and
Piazzesi, 1990), and thus the increase in force is likely to arise from the higher force
developed per cross bridge.
The development of isokinetic dynamometry has enabled the characteristics of human
muscles to be determined in vivo. The curvature of the force-velocity relationship is
related to the fibre type composition of the muscle (Thortensson et al., 1976). Force
output is greater for fast twitch fibres which are selectively recruited during fast
contractions.
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2.2.5. Assessment of muscle function
Objective measurements of muscle function are important for the quantification of
skeletal disorders and symptoms of weakness and fatigue (Edwards and Hyde, 1977).
The developments of equipment such as the strain gauge and isokinetic dynamometers
have provided tools for measuring muscle force. The needle biopsy technique, used for
histochemical analysis of muscle samples (Edwards et al., 1980) and electromyography
employed to measured electrical properties of muscle (Stephens and Taylor, 1972;
Moxham et al., 1982; Cooper et al., 1988) have allowed the functioning of muscle to
be examined in greater detail. This has proven invaluable for the identification of the
properties of muscle and the aetiology of skeletal disorders.
2.2.5.1. Maximal voluntary muscle force
The function of muscle is to generate force. Strength is therefore an important
determinant of muscle function. The chain of commands which lead to a voluntary
contraction (Edwards, 1978) is shown in Fig. 2.2.4. Impairment in muscle function
may occur at anyone of these 'links' and result in a reduced capacity to produce
maximal strength.
Strain gauge systems have been employed to measure maximal voluntary isometric
force in the quadriceps (Edwards et al., 1977b), the first dorsal interosseus muscle
(Stephens and Taylor, 1972; Milner-Brown et al., 1973; Tanaka et al., 1984;
Rutherford and Jones, 1988) and the adductor pollicis muscle (Merton, 1954; Edwards
et al., 1977b; Phillips et al., 1993b,c). Measurement of maximal volitional force is
dependent upon the motivation of the subject. Studies which have examined motor unit
activation in human muscle have employed the twitch interpolation technique, the
superimposition of electrical impulses, to compare the force generated from a
voluntary contraction with that elicited from involuntary electrical stimulation. In the
absence of fatigue, disappearance of the superimposed impulses confirming maximal
activation has been reported for the quadriceps (Rutherford et aI., 1986), soleus
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(Bellemare et at, 1983) and the dorsiflexor (Belanger and McComas, 1981) muscles.
Certain muscle groups are easier to activate than others, and appear to be dependent
on their level of recruitment. Rutherford et al. (1986) reported that 30% of subjects,
male and females of different ages, who were able to activate their quadriceps fully
could not generate maximal activation of their biceps. This has also been found for the
plantar flexors (Belanger and McComas, 1981), indicating that differences in muscle
activation probably depends on the extent of their use and recruitment in maximal
movements.
Stimulation of the motor nerve is impractical for muscles such as the quadriceps.
Innervated by the femoral nerve, supramaximal stimulation of this muscle group is
painful and can be dangerous. Percutaneous stimulation using surface electrodes is
therefore used to assess the recruitment of the quadriceps during voluntary
contractions (Chapman et al., 1984; Rutherford et al., 1986).
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Fig. 2.2.4. Voluntary contraction of human skeletal muscle: From Edwards (1978).
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2.2.5.2. Electrical stimulation
Twitch interpolation is one of several applications used in the assessment of muscle
function by electrical stimulation. In addition to twitch interpolation, electrically
stimulated contractions provide information of contractility, relaxation rate and rate of
force fatigue of skeletal muscle. Duchenne in the last century was the first to use
electrical stimulation to examine the actions of normal and diseased muscle (Edwards
and Hyde, 1977), and also pioneered the development of the needle biopsy technique
(Edwards et al., 1980). Much of the earlier work employing electrical stimulation made
use of small peripheral muscles such as the first dorsal interosseus (Stephen and
Taylor, 1972), the adductor po1licis (Merton, 1954; Edwards et at, 1977b) and the
abductor digiti minimi (Burke et al., 1974) with accessible motor nerves. These
muscles have little functional significance compared to large muscle groups, such as
the quadriceps, which are mostly affected by skeletal disorders (Edwards et al.,
1977b). Maximum tetanic stimulation of the femoral nerve innervating the quadriceps
is painful and so only a portion of the muscle (20 to 40%) is routinely stimulated.
Percutaneous stimulation via superficial branches of the nerve is delivered through
large surface electrodes placed proximally and distally over the anterior side of the
thigh (Edwards et al., 1977b). The validity of this method has been questioned, with
claims that percutaneous stimulation is voltage dependent (Davies and White, 1982).
This has not been demonstrated in the quadriceps except at low voltages (Edwards and
Newham, 1984) or in either fresh or fatigued sternomastoid muscle (Edwards et al.,
1984).
Characteristics of contractile properties are assessed through delivering trains of
stimuli in a set pattern of frequencies e.g. 1, 10, 20,50, 100 and 1 Hz, to the muscle.
The is called a programmed stimulation myogram or 'PSM' (Cooper et at, 1988). The
force-frequency relationship is illustrated below (Fig. 2.2.5.).
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Fig. 2.2.5. Force-frequency curve infresh andfatigued muscle,
Contractile properties do not necessarily determine fibre composition of different
muscles. Round et al. (1984) examined the fibre composition of the human adductor
pollicis muscle during postmortem. The muscle was composed predominantly (80%) of
type I fibres although the contractile properties were similar to those obtained for the
quadriceps which have approximately equal amounts of type I and II fibres. The twitch
characteristics of the AP were different to the soleus, despite the higher proportion of
type I fibres of this muscle (Round et al., 1984). Edwards et al. (1977b) reported
similar force-frequency curves for the quadriceps and adductor pollicis muscle.
Contractile properties obtained in vivo are agreeable with those obtained in isolated
muscle preparations (Faulkner et al., 1979; Moulds et al., 1977).
2.2.6. Muscle weakness
Muscle weakness is a common symptom of neuromuscular disorders, manifest as the
inability to perform everyday activities. It is defined as the failure to generate force
which may be due to lack of motivation (neural drive), neurological disorders,
immobilisation of a limb after fracture or ageing (Edwards, 1978). Muscle weakness is
most pronounced in lower limb performance, and is of great concern due to its
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principle role in everyday activities. Several mechanisms responsible for weakness have
been identified through the development of different methods. So far, the inability to
produce maximum force output has been attributed to the failure of electromechanical
activation, depletion of fuel supply or degeneration of the contractile apparatus. In
light of these factors, Edwards (1978) devised a schematic representation which may
be used as a practical approach for diagnosing weakness (see Fig.2.2.6).
Electromechanical
activation
Impaired neuromuscular
:...:--- transmission
--- Impaired excitation-contraction
coupling
____ Reduced short-term energy stores
--- Impaired energy exchange
Contractile machinery
~ Smaller muscle cells
=---- Fewer muscle cells
Fig. 2.2.6: Practical scheme for analysis of muscle weakness
2.2.7. Muscle fatigue
Muscle fatigue, which leads to muscular weakness, is defined as the inability to sustain
expected force output (Edwards et al., 1981). Fatigue can occur anywhere between the
central nervous system (eNS) to cross-bridge cycling, an impairment at anyone (or
more) site listed in Fig. 2.2.4. It is therefore difficult to identify one site of fatigue.
Physiological changes are also manifest, such as the slowing of relaxation. In clinical
assessments, muscle fatigue is quantified using volitional and electrically stimulated
tests. Each technique is subject to criticism; volitional contractions are reflective of the
functional capacity of muscle representative of daily activities, but are dependent upon
the motivation and functional central drive of the subjects (Binder-Macleod and
Snyder-Mackler, 1993). Electrical elicited fatigue is independent of motivation and
determines whether failure to maintain the generated force is the result of lack of
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neural drive ('central fatigue') or processes occurring within the muscle ('peripheral
fatigue') (Edwards, 1978).
2.2.7.1. Central fatigue
Comparison of the volitional forces with electrically stimulated contractions has
provided a measure of 'central fatigue'. The contribution of central mechanisms in
eliciting fatigue was reported as early as 1892, when Lombard found that the work
capacity of the finger muscle was maintained during electrical stimulation, but reduced
during maximal voluntary contractions (MVC) (Fitts, 1994). It has been claimed that
muscle fibre recruitment between volitional contractions and electrical stimulation
differs and only those muscle fibres beneath the electrodes are activated during
electrical stimulation (Fitts, 1994). Volitional contractions produce more work
resulting in a higher rate of fatigue.
Several authors have used smoothed rectified electromyography (s.r.e) to record the
electrical activity of the muscle during a maximal voluntary contraction (MVC) and
electrical stimulated contractions (Stephens and Taylor, 1972; Bigland-Ritchie et al.,
1978). Sustained maximal voluntary contraction of the first dorsal interosseus muscle
and s.r.e fell proportionatly to loss of force during the first 60s of the contraction,
resulting in a constant s.r.e/force.With time, however, force declined more rapidly.
This was perceived as a failure of neuromuscular drive (Stephens and Taylor, 1972).
These findings differ to those performed on the quadriceps. Bigland-Ritchie et al.
(1978) found that s.r.e/force ratio remained constant even when force was decreasing.
Even inwell-motivated subjects the tendency of central fatigue was overcome during a
brief extra effort.
The causes of muscle fatigue are multifactorial, and can take place at various sites
within the central nervous system, the neuromuscular junction and several locations
Within the muscle fibres (Edwards, 1978). Under laboratory conditions, when subjects
are well-motivated, muscular fatigue has been shown consistently to have peripheral
origins.
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2.2.7.2. Peripheral fatigue
Merton (1954) was the first to demonstrate the importance of peripheral fatigue when
measuring maximal voluntary effort of the adductor pollicis muscle superimposed with
stimulations of the ulnar nerve. Fatigue was reported to be of peripheral origin,
occurring beyond the neuromuscular junction and attributed entirely to failure of the
muscle contractile system. These conclusions were based on the observations that
stimulation of the motor nerve failed to restore the initial force output and recovery
from fatigue was not restored when circulation of the muscle was occluded.
Subsequent studies have corroborated these findings, maintaining that events proximal
to the neuromuscular junction (NMJ), or transmission of information across the NMJ,
are not responsible for the the significant limitation to muscular performance (Bigland-
Ritchie and Woods, 1984).
The peripheral failure to generate force is due to metabolic factors involving a
reduction in ATP, accumulation of hydrogen ions (It) or the depletion of glycogen
stores. Two other forms of peripheral fatigue have been recognised, depending on the
site of fatigue. Low frequency fatigue is characterised by a loss of force when tested at
low frequencies of stimulation (10 to 20 Hz), measured as a lowered 20/50 Hz ratio
i.e. the force generated at 20 Hz as a percentage of the force at 50 Hz. This is
attributed to the excitation-contraction failure. Force which is reduced at high
frequencies of stimulation (50 to 100 Hz) is referred to as high frequency fatigue
resulting from the impairment of transmission at the neuromuscular junction or
conduction of the action potential also inhibits force production.. These forms of
fatigue are identified by changes in the force-frequency relationship.
2.2.7.2.1. Metabolic causes of fatigue
Whilst controversy exists as to the aetiology of fatigue, it is well acknowledged that
metabolic factors contribute, although may not be entirely responsible, for the
reduction in force output. The accumulation of hydrogen ions (It), ammonia (NH3)
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and inorganic phosphate (Pi) impair force generation, whereas the depletion of ATP,
phosphocreatine (PCr) and glycogen elicit fatigue.
The association between lactic acid, formed in muscle under anaerobic conditions, and
force led to the belief that this by-product of glycolysis causes fatigue. Following much
debate (see Fitts, 1994 for a review), it has since been established that the free It
derived from the dissociation of lactate adversely affects force production through its
effects on glycolysis and/or on the contractile mechanism (MacLaren et al., 1989). This
is most significant at work loads above 50-60 % of maximal aerobic capacity
(Hermansen, 1971) and preferentially affects fast type II fibres. High intensity exercise
also results in the accumulation of ammonia and acts as a possible inhibitory metabolite
(Fitts, 1994). Similarly to lactic acid formation, ammonia accumulation is pronounced
in fast twitch fibres. An increase in the concentration of inorganic phosphate is also
implicated in the aetiology of fatigue, and is considered to have an inotropic effect on
force production. The binding of Pi to myosin alters the cross-bridge to a weak-binding
state (Pate and Cooke, 1989) hence reducing the tension generated by the cross-
bridge.
Whilst the increase in Pi is associated with fatigue, the lack of intracellular phosphate
may result in the reduction of PCr resynthesis affecting the availability of this
immediate energy store (Fitts, 1994) and the regeneration of ATP. A reduction in ATP
is a predominant factor involved in fatigue during short-term anaerobic work. Whilst
the exhaustion of glycogen influences the capacity to undertake high intensity
activities, this source of fatigue is important during submaximal exercise where slow
oxidative fibres are recruited. Using muscle biopsy, the depletion of glycogen stores
has been reported to be closely related to fatigue during sustained exercise at 65-75%
ofmaximal oxygen uptake (Hermansen et al., 1976).
It is impossible to isolate anyone metabolic factor in the cause of fatigue, although the
contribution from different metabolites is controlled by the intensity of exercise and the
fibre composition of the muscle involved.
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2.2.7.2.1. High frequency fatigue
Fatigue at the neuromuscular junction (NMJ) is the first site of fatigue resulting from
high frequencies of stimulation. Jones et al. (1979) reported a reduction in force
following stimulation at high frequencies of around 80 Hz after a few seconds of 10 to
20% of the initial value. This rapid force loss is accompanied by a change in EMG,
suggesting a failure of action potentials along the surface membrane of the muscle fibre
(Moxham et al., 1982). Stephens and Taylor (1972) proposed that during a maximal
voluntary contraction of the FDI, fatigue originates initially from failure at the NMJ.
Conversely, Bigland-Ritchie et al. (1982) found that NMJ failure is not responsible for
fatigue during the first 60 seconds of a maximal voluntary contraction and is therefore
not a significant factor.
The development of high frequency fatigue has been attributed to the accumulation of
potassium in the t-tubules and extracellular spaces, which results in the slowing of the
action potential (Jones et al., 1979, 1981). Observations on calcium gradients support
these propositions (Westerblad et al., 1990), although the effects of potassium on high
frequency fatigue is supported by Sacco et al. (1994). The tibialis anterior was
stimulated under ischaemic conditions at optimum and shortened lengths of different
frequencies. Delivery of 30 Hz to the shorter muscle generated the same characteristics
as stimulating the muscle at an optimum length at a higher frequency of 60 Hz.
Recovery was most rapid when the muscle was shortened. This is possibly due to the
restriction from shortened muscle in the movement of potassium which accumulates in
the t-tubules, and when the muscle is lengthened, the potassium can diffuse freely out
of these areas (Sacco et al., 1994).
The importance of high frequency fatigue is questionable since the firing rates of motor
units during voluntary contractions are within the range of 5 to 30 Hz. The fall in firing
rate from 30 Hz during sustained isometric contractions (Bigland-Ritchie et al., 1986)
appears to reduce the tendancy of fatiguing from high frequencies and thus preventing
the accumulation of potassium.
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2.2.7.2.2. Low frequency fatigue
Low frequency fatigue is characterised by a loss of force at low frequencies of
stimulation, and a right-hand shift in the force frequency curve (Fig. 2.3.5). Adequate
excitation of the muscle membrane suggests that failure of exitation-contraction
coupling occurs. This form of fatigue has been found to occur after dynamic exercise,
and may last up to 24 hours. Edwards et al. (l977a) have examined electrically
stimulated force generation of the quadriceps following box-stepping and cycling
exercise. They reported a reduction in 20 to 50 Hz tetanic tensions of 50% following
box-stepping and in one instance, cycling. This loss in force reflected the occurrence of
low frequency fatigue due to excitation-contraction uncoupling. This form is fatigue is
characterised by the slow recovery rate of up to 24 hours.
Davies and White (1982) investigated three types of dynamic exercise, level running,
uphill walking and box-stepping on low frequency fatigue. Twitch and tetanic tensions
following the box-stepping was reduced at 10 and 20 Hz, and 20/50 Hz ratio was
lower, which lasted 22 hours. Even though their results were similar to Edwards et al.,
(1977a), Davies and White (1982) claimed that their subjects were weaker, but not
more fatiguable following exercise. They also questioned the use of percutaneous
stimulation in generating force at 20 and 50 Hz, suggesting that the shape of the force-
frequency curve is voltage dependent. Edwards et al. (1984) have subsequently
reported that the 20/50 Hz ratio is a reliable indicator of force-frequency relationship
of the stemomastiod muscle using percutaneous electrical stimulation in fresh and
fatigued muscle.
The mechanisms involved in the loss of force resulting from a failure of excitation-
contraction coupling could be due to the impairment of sarcoplasmic calcium (Ca2+)
release or myofibrillar Ca2+ sensivity (Cooper et al.,1988). Force loss induced by
increases in myoplasmic inorganic phosphate (Pi)' causing myofibrillar Ca2+
insensitivity, cannot explain the persistance oflow frequency fatigue since Pi returns to
normal within minutes of cessation of activity. Metabolic or ionic changes are therefore
unlikely to cause low frequency fatigue characterised by a long recovery rate. It is
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possible that damage to the muscle fibre is responsible for this form of fatigue (Jones
1981), since it is most evident in muscles following eccentric or lengthening
contractions (Newham et al., 1983) and when the muscle is exercised isometrically at a
long length (Jones et al., 1989).
2.2.7.3. Relaxation rate
The slowing of relaxation following tetanic contractions is characteristic of fatigued
skeletal muscle. The reduction in relaxation rate is believed to be the contribution to
the maintenance of force (Jones, 1981), and prevent the muscle from performing rapid
continuous movements. Metabolic changes are suggested to regulate the relaxation
rate, although precise mechanisms are inconclusive. A reduced rate in the dissociation
of cross-bridges may be involved (Edwards et at, 1975), a process requiring the
removal of calcium by sequestration in the sarcoplasmic reticulum (Westerblad and
Allen, 1996). In a comparison of normal subjects and patients with myophosphorylase
deficiency, Cady et al. (1989) demonstrated that whilst It accumulation is responsible
for slowing of relaxation, there is another process which is independent of H', Wiles et
al. (1979) reported similar relaxation rates from electrically stimulated and volitional
contractions, but were not able to find a relationship between relaxation rate and fibre
composition, determined from muscle biopsy.
Whilst the purpose of the slowing of relaxation is apparent, the precise mechanisms
involved remain inconclusive. There is evidence to support the role of hydrogen ion
accumulation, although current evidence suggests that other factors are also involved
which have not been confirmed. A reduction in the rate of cross-bridge dissociation, an
ATP-dependent process, is implicated in the slowing of relaxation. Therefore, a
combination of metabolic factors which are difficult to isolate are responsible for the
slowing of relaxation, which occurs independently of fibre-type and the mode of
stimulation (electrical versus volitional contraction).
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2.2.8. Factors affecting muscle strength
The factors which affect muscle strength are numerous and to review them all would
exceed the scope of this thesis. The two most relevant factors appertaining to this
work are ageing and reproductive hormones. References to isometric, dynamic and
eccentric actions will be made.
2.2.8.1. Ageing
As life expectancy increases, so does the percentage population of elderly people.
Understanding the effects of ageing in skeletaI muscle has therefore become an
increasingly important area of research. Muscle strength is correlated with the capacity
to undertake activities such as walking speed and stair climbing (Aniasson et al., 1983).
A reduction in muscle strength will therefore compromise the functional status of the
elderly.
2.2.8.1.1. Muscle strength
Maximal strength is attained in young adulthood around 20-30 years, and declines with
age. This was first reported as early as 1835 by Quetelet, who found loss of strength
from 30 years (Larsson et al., 1979; Vandervoort and McComas, 1986; Narici et aI.,
1991). The onset of weakness has since been proposed to develop later, although there
is controversy as to when this occurs. Larsson et aI. (1979) found that maximal
isometric and dynamic leg strength measured on an isokinetic device is attained at 20-
29 years, and remains constant unti140-49 years. After 50 years, strength declined by
28.1 % at 70 years compared with a younger group. These findings are in agreement
with Asmussen and Heeboll-Nielsen, (1961), who reported peak isometric strength of
the knee extensors at 30 years in males. In females, strength peaked at 20 years and
decreased at an accelerated rate from 40 years. Aniansson et aI. (1983) found a
significant decrease in isometic and isokinetic torque in both sexes for the knee
extensors between 70 and 75 years, whereas Borges (1989) reported a significant
decrease in isometric strength at 60-70 years in males and females. A further 30% loss
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in peak torque of the knee extensors in both sexes was documented in 78-81 year olds
(Danneskiold-Sarnsoe et aI., 1984). Strength losses with age are more pronounced in
lower limb proximal muscles (Larsson, 1978). However, reductions in strength of
other muscles are also manifest. Under isometric (Vandervoort and Hayes, 1989) and
isokinetic (Cunningham et at, 1987) conditions, maximal strength of the plantar flexors
declined with age.
Eccentric strength is not compromised to the same extent as concentric strength for
knee extensors in elderly males and females (Vandervoort et al., 1990; Poulin et al.,
1992), although the mechanism for this is not known. Narici et ai. (1991) measured
maximum strength in a distal upper limb muscle, the adductor pollicis (AP), in males
aged 20-91 years and found that strength declined significantly from 59 years, and by
the eighth decade strength was 57.6% of males in the second decade. Frontera et al.
(1991) reported strength of the elbow extensors and flexors at 22.2 and 16.7% lower
respectively in older women. In a longitudinal, Kallman et al. (1990) found that grip
grip increased into the fourth decade, with an accelerated loss of strength thereafter.
However, they also found that many older subjects maintained their strength
throughout the duration of the 9 year study, whereas middle-aged and younger
subjects lost strength. These findings demonstrate that great inter-individual variation
in strength loss exist across all ages.
There is evidence to suggest that isometric strength is better maintained than dynamic
strength in the elderley. An increased speed-dependent loss of force with age has been
documented in several studies (Larsson, 1978; Larsson et al., 1979; Murray et al.,
1985; Harries and Bassey, 1990; Laforest et al., 1990). Aniansson et al. (1983)
reported a loss of force with increasing angular velocities which was more marked in
males and females aged 70 years. Since peak torque was recorded at a knee angle of
0.52 rad (60°) there was probably insufficient time to allow for maximal activation at
faster velocities. Borges (1989) reported that the time course, or onset, for the
significant reduction in isokinetic torque occurs between 40-50 years in females across
velocities of 0.21, 1.57 and 2.62 rad/s. This selective loss in dynamic leg strength
measured isokinetically at increasing angular velocities is attributed to a reduction in
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fast twitch fibres with age (Grimby and Saltin, 1983). This may be secondary to a
decrease in physical activity recruiting these muscle fibres.
2.2.7.8.2. Muscle mass
Muscle strength is proportional to the "active cross-sectional area" of the muscle
(Larsson, 1978). The relationship between strength and cross-sectional area (CSA)
(Ikai and Fukunaga, 1968) would therefore indicate that the decrease in strength is
attributable to a reduction in muscle mass. Indeed, substantial atrophy has been
detected in the quadriceps of old women, which was 33% smaller than young women
(Young et al., 1984) and 25% smaller in old compared to young males (Young et al.,
1985) ..
Changes in the components of muscle account for the decrease in muscle mass.
Atrophy of type II muscle fibres (Larsson et al, 1979; Lexell et al, 1988), a loss of
muscle fibres (Grimby and Saltin, 1983; Lexell et al., 1988) and a loss of functioning
motor units (Campbell et al., 1973) have been proposed. It has been claimed that the
loss of fibres begin at 25 years, and accelerates thereafter (Lexell et al., 1988). These
latter results support the increase in the speed-dependent loss of force with age.
2.2.8.1.3. Specific force
While a certain percentage of strength loss is attributable to a reduction in muscle
mass, there is growing evidence to suggest that there are qualitative changes inmuscle
such that weakness is greater than loss of muscle mass. This specific decrease in force,
has been reported inmice (Brooks and Faulkner, 1988; Phillips et al., 1991) and human
(Bruce et al., 1989) muscle. Brooks and Faulkner (1988) detected a decrease in force
per cross-sectional area (forceJCSA) of around 11% in the soleus muscle and 20% of
the extensor digitorum muscle (EDL) for isometric and shortening velocities. Phillips
et aI. (1991) reported a similar magnitude in loss of 13.3% for the soleus muscle in
aged mice.
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This weakness in animals has also been detected in humans. Using a method validated
for measuring CSA of the AP muscle (Bruce et al., 1989), a 27% reduction in
normalised force was found in elderly muscle compared with young controls,
confirming the occurrence of a specific loss of force in human muscle not attributable
to atrophy (Bruce et al., 1989). Young et al. (1984, 1985) reported a reduction in
maximal voluntary force/CSA for elderly males (Young et al., 1985) but not for elderly
females (Young et al., 1984). However, the problems inherent in accurately assessing
the CSA of a large, multi-pennated muscle group such as the quadriceps, particularly
when a large amount of atrophy has occurred, may have resulted in the failure to detect
such losses. Some ageing studies which have estimated muscle mass have failed to
detect a loss of specific strength. Frontera et al. (1991) proposed that muscle weakness
of knee and elbow extensors and flexors in the elderly was proportional to muscle
mass, as estimated from urinary creatinine excretion. Davies et al. (1986) found that
specific tension of the triceps surae was 40% lower in the elderly compared to young
subjects, although the error of calculating CSA from anthropometric measurements
probably disguised the 'real' change in specific force. Measurement error will always
confound accurate readings of CSA. However, there are improved methods of
measuring muscle size available, albeit expensive (i.e. nuclear magnetic imaging,
computed tomograghy). Using computed tomography, Overend et at. (1992) measured
the ratio of CSA and isometric (90°) and dynamic strength (2.09 rad/s) of knee
extensors and flexors. The authors did not report any age-related difference in
isometric strengthlCSA, although the concentric strength ratio was significantly lower
in elderly men, indicating a loss of strength greater than the decrease in muscle mass.
In humans, a reduction in specific strength has only been documented for isometric
strength.
2.2.8.1.4. Contractile properties
Ageing of skeletal muscle is not only characterised by changes in strength: alterations
in the contractile properties have also been found to occur. Electrically evoked
impulses of whole muscle demonstrate that time to peak tension and relaxation
time/rate are slower in elderly muscle compared with young for the triceps surae
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(Davies et al., 1986), adductor pollicis (Narici et al., 1991) and quadriceps (Beltran-
Niclos et al., 1995). Davies et al. (1986) reported not only significantly weaker muscles
in the elderly, but greater fatiguability. In contrast, Narici et al. (1991) found the AP
more resistant to fatigue in older subjects, possibly due to the decrease in size and
number of type II fibres and an increase in the fatigue resistance of the existing large
proportion of type I fibres. The inconsistency in findings are probably due to the
different muscles tested and the variation in fatigue protocols. A leftward shift in the
force-frequency curve (Narici et al., 1991) is supported in other studies of the human
quadriceps (Beltran-Niclos et al., 1995) and aged mice (Brooks and Faulkner, 1988).
This was suggested to occur as a result of significant muscle atrophy.
2.2.8.2. Reproductive hormones
A vast number of hormones have direct or indirect effects on skeletal muscle. For a,,
review, see FIorini (1987). The role of female sex hormones on muscle function has
received relatively little attention. This is surprising given the widespread use of
oestrogens to enhance meat production in farm animals (FIorini, 1987). The most
frequently used model for the examination of reproductive hormones on muscle
performance has been the human menstrual cycle. Lately, the endocrinopathology of
the menopause has also generated interest in its effects on muscle strength.
2.2.8.2.1. The human menstrual cycle
With increased participation of females in sporting activities, much of the earlier work
investigating the menstrual cycle on muscular performance was prompted from
speculation of a possible detrimental effect of the cycle phase on athletic performance.
Athletes have supported these claims, perceiving that the premenstrual and first two
days of the menstrual phase impairs performance (Erdelyi, 1962). However, it is the
studies which measure muscular performance objectively which have practical
applications. Wearing et al. (1972) measured hip flexion/extension and performances
from the standing broad jump, and reported that the poorest performance occurred
during menses, consistent with self-reports from athletes (Erdelyi, 1962), but peaked
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pre-menstrually. Quadagno et al. (1991) measured performance of weight-lifters and
swimmers at three phases, pre-menstrual, menstrual and post-menstrual across three
cycles. They did not report any difference over the three phases. The problems
associated with comparing explosive sports is the variability in the nature of the
activity, and fitness of the subjects who are prone to disruptive cycles with increasing
levels offitness (Loucks and Horvath, 1985).
Studies in which dynamic strength performances have been assessed under laboratory
conditions have failed to detect any changes in leg strength measured isokinetically
across angular velocities of 1.05 to 4.18 radls (Dibrezzo et al., 1988, 1991, 1994;
Richardson and George, 1993). Conversely, there have been several report of changes
in isometric strength across the menstrual cycle for different muscles (Wirth and
Lohman, 1982; Davies et al., 1991; Phillips et al., 1993a, 1996; Sarwar et al., 1995).
These studies, however, have not yielded consistent findings. Wirth and Lohman
(1982) reported greatest handgrip strength during the follicular phase compared with
the luteal phase. In another study, hand grip was highest during menses with respect to
the follicular and luteal phase (Davies et al., 1991).
Petrofsky et al. (1976) measured isometric grip strength in 7 females, 3 of whom were
taking oral contraceptives (OC). Whilst there were no changes in force production
between the pre-ovulatory and luteal phases in non-OC users, endurance time at 40%
of maximal isometric strength was lower during the luteal phase. The low number of
subjects tested may be accountable for this discrepancy with previous studies. Allen
and Bailey (1982) assessed grip strength in two groups of subjects, one group was
motivated and the other group was a control, across four phases - pre-menstrual,
menstrual, post-menstrual and mid-cycle - and found no significant change in strength
across the cycle between groups.
Motivating subjects does not guarantee maximal effort during a voluntary contraction.
Furthermore, the palmar flexors may be more difficult to maximally activate compared
with the quadriceps which are probably recruited more frequently at high intensities.
Sarwar et at. (1995) found that hand grip strength peaked mid-cycle compared with
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early follicular, mid-follicular, mid-luteal and late-luteal phases. Whilst maximal
activation of the palmar flexors was not determined, the pattern of force change
emulated those of the quadriceps, in which twitch interpolation confirmed that strength
changeswere peripherallymodulated.
These findings so far support a role of reproductive hormones influencing force
production. The variability in cycle phase and research design masks the hormone
milieu responsible for these changes. The most detailed study to date of the hormonal
fluctuations during the menstrual cycle is the work on the adductor pollicis (AP)
muscle. In a preliminary report, a peak in force of the AP was found during the
follicularphase with a rapid reduction around mid-cycleof20% (Phillips et al., 1993a)
In the full study, Phillipset al. (1996) made 8 measurements of force production of the
AP over 3 cycles, and interpolated missing values. The results supported their
preliminary findings of an ovulatory dip in force, preceded by a follicular peak in
strength.
These authors further advocate the role of oestrogen in exerting a positive inotropic
effect on skeletal muscle. The change in strength from peak to trough occurred within
2 days. Since the pre-ovulatory transient surge in oestrogen lasts -24 hours (Ojeda,
1992), these endocrinological changes could easily be missed. Furthermore, oestradiol
levels did not correlate with strength measured at the same time. Phillips et al. (1996)
attributed this discrepancy to a phase lag between oestrogen and muscle force changes.
Petrofsky et al. (1976) also suggested that some latency exists between hormonal
changes and the isometric muscular response. However, other studies which correlated
strength with oestrogen found similar results to Phillips et al. (1996). Bassey et al.
(1995) reported a negative association between oestrogen and handgrip strength,
which has been implicated in previous studies (Wirth and Lohman, 1982; Davies et al.,
1991). Rice (1988) performed a battery of strength tests during 1 to 5 days of the
menstrual cycle and correlated these indiceswith oestradiol levels. They did not detect
a significant relationship between these two variables. These results indicate that
another hormone in addition to/instead of oestrogen is likelyto be involved.
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Muscle function can also be described from the contractility of the muscle. Sarwar et
al. (1995) examined the contractile properties of the quadriceps through percutaneuos
stimulation at 5 phases - early/mid-follicular, mid-cycle, mid-luteal and late-luteal. A
leftward shift of the force-frequency curve as a result of slowing of relaxation was
reported at the ovulatory stage, when the muscle was also more fatiguable. The
mechanisms affecting these characteristics of contractile properties are probably related
to metabolic changes, such as an increase in Pi or decrease in pH (Cady et al., 1989)
rather than direct effects of reproductive hormones. The increase in fatigue resistance
mid-luteal has also been reported in respiratory muscles (Chen and Tang, 1989),
probably attributed to the progesterone-induced rise in basal body temperature,
resulting in an increased blood supply to the muscle and the reduction in fatigue. These
results however, are not consistent with findings of Petrofsky et al. (1976) who
demonstrated lower endurance mid-luteal compared with pre-ovulatory measurements.
With only two measurements, and few subjects (n=4) this latter study is flawed.
The effects of oral contraceptives on muscle strength have not been as well
documented, despite the widespread use of these exogenous compounds in athletes
(Lebrun, 1994). Despite few subject numbers, Petofsky et al. (1976) did not find any
difference in hand grip strength between the OC and non-OC users. Isometric
endurance at 40% maximal force was also stable in the OC group (n=3) but fluctuated
in the non-OC users, depending on forearm temperature. Wirth and Lohman (1982)
found no variation in isometric grip strength in ~C-users across two phases, but
reported lower endurance time and force production compared with non-OC's. The
lower strength values for the quadriceps and hand grip in ~C-users across 5 phases of
the cycle was attributable to lower body weight of the' control group (Sarwar et al.,
1995). The suppressive effects of endogenous hormones by oral contraceptives
stabilises force production in OC-users, and do not appear to be detrimentral to
muscular performance.
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2.2.8.2.2. The menopause
An examination of the time course of age-related losses in specific force of the
adductor pollicis muscle have revealed that the onset of this weakness differs between
males and females (Phillips et al., 1993b). A significant reduction in the force per
cross-sectional area (CSA) is manifest around 50 years of age in females, whereas in
males this force loss begins much later at 60 years plus. These results are shown in Fig.
2.3.7. These findings implicate an involvement of reproductive hormones influencing
force production, since women of this age group are experiencing declining levels of
reproductive hormones in response to ovarian failure. This has also been corroborated
in animal studies. Ovariectornised mice have a lower force/CSA of the soleus muscle
than young control mice (Phillips et aI., 1993c). Oestrogen deficiency is the single most
significant factor in post-menopausal osteoporosis (Riggs et aI., 1982) and Rutherford
and Jones (1992) reported a significant weakness of the quadriceps in osteoporotic
women compared with an age-matched healthy group.
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Fig. 2.2.7: The relation hip between mean (±SE) specific force and age in males and pre-menopausal
females 45 years and under (II), peri- or post-menopausal women (n=67) not on HRT (A) and peri-
or post-menopausal women (n=25) on HRT (V). Specific force is expressed as a percentage of the
mean value for young ubjects. From Phillips et al., 1993b.
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Whilsta reduction in reproductive hormones is associated with a loss of specific force,
its effects on absolute strength are conflicting. Petrofsky et al. (1975) and Cauleyet al.
(1987) observed a reduction in handgrip strength in females 50 years and older.
Handgrip strength in post-menopausal women was greater in those taking HRT,
although when age, height and physical activity were taken into account, hormone
status became less significant(Cauley et al., 1987). Bassey et al. (1996) examined data
from a large representative survey and reported muscle function parameters between
four groups of women. These comprised women who had regular menstrual cycles,
irregular menstrual cycles, post-menopausal, amenorrhoeic women and a group taking
hormone replacement therapy. There were no differences in leg extensor power or
isometric strength of the quadriceps or handgrip between the four groups after
correcting for fat free mass. In an older group of women (60 to 70 years), muscle
performance measured through conventional isotonic exercises (e.g. 1 repetition
maximum) was not significantlydifferent between oestrogen replacement users versus
hypoestrogenic females. Calmels et al. (1995) however, found that isokinetic
measurements of the elbow flexors at 0.52 and 3.13 radls declined rapidly during the
5th and 6th decades in post-menopausal females.
Phillips et al. (1993b) demonstrated a loss of specific force, i.e. a loss of force per
cross-sectional area. Comparisons in absolute strength may therefore be confounded by
differences in muscle size. The problems with measuring CSA in older women,
particulary using the technique employed by Phillips and co-workers is the increasing
amount of fat which replaces contractile material (Forsberg et al., 1991) which
exaggerates the amount of contractile tissue contributing towards force production.
This tends to be more pronounced in women taking HRT.
Hormone replacement therapy is proposed to confer protection against muscle
weakness associated with the menopause. Controlling for age, height and weight,
Phillips et al. (1993b) reported higher force/CSA in women taking HRT compared
with females who were not (Fig. 2.3.7.). In a recent large prospective randomised
controlled trial, 116 post-menopausal women were tested for handgrip strength over
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48 weeks and leg extensor power over 24 weeks. Hormone replacement therapy, of
oestrogen only or oestrogen and progestogen preparations, was not found to increase
handgrip strength or leg extensor power (Armstrong et aI.,1996). These findings are
consistent with those ofKohrt et al. (1995). Following the adminstration ofHRT of
the same preparation, 32 healthy women aged 60 to 72 years were tested over 11
months. Peak torque of the quadriceps and hamstrings at 0 and 1.05 rad/s did not
change in the control or HRT groups (Kohrt et aI., 1995).
The mechanisms by which reproductive hormones exert their effect is uncertain. In the
human adductor pollicis muscle of elderly (Phillips et at, 1991), hypo estrogenic post-
menopausal women (Phillips et al., 1993b), and in the soleus muscle of ovariectomised
mice (Phillips et aI., 1993b) weakness is restored by applying a rapid stretch during an
isometric contraction. Lengthening the muscle forces all the cross-bridges into the high
force state regardless of the force state at the onset of the stretch (Lombardi et al.,
1990). It is therefore apparent that the hormones may affect the equilibrium between
"high" and "low" force states at the cross-bridge. This model of varying tensions at the
cross-bridge is discussed in section 2.3.2.1. Phillips et al. (1993b) proposed that this
inotropic effect may be caused by oestrogen altering the sensitivity of the cross-bridges
to the metabolites inorganic phosphate [Pi] or lowered pH. The precise mechanism, or
the hormone responsible i.e. oestrogen or progesterone, has not been confirmed.
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CHAPTER THREE
THE DE\fELOPMENJT OF
EXPERIMENJT AL
METHODS
3.0. THE DEVELOPMENT OF EXPERIMENTAL METHODS
The aims of this chapter are to establish the inherent mechanical and biological
variability of the equipment employed in the experimental work (Chapter 4.0). Study
3.2 was undertaken to determine the reliability of the LIDO Active® isokinetic
dynamometer for measuring concentric strength across a range of slow and fast
angular velocities. The results are used in the design of the experimental protocol for
Study 3.3 in the assessment of reliability of muscular performance in middle-aged
women. Reliability of the strain gauge system, used for measuring volitional and
electrically stimulated contractions, is established in Study 3.4. These results will be
importantfor interpreting changes in musclefunction withfluctuations in endogenous
hormones in Chapter 4.2. Finally, the repeatability of the hand dynamometer for
measuringforce production of thefirst dorsal interosseus (FDI) is examined in Study
3.5. It is also important to determine the reliability of stimulating this small muscle
percutaneously.
3.1. Introduction
The assessment of skeletal muscle function, either pre- or post- intervention or in
single measurements, necessitates reliable and reproducible measures of force output
during day-to-day testing (Stokes, 1985). The degree of reliability, however, depends
on the purpose for which the results are used. The measurement of maximal strength
provides an index of muscle function and is a useful method to assess both ageing
populations and patients with myopathic disorders (Edwards et al., 1977b). Where
sequential measurements during treatment are necessary, it is important to reduce any
variability which may disguise real changes in strength. This can be accomplished
through carefully designed protocols, standardised application of the protocol and the
use of sensitive equipment (Frontera et al., 1993).
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3.1.1. Methods of assessingmuscle performance
Muscular performance is commonly assessed by measunng maximal voluntary
contractions in a static position. This facility is available on computerised isokinetic
dynamometers, although cheaper alternatives such as the strain gauge (Edwards et al.,
1977b) and torque transducer are commonly used. Many of the earlier studies
measured isometric strength of small muscles such as the adductor pollicis (Merton,
1954;Edwards et al., 1977b),jirst dorsal interosseus (Stephens and Taylor, 1972) and
abductor digiti minimi (Burke et al., 1974). In 1977, Edwards and Hyde introduced
the hand held myometer for measuring a muscle group where the patient was required
to push against the device, counteracted by the experimenter's resistance. Problems
were encountered with this technique, which included the lack of precise positioning
and the limitations of the strength of the tester, and thus its use was restricted to
children and adults with severe weakness. Unfortunately, the repeatability of these
pieces of equipment has not been reported and it is therefore difficult to compare
different devices for reliability.
The quadriceps muscle group, which has an important role as a weight-bearing muscle,
is most often examined isometrically (Young et al., 1984, 1985) using a strain gauge
systemwith the knee flexed at 90° (Edwards et al., 1977b). The coefficient of variation
(CV) for repeated measurements employing this method has been reported in young
females at 7.7% (Young et al., 1984) and 8% for young males (Young et al., 1985).
The use of CV as an estimate of reliability will be discussed later (section 3.1.2).
Electrical stimulation is routinely used to determine maximal activation of the muscle
during an isometric contraction (Merton, 1954; Belanger and McComas, 1981;
Rutherford et al., 1986) in which superimposed 1 Hz impulses disappear during
maximal contractions. In the quadriceps, the muscle is usually stimulated
percutaneously although suprarnaximalstimulation via the femoral nerve has been used
(Edwards et al., 1977b). This method is not advised since it is painful and there is
danger of dislocating the patella (Edwards, 1978). Smaller muscles with easily
accessiblemotor nerves e.g. adductor pollicis, can be stimulated supramaximally.
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Developments in the use of hand dynamometry have provided the opportunity for
measuring grip strength. This measurement is particularly useful in monitoring
generalisedor local disease (Anderson and Cowan, 1966) and is correlated with other
performance indices (Danneskiold-Samsoe et al., 1984; Kallman et al., 1990).
Repeatability studies on grip strength are limited.Kallman et al. (1990) reported a 6%
CV for repeated grip tests using an adjustable hand dynamometer in subjects aged 20
to 100years. When elderly subjects (7th decade) are considered separately, an increase
in CV to 14.1 and 13.7% are reported for females and males respectively (Anderson
and Cowan, 1966). It was not reported whether the CV represented repeated
repetitions or day-to-day trials.
Isometric contractions do not represent habitual daily movements and isokinetic
dynamometry which measures concentric strength, has therefore gained popularity
(Lord et al., 1992). Isokinetic devices allow dynamic movements through a range of
motion (ROM) where the velocity remains constant and the change in muscular torque
is 'accommodated' by the dynamometer. The reliability of these devices have been
assessed (Moffioid et al., 1969; Johnson and Siegel, 1978; Tredinnick and Duncan,
1988; Gleeson and Mercer, 1992), and CV's of 2.9 - 13.1% have been reported for
peak torque of the quadriceps at different velocities over separate days (Thortensson et
al., 1976;Naricietal., 1991;Gleeson and Mercer, 1992).
The movement involved in isokinetic dynamometry results in a change in muscle
length. Standardisation of positioning of the subject on the device is therefore a
prerequisite of testing. Reliable test protocols have been established to ensure maximal
efforts are recorded. Maximum warm-up contractions are required before recording
true peak torque (Johnson and Siegel, 1978) and a minimumof 3 trials is necessary to
achieve stable isokineticdata for peak torque (Gleeson and Mercer, 19922). Sawhill et
al. (1982) maintained that more trials are needed at higher angular velocities (6.96
rad/s). These results from young healthy subjects do not represent the performance
from other populations. In the elderly, for example, it has been reported that two trials
are insufficient in attaining stable peak torque (Murray et al., 1985; Harries and
Bassey, 1990; Frontera et al., 1993). Furthermore, a five percent increase was found to
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occur from the first to second repeated test at 1.74 radls in 68 year old females
(Harries and Bassey, 1990), twice that observed by Frontera et al. (1993). Murrayet
al. (1985) also reported a greater peak torque in the second test, although only the
isometric test at 450 reached statistical significance.
3.1.2. Statistical errors in repeatability studies
In many studies in which reliability has been reported for muscle strength devices,
incorrect statistical techniques have been used. Results from prior studies must
therefore be interpreted with caution. The analysis of variance or t-test techniques
determine if there are any systematic changes or trends in the data as a result of a
practice or familiarisation effect. If this is significant, subsequent tests of reliability are
invalid. The correlation coefficient is often employed to measure reliability (Francis and
Hoobler, 1987; Brown et al., 1992; Lord et al., 1992., Frontera et al., 1993). This
technique is highly influenced by the heterogeneity of subjects, and is a measure of
relationship rather than agreement (Bland and Altman, 1986). Intraclass correlation,
recommended for repeatability studies (Vincent, 1994), may also be compromised by
large inter-individual differences (Atkinson, 1995). The coefficient of variation (CV%)
measures agreement of test-retest data, and is reported as an index of reliability (Sale,
1991). This statistical technique is also subject to error and criticism. Firstly, there are
eight different methods of calculating CV which may yield different results. Secondly,
the CV should only be used if the variability increases as the scores diverge i.e. the CV
assumes that stronger subjects are more variable in repeated measures. This feature,
known as heteroscedasticity, is present if the relationship between the mean scores and
differences of test-retest data is significant. Finally, the CV uses the standard deviation
which excludes one third of the population ie. the CV does not imply a 95% error
range (Strike, 1991). To allow for this, the standard deviation should be multiplied by
1.96 (then divided by overall mean x 100). It is therefore apparent that the CV
reported in studies is underestimated.
Bland and Altman (1986) advocated the use of 95% limits of agreement for expressing
reliability. The agreement limits are calculated from the mean of the difference in test-
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re-test scores ± 2 standard deviations and assumes that for any new subject tested, two
repeated measurements would differ by ± newtons or less. Plotted on a graph, the
variability can be illustrated and interpreted more easily. If the data are prone to
heteroscedasticity a logarithmic transformation should be undertaken before plotting
the data. Each of the following studies will be analysed using the above techniques.
3.2. DAY-TO-DAY RELIABILITY OF LEG STRENGTH MEASURED
ISOKINETICALLY USING THE LID09 ACTIVE DYNAMOMETER
Aspects of this work have been presented at the British Association of Sport and
Exercise Sciences Annual Conference, Aberdeen, 1994.
3.2.1. Introduction
The reliability of the LIDO Active" dynamometer (Loredan, Davis, CA, USA) for
measuring leg strength, utilising the isokinetic mode, was assessed in this study. The
aims of the study were to:
1] Examine the day-to-day variability in maximal strength of the knee extensors
(KE) and knee flexors (KF) using reciprocal movements.
2] Assess the reliability of slow and fast angular velocities on maximal repeated
performance. These aims were fulfilled using a protocol adapted from
previous studies, as reported in the literature (Johnson and Siegel, 1978; Gleeson
and Mercer, 1992).
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3.2.2. Methods
(i) Subjects
Ten subjects, seven males and three females, volunteered to participate in the study and
gave written consent. Subjects were recruited if they were free of pain and injury to the
lower extremities. Ethical approval was obtained from Liverpool John Moores
University Human Ethics Committee. Table 3.2.1 summarises subject characteristics of
age, height and mass.
Table 3.2.1: Mean (:tsd) of age, height and mass of young, healthy subjects
Sex n Age (years) Height (em) Mass (kg)
Male 7 24.1 (1.6) 1.79 (0.61) 77.7 (13.1)
Female 3 25.3 (0.6) 1.66 (0.90) 57 (8.5)
(ii) Procedure
Dynamic concentric strength was measured on an isokinetic dynamometer (LIDO
Active", Loredan, Davis, CA). Each subject was tested with the same protocol on four
separate occasions, at least two days apart and at the same time of day (10.00±1 hr).
The first sessions was a familiarisation with the equipment and the procedures
involved. Subjects were measured for height and mass. The dominant leg was reported
as the right leg for the whole group.
A standardised warm-up was initially performed on a Monark Cycle ergometer for 5
min with no resistance, at 60 rev/min. This was followed by 3 min of static stretching
of the relevant muscle groups. The subjects were seated in an adjustable chair; the
upper body stabilised with straps secured across the shoulders, chest and hips. A
resistance pad was also positioned on the thigh, proximal to the knee joint to localise
the quadriceps and hamstrings (Plate 3.2.1).
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The axis of rotation of the dynamometer shaft was aligned with the axis of rotation of
the knee joint, midway between the lateral condyle of the tibia and the lateral condyle
of the femur. The cuff of the dynamometer's lever arm was attached to the ankle,
proximal to the malleoli. These positions were recorded for individual subjects and
standardised for subsequent trials. Range of motion (ROM) was preset to 0 to 90°.
The gravity compensation procedure required subjects to relax, while the leg was
passively extended and flexed through the entire ROM.
Subjects were instructed to grasp the handles adjacent to the chair during the tests and
they then performed two submaximal knee extension and flexion contractions. Testing
consisted of four reciprocal maximal voluntary isometric movements at angular
velocities of 1.05 rad/s, 3.13 rad/s and 5.22 rad/s. This testing order for velocity was
standardised from the slowest to the highest as recommended by Wilhite et al. (1992).
Each trial was separated by one minute of passive recovery. Verbal instructions were
also standardised and visual feedback was given. Gravity corrected peak torque was
selected from the strength indices as a measure of muscular performance.
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Plate 3.2.1. The isokinetic dynamometer (LidoActive", Loredan, Davis CA) measuring dynamic
strength of the knee extensors andflexors
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(iii) Data analysis
The Statistical Package for the Social Sciences (SPSS) and Excel (Windows version
3.1) were used for data analysis. The following tests were undertaken on the data for
each reliability study:
1. Analysis of variance with repeated measures (or t-test for two sets of data) was
employed to detect mean differences between the test-retest trials for leg extensors
and flexors across the range of angular velocities.
2. Parameters which revealed non-significant differences, indicating no trend in mean
strength, were analysed for error linearity i.e. the relationship between the mean and
differences of test-retest scores.
3. The 95% limits of agreement were calculated from mean difference between the
two tests ± standard deviation x 2. The Bland-Altman plots illustrate the deviation
from the mean across individual samples. If the error linearity was significant,
demonstrating heteroscedasticity, logarithmic transformations of the data were
performed. Significant differences also support the use for coefficient of variation
(CV%).
4. The coefficient of variation was calculated using conventional methods (SDI overall
mean x 100).
3.2.3. Results
The results of the repeated measures ANOV A and reliability measurements for leg
extensors and flexors across velocities are shown in Table 3.2.2.
Leg extensors
There were no significant differences (p>0.05) in peak torque between trials at each
velocity for muscle performance as revealed by the ANOV A results. There was a lack
of relation between mean scores and difference in test-retest data at all velocities,
hence the CVs reported are not 'true' indices of reliability. Peak force decreased with
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higher angular velocities (Fig. 3.2.1) and consequently limits of agreement were
narrower at 3.13 and 5.22 rad/s compared with the slower velocity of 1.05 rad/s.
However, at 5.22 rad/s the agreement limits were wider than at 3.13 rad/s. The
reliability at fast velocities must therefore be questioned.
Leg flexors
The ANOV A results do not reveal a serial effect over the three trials for any angular
velocity tested (p>0.05) (Table 3.2.2). At the slower velocities, the error linearity was
not significant. This relationship was significant at 5.22 rad/s (r = 0.68; p<0.05). The
95% limits of agreement for flexors across all angular velocities were high, whereas at
3.13 and 5.22 rad/s they exceeded those of leg extensors. This demonstrates that the
flexors have poor reliability since peak torque is much lower for flexion compared with
knee extension (Fig. 3.2.1).
Table 3.2.2: Results of the repeated measures ANOVA, coefficient of variation (CJIO/o), error linearity
and 95% limits of agreement for knee extensors and flexors of the dominant leg
Muscle group 95°/. limits of cvss F,.,values Error linearity+
Velocity (rad/s) agreement (Nm) (p values)
Right ntenson
1.05 rad/s -34.9 to 50.3 9.6 0.49 (0.62) 0.44
18.9*
3.13 rad/s -11.4 to 15.0 4.1 0.02 (0.98) 0.10
7.9*
5.22 rad/s -18.2 to 18.4 7.3 0.53 (0.62) 0.40
14.2·
Right Flexors
1.05 rad/s -31.4 to 33.8 12.7 2.35 (0.12) 0.31
24.8·
3.13 rad/s -20.9 to 13.1 8.2 1.93 (0.17) 0.45
16.1·
5.22 rad/s -17.0 to 10.8 7.9 1.22 (0.32) 0.68
15.5*..cv%. = standard deviation x 1.961 overall mean x 100
t ""the relationship ofr is calculated from the mean oftllt2 and the difference in scores
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Mean (± SEM) peak torque (Nm) for knee extension and flexion across three test
sessions are shown in Fig. 3.2.1. a) and b). It is evident that peak torque declines as the
angular velocity increases.
Fig. 3.1.1: Mean (±SE)peak torque of the leg extensors (a) andflexors (b) across three trials at
angular velocities of 1.05, 3.13 and 5.22 rad/s.
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The 95% limits of agreement are plotted on graphs (Fig. 3.2.2). They illustrate the
variability in strength performance under controlled conditions day-to-day.
Bland-Altman Plot of Knee Extensors at Bland-Altman Plot of Knee Flexors at 1.05
1.05 radls radls
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Fig. 3.2.2: shows the relationship between the mean (centre line) and difference in day-to-day scores
across a range of velocities for leg extensors and flexors. The outer lines denote the 95% limits 0/
agreement ± 2 standard deviations. Poor reliability or agreement is characterised by the deviation 0/
data points away from the mean.
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3.2.4. Discussion
Determining the inherent variability in repeated testing of muscular strength is
important for subsequent interpretation of changes in performance resulting from
experimental intervention, rehabilitation and/or training protocols. In the present study,
there were no significant changes in peak torque between test sessions at each velocity.
This indicates that performance was not affected by serial influences such as training or
learning, and that random error was responsible for overall variability.
The coefficients of variation (CV) were reported for comparison purposes. The mean
CV ranged between 4.1-12.7% depending on muscle group and angular velocity of
movement. These results compare favourably with other studies (Thortensson et aI.,
1976; Gleeson and Mercer, 1992) for gravity-corrected peak torque. The CV for
flexors was greater than those obtained for the extensors, although they are within the
range of normal biological systems of 10-15% (Stokes, 1985). The results suggest that
the test protocol is reliable and can be used to measure quadricep and hamstring
strength during sequential measurements. However, there was a lack of relation
between mean scores and differences in test-retest data (except for flexors at 5.22
rad/s), which contravenes the use of CV's. Coefficient of variation assumes that the
test-retest variability increases with the stronger subjects (Bland, 1987). Futhermore,
the CV's were much higher with the inclusion of the whole population (Table 3.2.2),
and thus may be deemed less reliable.
Under these conditions, it is important to report the 95% limits of agreements. They
give some indication of the variability in performance day-to-day, although the range of
values considered reliable is dependent on the judgement of the experimenter. The
limits of agreement of the extensors at the low velocity represent 15-23% of the mean
test-retest scores. Whilst this appears to be high, the corresponding CV is 9.6%. The
95% limits of agreement at 3.13 rad/s (7.0 to 9.0% of mean test-retest) indicate that
repeated measurements at this velocity are most reliable for the extensors. The
negative mean scores for flexors at 3.13 rad/s and 5.22 rad/s show a tendency towards
a decrease in performance from the second trial to the third trial. This reflects the
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greater variability observed in flexor strength measurements (Burdett and Van
Swearingen, 1987) which may be compromised by the reciprocal movements. This
variabilityis also reflected in the agreement limitswhich range between 12.0 to 26.3%
of the mean test-retest scores across all velocities. Therefore, greater verbal
encouragement is probably required when undertaking reciprocal movements,
particularlyduring flexion.
The results from this study have identified biological and mechanical variation as
sources of error, and any changes which occur from experimental intervention must
therefore exceed this variability. The risk of a type I error may otherwise confound
correct interpretation of muscular performance. The application of the coefficient of
variation is useful only if the same statistical methods are employed, the variability is
proportional to mean scores and adjustments are made for inclusion of the whole
population. Ifthese conditions are not met, then it is necessary to use the 95% limitsof
agreement, although it is difficult to compare reliability with other studies as this
technique is not yet widelyused.
In conclusion, day-to-day testing of peak torque on the LIDO Active" dynamometer
using the protocol described is recommended at slower angular velocities.
Measurements at faster velocities (5.22 rad/s plus) and of flexors at all velocities are
highly variable. Recommendations for future testing include the use of slower angular
velocities, with four efforts following a warm-up to record true peak torque. More
trials should be undertaken with the flexors, although care should be taken not to
fatigue the muscle groups. This is more important with the extensors when isometric
strength is also to be measured. These recommendations will be used to modify the
testing protocol and this will be examined in section 3.3.
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3.3. REPEATABILITY OF ISOKINETIC AND ISOMETRIC MUSCLE
STRENGTH IN MIDDLE-AGED WOMEN
3.3.1. Introduction
The reliability of isokinetic muscle testing in a young heterogeneous sample using the
LIDO Active" dynamometer has been established in section 3.2. These results
demonstrated poorer reliability for the flexors at all velocities, and at higher angular
velocities for the extensor muscles. It is important that the variability of measurements
be assessed in the population in which they are to be used (Stokes, 1985). If this
variability is large, erroneous interpretation of muscle strength changes may be made.
The aims of this study were to:
1] Examine the variability in leg strength using slower angular velocities of 1.05,
2.09 and 3.13 radls as recommended in sections 3.2.
2] Assess the reliability of isometric strength of the leg (900 knee flexion) and grip
strength.
3.3.2. Methods
(i) Subjects
Twenty three middle-aged females were recruited from staff at Liverpool John Moores
University after giving written consent. Eleven subjects were taking hormone
replacement therapy (HRT) and 12 were not receiving treatment. A questionnaire was
completed prior to participation to exclude subjects who suffered myopathic disorders,
and those who were physically active. Age, height and mass of subjects are
summarised in Table 3.3.1.
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Table3.3.1: Mean (r SD) for age, height and mass of post-menopausal subjects
Group n Age (years) Height (em) Mass (kg)
Range
Non-HRT 12 53.2 (4.5) 158.7 (6.0) 62.8 (9.9)
47-60
HRT 11 50.5 (4.8) 160.0 (6.2) 69.8 (13.3)
47-61
(ii) Procedure
Dynamic and isometric strength was measured on the LIDO Active'" (Loredan, Davis,
CA) dynamometer on three separate occasions within a two week period. Test sessions
were scheduled at the same time of day for each subject. The first visit to the
laboratory was used as a practice session.
Prior to testing, subjects cycled on a Monark drop-load cycle ergometer for 5 mins at a
low resistance, at 60 rev/min. This warm-up was standardised. Subjects were seated on
the dynamometer chair, positions were recorded for subsequent trials and muscle
function of the dominant leg was measured.
3.3.2.1. Dynamic muscle strength
Standardised measurements of muscle torque for extensors and flexors were made at
angular velocities of 1.05, 2.09 and 3.13 rad/s. The highest velocity measured in this
study was 3.13 rad/s according to the recommendations from section 3.2. The
procedure of use to measure isokinetic muscle strength have been described previously
(section 3.2). Two submaximal and 2 maximal warm-up trials were undertaken prior to
performing 4 maximal reciprocal movements. Subjects were encouraged to extend and
flex the leg as hard as possible. Instructions were standardised.
3.3.2.2. Isometric muscle strength
Maximal voluntary contraction (MVC) of the leg extensors was measured at 900
flexion of the knee joint 5 mins after undertaking the dynamic strength testing. The
quadriceps were isolated as much as possible and arms were folded throughout the
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test. Subjects were instructed to push hard against the measuring device until maximal
force was attained. Three maximum contractions were repeated, with 1 min rest
periods between each trial. The highest value was recorded.
Grip strength was measured using a hand-held dynamometer (Takei, model 5101 Grip-
D, Tokyo). Subjects were instructed to hold the dynamometer above the head with the
arm extended. The arm was brought downward whilst full force was exerted onto the
torque transducer. The highest grip strength of three maximal efforts was recorded.
(iii) Data analysis
The Statistical Package for the Social Sciences (SPSS) and Excel (Windows version
3.1) were used to analyse data. Mean strength between two test sessions was analysed
using the dependent t-test for paired sample. The error linearity, 95% limits of
agreement and coefficient of variation (CV%) were calculated according to the criteria
described in section 3.2.
3.3.3. Results
3.3.3.1. Dynamic leg strength
Leg extensors - concentric
The t-test revealed a significant difference in strength at 1.05 rad/s from test 1 to test
2, implicating a serial effect of repeated testing at this velocity (t=-2.67; p<0.05). This
did not occur at 2.09 or 3.13 rad/s, where the percent change in strength was much
lower (Table 3.2.2). The error linearity was not significant across all velocities and thus
the use of CV's is inappropiate in this instance. The 95% limit of agreement are plotted
in Fig. 3.3.1.
Legflexors
A significant difference between test 1 and test 2 data was also found at 1.05 rad/s
(t22= -3.49; p<O.Ol) and 2.09 rad/s (t22= 2.28; p<0.05). This is reflected by an 8.6 %
increase in mean strength at 1.05 rad/s. There were no significant changes at the faster
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velocity (3.13 rad/s). The variability of flexors are shown in Fig. 3.2.1, where the 95%
limits of agreement are illustrated.
3.3.3.2. Isometric strength
The results of the t-test did not show any significant differences in strength over the
two test sessions for isometric leg strength (t22= -0.43; p>0.05) or grip strength (b =
-0.37; p>O.OS).The r value from the error linearity test were also not significant (Table
3.2.2), hence the CV reported are not representative of its reliability. Bland-Altman
plots of all parameters, displaying the 95% agreement limits and the mean of test-retest
differences are plotted in Fig. 3.3.1 .
. Table 3.3.1: Mean (ISD), percent change and t values for test one and two.
Variable Test 1 (Nm) Test 2 (Nm) % chanae tuM
Knee extensors
1.05 rad/s 110.7 (25.8) 115.1 (27.8) 4.0 -2.67 (0.05)t
2.09 rad/s 83.6 (16.5) 84.7 (16.6) 1.2 -0.91 (0.38)
3.13 rad/s 65.0 (17.0) 65.2 (16.3) 0.3 -0.22 (0.83)
Knee flexors
1.05 rad/s 58.7 (12.7) 63.7 (15.5) 8.6 -3.49 (0.002)*
2.09 rad/s 48.5 (10.2) 51.0 (12.1) 2.2 2.28 (0.03)t
3.13 rad/s 40.4 (9.8) 40.4 (9.2) -0.1 0.05 (0.96)
Isometric
Leg 90° 103.9 (22.7) 104.9 (21.7) 0.96 -0.43 (0.669)
Grip 27.4 (4.58) 27.S7 (3.97) 0.66 -0.369 (0.716)
(ft Ibs) (ft Ibs)
tSlgmficant at p<0.05 levels for two-tailed t-test
• Significant at p<O.Ot level for two-tailed t-test
Table 3.3.3: Tests of agreement of the test-retest data - error linearity (r,) 95% Limits of agreement
and coefficient of variation ("/q) in middle-aged females.
Muscle group Error linearity 95% Limits of Coefficient of
(r) ae:reement (Nm) Variation (%)
Knee extensors *
1.05 radls -0.11 -16.0 to 24.8 9.0 17.7
2.09 rad/s 0.20 -11.0 to 13.3 7.4 14.5
3.13 radls -0.04 -7.6 to 8.0 6.1 11.6
Knee flexors
1.05 radls 0.t7 -7.6 to 17.7 11.3 22.2
2.09radls 0.29 -8.1 to 13.1 10.7 20.9
3.13 radls -0.17 -8.9 to 8.8 10.9 21.4
Isometric
Leg 90° 0.37 -20.2 to 22.1 10.1 19.5
Grip O.tO -4.02 to 4.36 (ft lbs) 7.6 14.9..• Coefficient of "lnlhoD (./.) .. standard deviation x 1.961 overall mean x 100
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Fig. 3.3.1: The relationship of the mean and difference in strength scores between day 1 and day 2
for different muscle groups and across varying velocities. The closer the mean (centre line) is to zero,
and central tendency of data points towards the mean, the better the agreement. The 95% agreement
limits (outer lines) represent both non-HRT and HRT subjects combined. The data points of both
groups have been plotted separately to show the variability. =Non-HRT; * = HRT group.
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3.3.4. Discussion
Sequential measurements of muscle strength are often required to evaluate responses
to treatment, monitor effects of training programmes and muscle weakness due to
disease, immobilisation and so on. It is therefore important that dynamic and isometric
strength are adequately reproducible for the sample population tested. In this study,
repeatability was assessed in middle-aged hypo estrogenic females and age-matched
subjects taking hormone replacement therapy (HRT), sample groups matched to those
required in study 4.1.
The results show that a systematic increase in strength of the knee extensors at 1.05
radls occurred between test 1 and test 2 (p>0.05), an increase of 4%. These results
agree with previous studies (Harries and Bassey, 1990), where a five percent increase
in strength measured at 1.74 radls was reported between the first two test sessions. An
initial practice session, given to mitigate this tendency, was not sufficient to familiarise
subjects with movement at this velocity. Strength of the flexors also increased
significantly by 8.6% (p<O.OI) suggesting that reciprocal movements are not effective
for attaining peak. torque of both muscle groups. The use of reciprocal, maximal
contractions have been criticised (Rothstein et al., 1987), although the reliability of
these measurements have been reported (Levine et al., 1991). The 95% agreement
limits, calculated for strength of the KE's at 1.05 rad/s (14 to 22% of mean test-retest
scores) were in the same range as those observed in young subjects. Increasing the
number of practice trials rather than sessions, may compensate for this learning effect.
This will be considered in future testing of the post-menopausal women of the
longitudinal study.
In agreement with the findings from young subjects, the flexors demonstrate poor
reliability. The coefficients of variation for this muscle group across all velocities were
high (Table 3.3.3), although the lack of linearity contravenes the use of this reliability
index. The variability of this muscle group has been documented previously for females
(Burdett and Van Swearingen, 1987), males (Gleeson and Mercer, 1992) and both
sexes (study 3.2). Even though a physiological explanation cannot be proffered, all
studies employed reciprocal movements during extension and flexion.
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Maximal isometric strength of the knee extensors measured at 90° of knee flexion was
lower than concentric strength assessed at 1.05 rad/s. These results do not conform
with normal force-velocity relations determined in vivo where torque decreases as
velocity increases (Thortensson et al.,1976), or corroborate previous findings in elderly
females (Harries and Bassey, 1990; Murray et al., 1985) and in males (Osternig, 1975;
Thortensson et al., 1976). In theory, greater strength is generated during static
contractions since more myosin cross-bridges have time to attach (Edman, 1992).
During dynamic contractions, there is less time for the formation of cross-bridges as
the fibres shorten. Less tension is therefore elicited. It is presumed that force
generation at 90° of flexion is lower due a mechanical disadvantage. At this angle,
fibres lengthen and less cross-bridges attach. The employment of twitch interpolation
through electrically stimulated contractions is important to confirm maximal activation
of the muscle (Rutherford et al., 1986). This technique was not available for this study,
but will be utilised in study 4.1, where it will be important to preclude central
inhibition/motivation as factors in muscle weakness.
So far, there has been no indication of heteroscedasticity in the data. It appears from
Fig. 3.2.1 however, that stronger subjects yielded greater between-test variability for
isometric grip strength than weaker subjects. Surprisingly, the correlation coefficient
was not significant, indicating a lack of relation between mean scores and difference in
test-retest data. The coefficient of variation (7.6%) compares favourably with 6%
reported for grip dynamometry of repeated measurements (Kallman et al., 1990).
However, as suggested by the r value, the 95% limits of agreement are more
appropriate to report the variability of this data. There is good consistency between
day-to-day testing, where the limits of agreement are within 15 to 16.0% of the mean
test-retest scores. The disadvantage with grip dynamometry is the difficulty in
standardising hand position in subsequent tests. This did not appear to affect
differences in the mean day-to-day scores in this study.
There was evidence of a learning effect at the slower angular velocity (1.05 rad/s). This
could be multifactorial as a result of too few familiarisation sessions, warm-up/practice
trials and/or greater effort involved in reciprocal movements. Extension and flexion
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should, therefore, either be performed separately or more contractions undertaken to
achieve stable peak torque values. The variability of the flexors across all velocities in
middle-aged women is consistent with the findings in young subjects. Isometric grip
and leg strength appear to be reliable using the methods employed, although twitch
interpolation should be used during maximal isometric contraction of the knee
extensors.
In conclusion, based on these findings the protocol needs to be modified before being
employed in the longitudinal study (section 4.1) so that a greater number of
practice/warm up trials are allowed prior to testing. This will ensure the attainment of
peak torque at 1.05 rad/s. The flexors were highly variable when measured in post-
menpausal women, as reported in younger subjects in study 3.2. The interpretation of
changes in strength of this muscle group are therefore made with caution.
Superimposed electrical impulses to the knee extensors during a maximal voluntary
isometric contraction is recommended to confirm maximal activation of the muscle.
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3.4. DAY-TO-DAY VARIATION IN MUSCLE FUNCTION OF THE
QUADRICEPS ASSESSED FROM MAXIMAL VOLUNTARY
CONTRACTION AND PERCUTANEOUS ELECTRICAL STIMULATION.
3.4.1. Introduction
In the previous study, the reliability of isometric leg strength measurements was
assessed using the computerised LIDO® isokinetic dynamometer. This system is not
sensitive enough to analyse force production from electrically stimulated contractions
using the isometric mode. It was therefore necessary to utilise a strain gauge system
similar to that described by Edwards et al. (1977b) to measure maximal 'voluntary
contractions (MVC) and force generated from electrically stimulated contractions of
the quadriceps. These included responses to a train of electrical impulses of increasing
frequencies, referred to as the programmed stimulation myogram (PSM), and the
fatigue index (FI%) calculated from the force loss induced by repeated electrical
stimulation. The reliability of the protocol designed to measure these indices of muscle
function will be examined in this section. Depending on the results of this study, the
protocol will be implemented and/or modified for the use in study 4.2, to assess the
temporal changes in reproductive hormones on muscle function.
The aims of the study were to:
1] Investigate the reliability ofMVC of the quadriceps utilising the strain gauge
system.
2] Assess the reliability and repeatability of forces generated from electrically
stimulated contractions of increasing frequencies.
3] Compare, and examine the reliability of two fatigue protocols of different
stimulation patterns.
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· 3.4.2. Methods
(i) Subjects
Twelve young males volunteered to participate in the study with mean (±Sd)
characteristics: age 27.1 (±3.1); mass 82.8 (±17.4); height 1.76 (±0.06). Written
informed consent was obtained after details of the experiment were explained. All
subjectswere free of injury to the lower limb and were required to undertake the same
activities24 hours prior to testing.
(ii) Procedure
Voluntary and electrically stimulated contractions were measured with the subject
seated in an adjustable chair with the leg suspended at a 900 angle. To prevent
extraneous bodily movements, the hips and shoulders were restrained with straps.
Force of the quadriceps was measured from the ankle, where the attachment was
connected to a strain gauge by a metal force transducer (Plate 3.4.1). The quadriceps
were electrically stimulated using surface electrodes (7.6 by 12.7 em, Chattanooga,
Bicester, UK) positioned on the proximal and distal anteriolateral side of the thigh of
the dominant leg. Electrical impulses were delivered through the electrodes at 250
volts with a pulse width of 200 us using a computer driven stimulator (Model DS7,
Digitimer Ltd, Welyn Garden City, UK). Force output was channelled through an
amplifier, interfaced with a data acquistion system (Biopac MPI00WS~ Santa Barbara,
CA).
(iii) Experimental protocol
3.4.2.1. Maximalvoluntary contraction
Maximal voluntary contraction (MVC) of the quadriceps was measured three times
with a 1 min rest between each effort. Maximal activation of the quadriceps was
confirmed using percutaneous electrical stimulation of 1 Hz impulses, delivered to the
95
muscle during each contraction (Rutherford et al., 1986). The disappearance of the
impulses indicates maximal effort as shown in Fig. 3.4.1. Subjects were required to
fold their arms during each contraction, and to 'kick out' as hard as possible and as
fast on instruction from the experimenter.
lOON[
Fig. 3.4.1. A voluntary contraction at differing levels of effort, showing the extra force generated by
superimposed twitches. AI maximum voluntary contraction, the superimposed twitches disappear.
From: Rutherford et al., 1986.
3.4.2.2. Electrical stimulation
3.4.2.2.1. Contractile properties
A train of electrical impulseswas delivered to the quadriceps at increasing frequencies
of 1, 10, 20, 50 and 100 Hz. Each tetanic stimuli lasted 3 s and aSs rest was
programmed between each frequency (Fig. 3.4.2). The current was estimated from the
maximal 1 Hz impulses tolerated. For subjects Whodid not respond favourably to the
voltage selected, particularly at the higher frequencies, the current was reduced until a
tolerable level was attained. Although the aim was to stimulate over 20% of the
muscle, the force generated at 100 Hz ranged 10 to 46 % of maximal voluntary
contraction across the sample. The force-frequency relationship, plotted as an index of
the contractile properties of muscle, is normalised so the lower frequences are
expressed as a percentage of the force generated at 100 Hz. The response of
quadriceps muscle group to this pattern of frequencies, termed the programmed
stimulation myogram (PSM), was examined in fresh and fatigued muscle and the
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reliability of this test assessed under both conditions. The ratio between low, unfused
tetani and high, fused tetanic contractions (20/50% or 10/100%), as an index to the
shape of the force-frequency curve, was calculated from the forces generated during
thePSM.
Fig. 3.4.2: A train of electrical impulses (1,10,20,50, 100, 1Hz) of three seconds duration, with 5
seconds rest, delivered 5minutes be/ore, and immediately after thefatigue test. The unfused tetani at
10 and 20 Hz are evident in this myogram (as shown by arrows).
3.4.2.2.2. Fatiguability
Fatigue of the quadriceps was induced using electrically stimulated contractions,
modified from the protocol of Burke et al. (1973). Two different fatigue exercises
were employed to determine the most reliable and effective protocol for inducing
fatigue. Frequency of 40 Hz impulses were delivered over 3 min in both tests, with
differences in the duration of stimulation and on/off times of contractions. In the first
fatigue test, impulses lasted 3 s with aSs rest interval. In the second protocol, 1
second impulses were separated by a 1 s rest interval. The force generated during the
last 5 twitches of the test was expressed as a percentage of the initial 5 twitches and
called the fatigue index %.
The tests of muscle function of the quadriceps were assessed 6 times over a 3-month
period. The two fatigue protocols were assessed across 3 trials each, whereas other
indices of muscle function (MVC, contractile properties) were examined during the
initial three sessions. A standardised 5 min warm-up on a cycle ergometer (Monark) at
70 rev/min preceded the strength tests which were conducted at the same time of day
(± 1hour) on each occasion.
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The experimental protocol was as follows:
• 5 min warm-up on cycle ergometer
• 1 Hz impulses - to determine maximal tolerable current for MVC
• Stimulation at 1, 10, 20, 50, 100Hz - to determine maximal tolerable current
e 3 min rest:
• Maximal voluntary contractions x 3
e 5 min rest
• Stimulation at 1, 10, 20, 50 and 100 Hz
e 5 min rest
• Fatigue test
• Stimulation at 1, 10, 20, 50 and 100 Hz
(iv) Data analysis
The Statistical Package for the Social Sciences (SPSS) and Excel were used for data
analysis. Repeated measures ANOV A was initially performed on the data. If no serial
trends occurred, the error linearity test, 95% limits of agreement and coefficient of
variation (CV%) were calculated between data of test 2 and 3. These methods have
been detailed in section 3.1.
3.4.3. Results and Discussion
3.4.3.1. Maximal voluntary strength
There were no significant differences in MVC across the first three test sessions (F2,22
= 0.11; p>0.05). This suggests that there were no learning influences during the initial
tests. This is not an indicator of agreement and further analyses were subsequently
undertaken. The linearity between mean scores and difference of test and retest data
was non-significant (r = -0.36). This lack of relation violates the use of the coefficient
of variation as discussed earlier (section 3.1). For comparison purposes, however, CV
was calculated across all parameters. The CV's of both methods are shown in Table
3.4.1. The CV (%) for isometric strength of the quadriceps was 6.8%, compared with
9.6% for dynamic leg strength at 1.05 radls (see section 3.2). Other authors who have
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used a similar device reported CV between 2 tests at 4.0% and 4.4% for young and
elderly females respectively (Young et al., 1984). The present results compare
favourably with those obtained in previous research. However, in addition to the
characteristics of the data which do not uphold the use ofCV (ie. lack of linearity), the
high CV of 13.4% calculated here is the result of using the adjusted method. The 95%
limits of agreement (-90.7 and 89.73N) are plotted in Fig. 3.4.5.
3.4.3.2. Contractile properties
Electrical stimulation is used to assess muscle function and reveal the characteristics of
contractile properties beyond that of maximal voluntary contractions. The pattern of
force generation with increasing frequencies of electrical impulses enables the force-
frequency relationship to be established and the identification of the nature of fatigue.
The shape of the force-frequency curve can be revealed by examining the force
generated at low frequencies as a percentage of force at high frequencies. The most
reliable index - 10/100 or 20150%, in fresh and fatigued muscle will be reported.
3.4.3.2.1. 101100% ratio
Fresh muscle
The results of the repeated measures ANOV A found that the mean ratio of 101100 %
in fresh muscle were not significantly different across the three test sesions (F2.22=
0.72; p>0.05). The coefficient of variation was large (22.1% and 44.3% after
accounting for 95% of the population), indicating poor reliability. Even though the lack
of linearity contravenes the use of CV, the 95% limits of agreement concur with the
poor reliability of this ratio, with a range of ± 44.0% of the mean test-retest scores
(Fig. 3.4.6).
Fatigued muscle
There were no sequential effects of the 10/100 % across three test sessions following
the first (F2.22= 2.27; p>0.05) and second (F2.22= 1.86; p>0.05) fatigue protocols. The
reliability indices are shown in Table 3.4.1. The 95% limits of agreement were
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narrower after the second protocol (ranging -29.5 to 44.8% of mean test-retest scores)
compared to the first protocol (-36.1 to 50.44% of mean test-retest scores) although
neither test demonstrated good repeatability. This is also reflected by the high CV's
(unadjusted values of21.6 and 18.6% for the first and second protocols respectively).
The error linearity was non-significant and therefore the limits of agreement are
important for interpreting the reliability of this data.
3.4.3.2.2.20150%
Fresh muscle
The 20150 % ratio is used more often as a characteristic of the force-frequency curve
compared to the 10/100% ratio. Over the first three trials of the test-retest data, there
were no significant differences in the 20150% (F2,22 = 2.24; p>0.05). The mean
difference between test 2 and 3 was high (3.28 N) although the CV (9.8 or 19.2% for
adjusted population) was much lower compared to the 10/100%. The 20/50% is
therefore more reliable than the lower ratio, as indicated by the 95% limits of
agreement (ranged 14 to 25% of mean test-retest scores) (Fig. 3.4.6). The CV's
reported here are considerably higher than that documented for the quadriceps (5.5%)
(Edwards and Newham, 1984) and sternomastoid muscle (4.5%) (Edwards et al.,
1984) measured in a single person. However, the detail of calculating CV by these
authors was not reported. The overall mean of the 20150% was lower (66.5%)
compared with 80.7% reported by Edwards and Newham (1984), which could be
attributable to the differences in force generated in the two studies. The percutaneous
stimulation of the quadriceps, activating only a portion of the muscle, has been
questioned in previous work (Davies et al., 1982), with claims that the relationship
between forces produced at low- and high- frequencies are voltage dependent.
Edwards and Newham (1984) reported forces >10% MVC with 50 Hz stimulation
compared with 10-46% MVC at 100 Hz for the sample in this study. Even though the
authors claimed this ratio to be reliable, they were cautious about its reliability at very
low levels of voltage. The present results suggest that the 20150% ratio is more reliable
than 10/100% in fresh muscle.
100
Fatigued muscle
The 20150% ratio, calculated across three test sessions following two different fatigue
protocols, were not significant different the first (F2,22 = 0.14; p>0.05) or second
fatigue protocols (F2,22 = 0.38; p>0.05). The unadjusted CV increased from 9.8% in
fresh muscle to 13.6% and 16.6% following the first and second fatigue test
respectively. Edwards et al. (1984) also reported an increase from 4.5% in fresh
muscle to 7.4% in the fatigued state for the sternomastoid muscle. The 95% limits of
agreement are shown in Table 3.4.1.
3.4.3.2.3. Force-frequency relationship
The response of the quadriceps across a range of stimulation frequencies is illustrated
in Fig. 3.4.3. Mean forces generated at each frequency did not vary across the three
trials. The ratios described above give an indication of the characteristics of the force-
frequency curve.
Force-Frequency Relationsbip Across Three Trials
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Fig. 3.4.3: The force-frequency curve over a range of stimulation frequencies of 1, 10, 20, 50 and 100
Hz. The comparison between three controlled test sessions.
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3.4.3.3. Fatiguability
Force generation at the end of the fatigue test was expressed as a percentage of the
initial value and termed the fatigue index (FI%). Two fatigue tests were performed to
i] determine which test is most effective inducing fatigue and ii] assess the
reproducibility of both protocols. The first test involved stimulating the muscle for 3 s,
with a 5 s rest period. The quadriceps in the second test were electrically stimulated for
1 s, with I a s rest. The frequency of stimulation of both tests was 40 Hz, and the
duration of stimulation lasted 3 min. The peak and mean tension of the impulse were
recorded and analysed separately.
Test 1 - ANOV A did not reveal any significant changes in FI% for peak tension (F2•22
= 0.11; p<0.05) or mean tension (F2.22= 0.16; p<0.05) over three test sessions. Thus,
any day-to-day fatigue or learning effects were controlled. The unadjusted CV (9.9 and
11.0 for PT and MT respectively) were within the 'acceptable' range for biological
systems (Stokes,1985), although the lack of linearity and high adjusted values do not
render the use of this reliability index. The limits of agreement are reported in Table
3.4.2. The fatigue trace in Fig. 3.4.4 illustrates the force loss over 3 min.
1 minute.. .
Fig. 3.4.4. The fatigue trace of the first protocol showing the force loss across time.
Test 2 - There were no significant differences in the test-retest data of the second
protocol for peak tension (F2.22= 0.9; p>O.05) and mean tension (F2•22 = 0.25; p>0.05),
excluding a serial effect of repeated testing. There was also a lack of linearity between
the mean scores and difference between test 2 and 3 in this method (r values in Table
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3.4.2.) which contravenes the use of CVs. Despite this, the CV (%) did not differ
widely between the two protocols. The second protocol was more comparable to the
fatigue test employed in other studies than the test of 3 s stimulation. The coefficient of
variation of the fatigue index documented for the adductor pollicis (16%) and the first
dorsal interosseus muscle (15%) (Rutherford and Jones, 1988), where the muscle is
stimulated for 250 ms every second for 3 min, are higher than those reported for the
quadriceps in this study. However, because of the different statistical methods of
calculating CV, it is misleading to make comparisons of different muscles across
studies, particularly if the error linearity is not known. Fig. 3.4.5 illustrates the fatigue
loss across this test.
1 minute
Fig. 3.4.5: Thefatigue trace of the second protocol. Force loss is greater across the test.
Many factors affect the force generated and rate of fatigue produced during electrically
stimulated contractions. These include stimulation intensity, pulse frequency, length of
test, duration of stimulus and on/off times. The first three factors were controlled or
standardised for each test, the latter factors were manipulated in two different
protocols. Any discrepancies between test-retest data were therefore due to random
variation. The 95% limits of agreement were slightly narrower for the first protocol
which may suggest better repeatability, although these differences were very small
(Table 3.4.2). Magnitude of force loss was significantly greater in the second protocol
for peak tension (PT) (36.7%) and mean tension (MT) (40.9%) (Fig.3.4.5) compared
with PT (21.7%) and MT (23.2%) of the first protocol (Fig.3.3.4). Significant
differences were found between these tests for the two parameters (PT - t=6.616; MT
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- t=6.635;p<0.01). The second protocol was considered a more effective method of
inducing fatigue.
In summary, ANOVA has shown that there were no learning effects across the three
trials for any parameter measured. The variability between test-retest trials were
therefore due to random biological and mechanical variation. The lack of linearity
between the difference in test-retest data and mean scores excluded the use of CV,
although this is the most frequently reported index of reliability across previous studies
and has therefore been calculated for comparison here. The 95% limits of agreement
are important despite a less defined interpretation of reliability; the degree of reliability
is judged by the experimenter. In conclusion, the protocol used in this study was not
subject to learning or serial influences of repeated testing, and will be employed in
study 4.2 to investigate the effects of endogenous reproductive hormones on muscle
function. The random variability was quite large however, particularly for electrically
stimulated contractions. This could be due to electrode placement and level of voltage.
Extra care will therefore be taken to standardise these variables. Following close
examination of the results, the use of the 20/50% ratio and the second fatigue protocol
(I s intervals) appears to be more consistent and reliable indices of muscle function
than the 10/100% and first fatigue protocol (3 s stimulation) respectively.
Table 3.4.1. Test-retest reliability indices for maximum voluntary contraction (MVC), 101100 and
20150 Hz ratios fA; in fresh andfatigued muscle.
FRESH FATIGUED
MVC 10/100 (%) 20/50 (%) 10/100 (%) 20/50 (%)
(N) Test t Test 2 Test 1 Test 2
Mean Difference -0.492 -0.025 3.283 2.27 2.42 0.79 1.81
SO (45.1 I) (6.01) (6.51) (6.85) (5.90) (8.02) (9.43)
OveralJ mean 660.64 27.19 66.51 31.66 31.76 58.8 56.73
Linearity (r) -0.36 0.18 0.21 0.07 0.17 0.01 0.06
CV%
t 6.8 22.1 9.8 21.6 18.6 13.6 16.6
: 13.4 43.3 19.2 42.4 36.4 26.7 32.6
95% -90.7 to - 12.1 to -9.7 to -11.43 to -9.38 to -15.2 to -17.1 to
LA 89.7 12.0 16.3 15.97 14.22 16.8 20.7
t SD of differences divided by overall mean x J 00
: SD x 1.96 divided by overall mean x 1
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Table 3.4.2: Test-retest reliability for fatigue index (FI%) of peak tension and mean tension
(expressed as the endforce as a percentage of initial force). Test1 involved stimulating the muscle for
3 s with a 5 s rest. One second impulses were delivered in test 2 with a 1 second rest.
FATIGUE TEST
METHOD Test 1 Test 2
Peak tension Mean tension Peak tension Mean tension
Mean of Di fference -0.56 0.32 42.21 1.03
(± SD) (7.79) (8.45) (8.20) (6.66)
Overall mean • 78.3 76.8 63.3 59.0
Error linearity (r) -0.46 -0.1 0.14 -0.06
CV%
Unadjusted t 9.9 11.0 12.9 11.3
Adjusted: 19.5 21.6 25.4 22.1
95% Limits of Agreement -ro.t to -17.2 to -14.2 to -LU to
15.0 16.5 18.6 14.4
• Test + retest
t SD of differences divided by overall mean x 100
: SD x 1.96 divided by overall mean x 100
95%U are the 95% limits of agreement
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Fig. 3.4.6: The relationship between the mean scores and difference in test-retest data for MVC,
101100%and 20150%infresh muscle.The outer lines represent the 95% limits of agreement where sd
denotes ± standard deviation. The broken line is the overall mean of the test-retest data.
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3.5. RELIABILITY OF A HAND DYNAMOMETER FOR MEASURING
MUSCLE FUNCTION OF THE FIRST DORSAL INTEROSSEUS MUSCLE
(FDI)
3.5 .1. Introduction
Small muscles, such as the adductor pollicis (AP) and first dorsal interosseus (FDI) are
often used for assessment of muscle function. They are easily accessible and less
complex than larger, multiple groups and can be stimulated painlessly via their
respective motor nerve. The hand dynamometer used in this study and later chapters
was constructed to measure force of the FDI. It was portable and could therefore be.
transported for testing outpatients visiting The Liverpool Women's Hospital. The
dynamometer was utilised for the measurement of force production of the FDI from
maximal voluntary contractions (MYe) in studies 4.2, 4.3 nd 4.4, and electrically
stimulated contractions in studies 4.3 and 4.4. The aims of the study were to:
1] Establish the reliability of the FDI for measurements ofMYC using the hand
dynamometer
2] Assess the repeatability of the forces produced from electrical stimulations
delivered percutaneously.
3] To measure force loss induced from repeated electrically stimulated contractions.
3.5.2. Methods
(i) Subjects
Young males subjects (n=14) gave written consent to participate in the study. Mean
(±SD) characteristics are age:26.9 (4.37), range 22-39 years; mass: 77.6 (8.45) kg;
height: 175.7 (6.97) metres. Subjects were excluded if they suffered pain or discomfort
of the hand, or were taking any medication likely to affect performance.
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(ii) Experimental procedure
Maximal voluntary contraction, contractile properties and fatigue resistance were
assessed on 3 occasions, separated by 3-5 days. Force production was measured using
a custom-built dynamometer designed to isolate the FDI muscle. The forearm, which
rested on the diagonal slope of the platform, was secured at the wrist, mid-forearm and
lower portion of the elbow joint. The lateral side of the distal interphalangeal joint of
the index finger was aligned with the force transducer attached to a strain gauge
(Model UL4000, Maywood Instruments Limited, UK). The strain gauge was
calibrated with known weights. The thumb was fully abducted and secured with a strap
around the proximal phalange. The remaining fingers were strapped together and
restrained by velcro webbing to prevent force production from other muscles (Plate
3.4.1.). Upward movement of the index finger was prevented by a clamp tightened at
the base of the phalange. The position of the hand was standardised for each session to
ensure the muscle length was consistent between trials. The hand and forearm were
initially immersed in warm water at 44°c for 10 min to increase blood flow and
throughout the experiment a reading lamp was positioned at a standard distance over
the muscle. Whilst muscle temperature was not measured, this procedure was
standardised and repeated on both occasions in an attempt to standardise muscle
temperature.
The FDI was stimulated percutaneously with self-adhesive surface electrodes (3S
healthcare, London, UK). The cathode was positioned on the belly of the FDI and the
anode placed near the carpometacarpal joint of the thumb. The muscle was stimulated
with 1 Hz and a 40 Hz tetani to confirm accurate location of the electrodes. Electrical
impulses were applied at 150 volts at a pulse width of 100 us duration with a computer
driven Digitimer stimulator (Model DS7, Digitimer Ltd, England). The force output
was amplified and visually displayed on an Apple Macintosh computer, interfaced with
a data acquisition system (Biopac MPIOOWS, Santa Barbara, CA).
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Plate 3.5.1. Dynamometer howing the index finger in relation to 1J force transducer 2J electrodes
and 3J thumb
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3.5.2.1. Maximal voluntary contraction
Maximal voluntary contraction of the FDI was measured whilst fully abducting the
index finger. This is the only muscle involved in producing this movement.
Superimposed percutaneous stimulation was employed to ensure maximal activation of
the FDI. Disappearance of the 1 Hz impulses confirmed maximal volitional force. Each
trial was preceded by a 60 seconds rest interval. The highest of three trials was
recorded.
3.5.2.2. Contractile properties
A train of electrical impulses were delivered percutaneously to the FDI using the same
protocol as the leg of 1, 10, 20, 50 and 100 Hz of 3 s duration, with a 5 s recovery.
The frequency at low velocities was expressed as a percentage of high frequencies
(10/100 and 20/50%) to characterise the force-frequency curve. This method has been
described in section 3.4.
3.5.2.3. Fatigue characteristics
Fatigue resistance of the FDI was assessed using a protocol modified from Burke et al.
(1973). This involved repeatedly stimulating the muscle for 3 min at 40 Hz with a 1 s
interval between each tetanic contraction. This protocol was adapted, based on the
recommendations in section 3.4. Using percutaneous stimulation, forces generated at
100 Hz ranged 5-53.7% (mean of 30.14% ±14.3) MVC. Typical myograms of a
tetanic contration in a fresh and fatigued state are shown in Fig. 3.5.1.a] and b]. The
fatigue index (FI%) was calculated as for the leg (end force as a percentage of initial
force). Speed of relaxation was measured as the time taken for peak force to reach
half-peak force. A 5 min rest was allocated between the train of increasing frequencies
and before commencing the fatigue test.
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Fig. 3.5.1: A 40 Hz tetanic twitch offresh [a] andfatigued [b] muscle. The horizontal arrow
represents the half-relaxation time (time taken/or muscle to reach half-relaxation).
(iii) Data analysis
The statistical methods of analysing the data have been described previously (section
3.2). A repeated measures ANOVA was initially used to identify any trends over the
test sessions. If a serial effect did not occur, the error linearity and 95% limits of
agreement were calculated between the first two tests. The coefficient of variation was
calculated irrespetive ofr, for comparison purposes.
3.5.3. Results and discussion
3.5.3.1. Maximal voluntary contraction
There were no significant differences in maximal voluntary contraction (MVC) over
the three trials (F2,24= 0.51; p>o.05). There was a lack of relation between mean
strength scores and test-retest difference and thus the 95% limits of agreement were
used to interpret the reliability. The overall mean was 44.18N with -8.54 to 8.43 N
95% limits of agreement (ranging ±19% of mean test-retest scores) (Fig 3.5.2.).
Hence, for any new young subject tested, two repeated measurements (including the
first visit) would differ by 8 N or less. Changes in strength due to hormonal influences
would have to exceed 8 N or otherwise they would be disguised by the inherent
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variability. Unadjusted CV was 9.6% compared with 12% for the FDI in other studies
(Rutherford and Jones, 1988).
3.5.3.2. Contractile properties
The repeatability of day-to-day measurements of contractile properities of the FDI
were assessed by comparing the forces generated at low frequencies with those at high
frequencies (10/100 and 20150% ratios).
3.5.3.2.1. 101100% ratio
There was no significant difference in the 10/100% ratio over the three trials (F2,24 =
1.10; p>0.05). There was a lack of linearity between mean scores and differences in
test-retest data (r= 0.46), and CV's were very high (64.1 % and 125.6% for unadjusted
and adjusted data respectively). This compares with 15.9 and 32.3% found for 20/50%
ratio, respectively. The 95% limits of agreement are also very wide (Fig 3.5.3) (-131.0
to 125.3 % of mean test-retest scores) which further suggests poor reliability of this
ratio as a feature of the force-frequency curve. This ratio will be excluded from
analysis in the experimental studies.
3.5.3.2.2. 20150% ratio
The repeated measures ANOVA was not significant for the 20/50% ratio over the
three trials (F2•24 = 1.43; p>0.05). The overall mean of the two trials was high (-3.95)
denoting a decrease in the percentage of this ratio from the first to the second test.
This was not statistically significant. The overall mean of 72.2% compares with 80.7%
for the quadriceps (Edwards and Newham, 1984) and 79.0% for the
sternocleidomastoid muscle (Edwards et aI., 1984). Results are shown in Table 3.5.1.
The limits of agreement demonstrates that this ratio is more reliable than the lower
ratio (10/100%) and will be used in the study 4.4.
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3.5.3.3. Fatiguability
There were no significant differences in the ANOVA for peak tension (F2,20= 0.08;
p>0.05); mean tension (F2,20= 0.35; p>0.05) or relaxation time (F2,20= 0.31; p>0.05)
across the three trials. The differences in test-retest data are shown in Table 3.5.2.
Overall mean of peak tension (49.2 N) was higher compared with mean tension (44.1
N), although the reliability does not differ. Relaxation time however, has poor
reliability, with a high mean difference and wide 95% limits of agreement. This is not
demonstrated by the CV and it was therefore not surprising that error linearity was not
significant. Table 3.5.2. lists the results of these parameters.
The reliability of the dynamometer for measuring muscle function of the FDI has been
assessed over three day-to-day sessions. The ANOV A results were not significantly
different for all variables measured, precluding a learning or familiarisation effect of
repeated measures. This is important since a practice session is not possible in the
experiments where this protocol will be employed. The variability is quite large,
possibly due to the inter-individual differences in stimulation intensity. Intra-individual
voltages were kept constant..
In conclusion, maximal volitional and electrically stimulated contractions are not prone
to a serial or learning effect measured day-to-day, and can therefore be used in studies
4.3 and 4.4, where a familiarisation session will not be given. The 95% limits of
agreement indicate that the measurement of maximal voluntary contraction of the first
dorsal interosseus muscle, using the hand dynamometer, is reliable. There is greater
variability with forces generated from electrically stimulated contractions. This is more
pronounced for the 10/100% ratio, and therefore this index of force/frequency will be
excluded. This poor reliability was also reported for the quadriceps. Relaxation rate
was highly variable, but will be reported as a measure of the speed of muscle. There is
a concomitant increase of the CV with the limits of agreement for electrical stimulation
compared with those reported for maximal force production. It is anticipated that the
repeatability of these variables will be enhanced if increased voltages are used.
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However, not all subjects were tolerant of higher voltages. This may be overcome with
supramaximal stimulation of the ulnar nerve. This was not undertaken due to problems
forseen with patients recruited and tested at the hospital, unfamiliar with the sensations
and procedure.
Table 3.5.1: Test-retest reliability for maximum voluntary contraction (MVC). 101100 and 20150 Hz
ratios (%).
METHOD MVC(N) 10/100% 20/50%
Mean Difference -0.05 -0.54 -3.95
(±SD) (4.24) (11.99) (11.54)
Overall Mean 44.18 18.71 72.23
Error Linearity (r) 0.31 0.46 -0.52
CV%
Unadjustedt 9.6 64.1 15.9
AdjustetJ: 18.8 125.6 31.3
95% Limits of -8.5 to 8.34 -24.54 to 23.45 -27.03 to 19.13
Agreement
t Unadjusted" SD 1overall mean x 100
: Adjusted = SO x 1.961 overall mean x 100
Table 3.5.2: Test-retest reliability for fatigue parameters - fatigue index (FfO/o)of peak tension (P1),
mean tension (MT) and relaxation rate. These indices are expressed as the end force as a percentage
of the initial force.
METHOD Peak Tension Mean Tension Relaxation Rate
Mean Difference -1.04 -2.71 -15.88
(±SD) (9.08) (9.08) (25.87)
Overall Mean (%)* 49.24 44.05 182.46
Error Linearity (r) 0.27 0.42 0.34
CV%
Unadjustedt 18.4 19.1 14.2
AdjustetJ: 36.1 37.3 27.8
95% Limits of -19.2 to 17.1 -19.2 to 13.7 -67.6 to 35.9
Agreement ...
• End force as a percentage of initial fort Unadjusted = SD 1overall mean x 100
: Adjusted - SO x 1.961 overall mean x 100
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Bland-Altman Plot ofMVC for the FDI
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Fig. 3.5.1: The relationship between mean scores and test-retest differences for maximal voluntary
contraction (MVC). /01/00% ratio and 20150% ratio. The centre line represents the mean of test I
and test 2. and the outer lines are the 95% limits of agreement (mean % 2SD).
115
3.6. Summary
1) The reliability of the LIDO~ Active dynamometer for measuring concentric strength
of the knee extensors was established in a sample of young heterogenous subjects.
Whilst the equipment was deemed reliable at 1.05 and 3.13 rad/s, the variability was
greater at higher angular velocities (5.22 rad/s).
2) The reliability of the knee flexors was compromised across all angular velocities.
This was attributed to the requirement to perform recriprocal movements.
3) The assessment of the variability in muscle performance of middle-aged women
revealed a systematic increase of peak torque of the knee extensors at 1.OSrad/s.
Whilst the effort involved in undertaking reciprocal extensor/flexor actions could
contribute to this learning effect, it is anticipated that extra warm-up trials will
stabilise peak torque. Strength of the leg flexors were also highly variable, and are
not considered a reliable muscle group for assessing hormonal influences.
4) Day-to-day measurements of maximal isometric handgrip and leg strength have
proven reliable, although it is recommended that the twitch interpolation technique
be employed to confirm the maximal activation of the quadriceps.
5) The strain gauge assembly, utilised for measuring the force-generating capacity of
the quadriceps, was reported to be a reliable system Forces generated from
electrically stimulated contractions were prone to greater variability in performance.
This was particularly noted for the ratio of forces at 101100 Hz. The variabilty was
also greater in fatigued, compared to fresh muscle.
6) The hand dynamometer was deemed reliable for measurements of maximal force
production of the first dorsal interosseus muscle. Forces generated from electrically
stimulated contractions were highly variable, particularly for the 10/100 Hz ratio.
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CHAPTER FOUR
THE EXPERIMENJTAL
STUDIES
4.0. THE EXPERIMENTAL CHAPTER
In the previous chapter the reliability of the equipment to be employed for assessing
hormonal influences on musclefunction was established. These results have been used
to determine the most reliable and effective methodsfor measuring aspects of muscle
function. Those which have exhibited great variability day-to-day will not be used.
The experimental studies described within this chapter aimed to establish the
influence of reproductive hormones on muscle function. Four separate studies were
undertaken, measuring different muscles in young and middle-aged women, and
assessing musclefunction through volitional and electrically stimulated contractions.
In study 4.1, the rate of force loss in hypoestrogenic post-menopausal women was
assessed over 12 months, a model which represents a chronic loss of hormones..
Performance was compared with a perimenopausal group and a sample of women
taking hormone replacement therapy (HRT). Additionally, the role of HRT was
investigated. Temporal changes in hormones on maximal force of a large muscle
group (quadriceps) and a small single muscle, the first dorsal interosseus (FDl) was
examined during the menstrual cycle (study 4.2). Responses to electrically stimulated
contractions were also examined in the quadriceps to gain further insight into the
mechanisms of hormonal action.
These studies will determine the effects of chronic and acute changes in reproductive
hormones on muscle function. The main objective of study 4.3 was to elucidate the
role of oestrogen on muscle strength, where acute changes in oestrogen were
examined in the FDI whileprogesterone remained relatively stable. Finally, study 4.4
investigated changes in musclefunction of the FDI and assessed the effects of HRT in
post-menopausal women. The influence on muscle function during changes from a
hypoestrogenic to a hormonally replenished state was determined, with afocus on the
differences of an oestrogen and oestrogen/progestogen primed muscle during the
phases of HRT.
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4.1. A LONGITUDINAL ANALYSIS OF MUSCLE STRENGTH IN MIDDLE-
AGED FEMALES OF DIFFERENT HORMONAL STATUS
Aspects of this work have been presented at the First European Congress of Sports
Science, Nice, May, 1996 and at the Neurobiology of Ageing Conference, Dublin,
March. 1997. An abstract has been published in the Journal of Physiology, 501.P.
170P,1997.
4.1.1. Introduction
An age-related decline in muscle strength of the order of30-40% (Larsson et at, 1979)
is concomitant with a reduction in muscle mass (Grimby and Saltin, 1983). Recently, a
decline in the force-generating capacity of the adductor pollicis muscle (AP), expressed
as force per cross-sectional area (force/CSA), was reported in the elderly at 27%
compared with younger controls (Bruce et at, 1989). Given the difficulty inmeasuring
physiological cross-sectional area in humans, even in a paralleI-fibred muscle such as
the AP, isolated whole muscle in rodents have been examined. A reduction (20%) in
specific force of hindlimb muscle has also indicated an age-related deficit in strength
independent of atrophy (Brooks and Faulkner, 1988; Phillips et al., 1991). The onset of
this weakness, investigated in males and females aged 17 to 90 years (Phillips et at,
1993b), is most rapid in peri-postmenopausal women. Since women taking hormone
replacement therapy (HRT) do not exhibit this weakness, a hormonal component is
strongly implicated.
Problems arise when reporting specific force in a multiple muscle group such as the
quadriceps. Due to its architectural complexity, the CSA is difficult to measure
accurately and, as a result, there have been conflicting reports of the changes in
specific force with ageing. A loss of strength in the quadriceps, unexplained by atrophy
has been documented in elderly men (Young et al., 1985) but not inwomen (Young et
al., 1984). Muscle mass in both studies was measured using ultrasound scanning.
Muscle mass, estimated from urinary creatinine excretion, was related to strength of
lower, proximal, and upper distal limbs (Frontera et al., 1991). However, using
computed tomography Rutherford and Jones (1992) found a decline in force/CSA
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from the 5th decade in women and a total loss of specific force between the 2nd and
8th decade of27%.
Whilst Phillips et al. (1993b) have reported the onset and time-course of muscle
weakness of the AP in a cross-sectional study, the rate of individual force loss has not
been examined. The object of this study was to monitor maximal strength of the
quadriceps over 12 months in hypoestrogenic women (1-3 years post-menopausal).
Muscle mass was not measured because of the difficulties associated with this muscle
group, although an aged-matched control group taking HRT was assessed. The
quadriceps was selected due to its role as a weight-bearing 'functional' muscle group;
hand grip strength was also examined as an upper limb comparison. The effects of
hypoestrogenia/progestogenia on shortening velocity of the quadriceps was also
examined. The following hypotheses were devised:
Hypothesis 1. Maximal strength declines inwomen within 1 to 3 years post-
menopause over 12 months.
Hypothesis 2. There is no change in maximal strength in females taking
hormone replacement therapy (HRT).
Hypothesis 3. Strength loss is of the same proportion with increasing
angular velocities.
The aims of this study were to:
1] Determine if strength loss occurs over a 12 month period.
2] Assess the role ofHRT in preserving muscle strength
3] Examine the effect of hormonal status on shortening velocity ofthe quadriceps
4] Investigate the response of different muscle groups to hypoestrogenia.
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4.1.2 Methods
(i) Subjects
Thirty middle-aged female subjects volunteered to participate in the study. Subjects
were recruited from the menopause clinic at Liverpool Women's Hospital and by
advertisements in a local newspaper. Subjects were subdivided into three groups;
eleven women were taking hormone replacement therapy (RRT) either shortly before
or soon after baseline measurements (RRT preparations are shown in Table 4.1.2).
Nine females were perimenopausal and experiencing symptoms of the climacteric ie.
vasomotor disturbances, irregular periods. Finally, ten postmenopausal women were
recruited according to the inclusion criteria listed below. A venous blood sample was
taken to confirm high follicle stimulating hormone (FSH) and luteinising hormone (LH)
levels (>20 U/L). Baseline characteristics of subjects are shown in Table 4.1.1. There
were no significant differences in mass (p=0.79) or height (p=0.86) between the three
groups. These parameters were used to calculate body mass index (BMI) (kg/m')
(Table 4.1.1.).
Table 4.1.1: Mean (±SD) baseline characteristics of subjects in the peri-, post- and HRT groups.
Variables Peri-menopause Post-menopause HRT
Age (yrs - decimal) 49.96 (3.11) 51.97 (3.08) 50.05 (3.84)
Height (m) 1.59 (3.52) 1.62 (6.85) 1.59 (5.45)
Mass (kg) 73.58 (9.11) 72.33 (14.57) 67.50 (10.31)
BMI • 28.88 (2.83) 27.36 (4.67) 26.56 (2.03)
LTPA (kJ/wk) ; 5168 (2539) 10409 (9741) 6181 (6149)
• Body mass index
; Leisure time physical activity
A questionnaire was administered to all volunteers for inclusion/exclusion into the
study. Medical and gynaecological profiles and history ofRRT were reported. Physical
activity was assessed using the Leisure Time Activity Questionnaire (Lamb and Brodie,
1991) to ascertain fitness levels of subjects. This survey requires the recollection of
leisure time physical activity over a 'typical' two week period (Appendix 1.0). Energy
expenditure was calculated from the weekly activities recalled. Differences in activity
levels are presented in Table 4.1.1. Large inter-individual variations exist, although
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energy expenditure was mainly attributed to gardenlhousehold activities. Ten percent
of subjects suffered from thyroid disease, which was treated with exogenous thyroxine
replacement.
Inclusion criteria Exclusion criteria
a) Sedentary, but physically healthy Myopathic/neuropathic/skeletal
disorders likely to affect performance
Medication possibly affect motivation
Hypertensive (> 140/90)
b) Aged 45-55 years
c) Normotensive
Postmenopausal group
d) Amenorrhoea at least 12 months
e) High FSHlLH levels (>20 U/l)
Amenorrhoea> 5 years
Premature menopause «40 years)
Perimenopausalgroup
f) Vasomotor symptoms Amenorrhoeic
g) Irregular periods (cycle length >35 days) Younger 45 years
HRT
h) Beginning HRT/taking HRT 1-2 months > 55 years
Table 4.1.2. Hormone replacement therapy preparations taken by subjects (n=ll)
Route of Preparation Oestrogen Progestogen
administration
Oral Climagest (xl) Oestradiol valerate Norethisterone
Oral Trisquens (x I) Oestradiol/oestriol Norethisterone acetate
Oral Prempak-C (x2) Oestradiol/oestriol Norgestrel
Transdermal Estracombi (xl) Oestradiol Norethisterone acetate
Oral Livial • (3) - -
Oral Premarin** (x2) Conjugated oestrogens -
Transdermal Estracombi" (xl) Oestradiol -
• Livial contains tribolone - a gonadomimetic .
•• These preparations are unopposed oestrogens taken by hysterectomised women
Dropouts
. Forty subjects were initially recruited into the study. Fourteen females were taking
hormone replacement therapy, thirteen subjects were assigned to the peri-menopausal
group and thirteen subjects were post-menopausal. Ten subjects (HRT = 3; peri-
menoapausal = 4; Post-menopausal = 3) dropped out between baseline and the second
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testing session due to medical and/or personal problems. Following the penultimate
testing session, three subjects in the postmenopausal group were withdrawn from the
study due to illness (x2) and death (xl). Analysis of data was therefore undertaken
over 9 and 12 months.
(ii) Procedure
On arrival at the laboratory, body mass of subjects was recorded and, following 5 min
of seated rest, blood pressure was measured using an automatic sphygmomanometer
(Model 8111, Dynamar, Critikom, Bracknell, UK). Subjects with values greater than
1501100 were diagnosed a hypertensive and were requested to seek medical advice
before continuing with the study. Leg and grip strength was then measured following a
5 min, self-paced warm-up on a cycle ergometer (Monark).
Strength measurements
Dynamic strength of the quadriceps and hamstrings was assessed using an isokinetic
dynamometer (LIDO Active", Davies CAl according to the protocol described in
Chapter 3.3. Due to the systematic increase in peak torque between test 1 and 2 at
1.05 rad/s in section 3.2, this parameter was stablised with 2 submaximal and 4
maximal practice trials. Maximal voluntary isometric contraction (MVIC) of the
quadriceps was measured with the leg flexed at the knee at an angle of 90°. The
maximum force-generating capacity of the muscle group was monitored with
percutaneous stimulation using surface eletrodes. One Hz twitches were delivered at a
tolerable current for 10 s. The MVIC was recorded when the superimposed twitches
diminished. One min rest was given between each contraction. Following a 5 min
recovery, the highest of 5 trials was recorded.
Intraindividual tests were undertaken at the same time of day (± 1 hour). A
familiarisation session preceded the baseline trial. Subjects were required to visit the
laboratory every ten weeks for 12 months, arranged with the experimenter one to two
weeks beforehand. A total of 5 sessions, excluding the familiarisation test, were
attended.
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(iii) Data Analysis
The Statistical Package for Social Sciences (SPSS) was used for data analysis. Mean
(± standard deviation) and percent changes were calculated. A two-way analysis of
variance (group x3) with a repeated measures factor of visit (x5), was employed to
calculate strength changes between groups over the 12 months. Analysis was also
undertaken across 4 visits (up to 9 months) of all the subjects (n=30) so that the
performances of the post-menopausal subjects who dropped out before the final test
session were analysed. A two-way ANOV A with a repeated measures factor of
velocity (x4) and visit (x2) was also used to calculated the differences in strength of the
three groups across all angular velocities, and standardised peak torque. To avoid the
occcurrence of a Type I error (when the assumption of sphericity, or homogeneity of
variance is not true), the Huynh-Feldt correction factor was used. Post-hoc tests
(Scheff e) were carried out to determine differences between variables from the
ANOV A. Significance was set at a 5% level.
Allometric modelling
Physiological variables are often dependent on body size. To normalize for differences
in body size allometric modelling was used to 'remove' these individual influences
from the analysis using the equation:
Y = ahbl.mb2 e (equation 1)
where Y represents the physiological variable, h = height, m = body mass and e the
multiplicative error ratio term. The model naturally overcomes the presence of
heteroscedasticity (when the error diverges with an increase in mean scores) and, after
log transformation, the model parameters can be fitted using' the linear regression
methods. Since strength varies with body size (Edwards et al., 1977b), force was
adjusted for height and mass according to the method of Nevill (1994).
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4.1.3. Results
Mean force values ± standard deviation (SD) of different muscle groups across all
angular velocities are shown in Tables A.l, A.2 and A.3 (Appendix 2.0) for HRT, peri-
and post-menopausal groups respectively. Measurements in three post-menopausal
women were not recorded at the last test due to reasons described in the methods, and
thus were excluded from analysis over 12 months.
4. J.3. J. Longitudinal changes in strength between peri-, post-menopausal and
hormonally replenished women over J2 months
Maximal force, measured across a range of angular velocities, was assessed over 12
months between three treatment groups. Force was log transformed and corrected for
covariates log of height and weight. The two-way ANOV A with repeated measures
did not reveal any significant differences between (group x 3) or within (visit x 5)
subjects (p>0.05). There was no significant group/visit interactions at any velocity for
the muscle groups tested. The interaction plots for these factors are shown in Fig 4.1.1
to 4.1.8. The F values (significance ofF), with b exponent of height and weight, for all
variables are shown in Table A.4 (Appendix 2.0).
The log of height and weight were incorporated into all analyses as covariates, and
were omitted if they were not significant. Height was not included as a covariate for
isometric strength, which affected the significance of the b exponent of weight. Height
and weight were included for concentric contractions (1.05 to 3.13 rad/s) and hand
grip strength.
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Fig. 4.1.1. Mean force values for isometric contraction (900 flexion) of the knee extensors between
the HRT, Post-menopausal (Post.M) and Peri-menopausal (Peri.M) groups over 12 months. HRT
N=II. Post.M N=7. Peri.M N=II. The F value is presented for Group v Visit interaction. Lnwt
indicate log of covariate weight and its b value.
Maximal Strength of the KE at 1.05 radls
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Fig. 4.1.2. Mean force values for concentric contraction of the knee extensors (KE) at 1.05 radls
between the HRT, Post-menopausal (post.M) and Peri-menopausal (Peri.M) groups over 12 months.
HRT N=II. Post.M. N=7. Peri.M N=ll. The Evalue is presentedfor Group v Visit interaction. Lnwt
and Lnht indicate log of covariates weight and height respectively - and their b values.
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Maximal Strength of the KE at 2.09 rad/s
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Fig. 4.1.3. Mean force values for concentric contraction of the knee extensors (KE) at 2.09 radls
between the HRT, Post-menopausal (post.M) and Peri-menopausal (Peri.M) groups over 12 months.
HRT N=l1, Post.M. N=7. Peri.M. N=l1. The Fvalue ispresentedfor Group v Visit interaction. Lnwt
and Lnht indicate log of covariates weight and height, respectively - and their b values.
Maximal Strength of the KE at 3.13 rad/s
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Fig. 4.1.4. Mean force values for concentric contraction of the knee extensors (KE) at 3.13 radls
between the HRT, Post-menopausal (Post.M) and Peri-menopausal (Peri.Mi) groups over 12 months.
HRT N=l1, Post.M. N=7. Peri.M. N=JJ. The Fvalue is presentedfor Group v Visit interaction. Lnwt
and Lnht indicate log of covariates weight and height, respectively - and their b values.
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Maximal Strength of the KF at 1.05 radls
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Fig. 4.1.5. Mean force values for concentric contraction of the knee flexors (KF) at 1.05 rad/s
between the HRT, Post-menopausal (Post.M) and Peri-menopausal (Peri.M} groups over 12 months.
HRT N=ll, Post.M N=7. Peri.M. N=ll. The Fvalue is presented for Group v Visit interaction. Lnwt
and Lnht indicate log 0/covariates weight and height, respectively - and their b values.
Maximal Strength of the KF at 2.09 radls
50
48+-~-r~~--~.-~~~-.~~
F=O.78
-+-HRT
--0- Post.M.
-x-Peri.M.
Lnwt=0.658
p= 0.121
Lnht= 2.714
p= 0.134
60 ~----------------------------~ .-------~
_ S8 x __ x ........... /"-x
~ 56 'x
';' 54
u
~ 52
~
o 6 9 123
Test Session (months)
Fig. 4.1.6. Mean force values for concentric contraction of the knee flexors (KF) at 2.09 rad/s
between the HRT, Post-menopausal (post.M) and Peri-menopausal (Peri.M) groups over 12 months.
HRT N=ll, Post.M N=7. Peri.M. N=ll. The Fvalue is presented/or Group v Visit interaction. Lnwt
and Lnht indicate log of covariates weight and height, respectively - and their b values.
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Maxirml Strength of the KF at 3.13 rad/s
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Fig. 4.1.7. Mean force values for concentric contraction of the knee flexors (KF) at 3.13 rad/s
between the HRT, Post-menopausal (Post.M) and Peri-menopausal (Peri.M) groups over 12 months.
HRT N=ll, Post.M. N=7. Peri.M N=ll. The Fvalue ispresented for Group v Visit interaction. Lnwt
and Lnht indicate log of covariates weight and height, respectively - and their b values.
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Fig. 4.1.8. Mean force values of isometric grip strength between the HRT, Post-menopausal (post.M)
and Peri-menopausal (Peri.M] groups over 12 months. HRT N=ll, Post.M N=7. Peri.M. N=l1.
The F value is presented for Group v Visit interaction. Lnwt and Lnht indicate log of covariates
weight and height, respectively - and their b values.
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4.1.3.2 Comparison of post-menopausal women and females taking HRT over 9
months
There were no significant differences in strength between the three treatment groups
over 12 months. The peri-menopausal group was removed, and the differences in
performance of hypoestrogenic post-menopausal females compared with a group
taking hormone replacement therapy (HRT). The role ofHRT on muscle strength was
also examined. Strength measurements up to 9 months were analysed so that all ten
post-menopausal subjects were included in the analysis. At the slow, or zero, angular
velocities of the knee extensors there was significant group x visit interaction for
isometric (F30S7= 4.4S; p<O.OS) and concentric strength at LOS rad/s (F3,S7= 4.04;
p<0.05).
There were also significant differences over time (the 'within' subjects factor) for both
variables. Post-hoc tests located significant differences in isometric strength for the
post-menopausal group between TI and T4, TI and T3, T2 and T4 and TI and T3
(p<O.Ol), whilst force remained stable for the HRT group (Fig 4.1.9). The deficit in
force measured isokinetically at 1.05 rad/s for the post-menopausal group was
significant between TI and T4; T3 and T4 (p<0.05); T2 and T3; T2 and T4 (p<O.Ol). A
slight increase in strength at the last session was observed for the HRT group, although
this was not significant (4.1.10). There were no sigificant changes in strength at the
faster angular velocities for the knee extensors (2.09 and 3.13 rad/s), although the
HRT group were were able to generate greater force compared with the post-
menopausal females at all time points (Fig. 4.1.11 to 4.1.12). Strength of the knee
flexors are not reported here because of the variability in force of this muscle group
(demonstrated in section 3.3), but are shown in Fig. 4.1.S to 4.1.7 for all groups.
The interaction plot of mean force for grip strength (Fig. 4.1.13) vary over the
duration of the testing for both groups. Significant differences between visits were
found (HRT group = T2 and T3; T3 and T4 (p<O.OS): Post-menopausal group = TI and
T2 (p<O.05); TI and T4 (P<O.Ol)) although these changes were variable.
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Fig. 4.1.9. The relationship betweeen mean (±SE) isometric force (900 knee flexion) of the knee
extensors (KE) between hypoestrogenic and hormonally replaced females over 9 months. The broken
line represents the meanforce of the number offemales who completed all j tests (n=7). Lnwt is the
abbreviation of log of covariate weight and its b value. SE = standard error.
Maximal Strength ofKE at 1.05 rad/s
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Fig. 4.1.10. The relationship betweeen mean concentric force (±SE) of the knee extensors (KE) at
1.05 rad/s between hypoestrogenic and hormonally replaced females over 9 months. The broken line
represents the meanforce of the number offemales who completed all 5 tests (n=Z). Lnwt and Lnht
are abbreviations of log of covariates weight and height respectively, and their b values. SE =
standard error.
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Fig. 4.1.11. The relationship betweeen mean concentric force (±SE) of the knee extensors (KE) at
2.09 radls between hypoestrogenic and hormonally replaced females over 9 months. The broken line
represents the mean force of the number offemales who completed all 5 tests (n=Z). Lnwt and Lnht
are abbreviations of log of covariates weight and height respectively, and their b values. SE =
standard error.
Maximal Strength ofKE at 3.13 radls
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Fig. 4.1.12. The relationship betweeen mean concentric force (±SE) of the knee extensors (KE) at
3.13 radls between hypoestrogenic and hormonally replaced females over 9 months. The broken line
represents the mean force of the number offemales who completed all 5 tests (n=7). Lnwt and Lnht
are abbreviations of log of covariates weight and height respectively, and their b values. SE =
standard error.
131
Lnwt=0.736
p<O.Q1
Lnht = 1.835
p< 0.1
Maxirral Isorretrc Grip Strength
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Fig. 4.1.13. The relationship betweeen mean force (±SE) of isometric grip strength between
hypoestrogenic and hormonally replaced females over 9 months. The broken line represents the mean
force of the number offemales who completed all 5 tests (n=7). Lnwt and Lnht are abbreviations of
log of covariates weight and height respectively, and their b values. SE = standard error.
4.1.3.3. Percent change over 12 months between three group
Differences in the percent change of strength of the knee extensors and grip strength
between baseline (TI) and 9 (T.) and 12 (Ts) months are illustrated in Fig. 4.1.14 to
4.1.18. A one-way ANOV A calculated differences in the magnitude of change in force
deficit (%). No significant changes were found between the three groups across 9
months or 12 months (p>0.05).
4.1.3.4. Percent change over 9 months - HRT versus post-menopausal women
Comparisons in the percent change in strength for baseline and 9 months were made
between the HRT and post-menopausal groups. Significant differences were found for
isometric (t19 = 2.43;p<0.05) and dynamic strength measurements at 1.05 radls (t19 =
2.29;p<0.05).
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Isorretrc strength of the KE
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Fig. 4.1.14. Percent change (± SE) inforce(Nm) from baseline (I'l) to 9 (1'~)and 12 (1'j) months for
isometric contraction of the knee extensors (KE) measured at 90° of knee flexion. SE = standard
error,' Post.M. = post-menopausal women; HRT = hormone replacement therapy; Peri.M. = peri-
menopausal females.
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Fig. 4.1.1S. Percent change (± SE) inforce(Nm)from baseline (I'l) to 9 (1'4)and 12 (Ts ) monthsfor
concentric contraction of the knee extensors (KE) measured at a velocity of 1.05 rad/s. SE = standard
error; Post.M. = post-menopausal women; HRT = hormone replacement therapy; Peri.M. = peri-
menopausal females.
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Fig. 4.1.16. Percent change (± SE) in force (Nm)from baseline (I'}) to 9 (1'4) and 12 (Ts ) months for
concentric contraction of the knee extensors (KE) measured at a velocity of 2. 09 rad/s. SE = standard
error; Post.M. = post-menopausal women; HRT = hormone replacement therapy; Peri.M. = peri-
menopausal females.
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Fig. 4.1.17. Percent change (± SE) inforce (Nm)from baseline (I'}) to 9 (1'4) and 12 (l'j) months for
concentric contraction of the knee extensors (KE) measured at a velocity of 3.13 rad/s. SE = standard
error; Post.M. = post-menopausal women; HRT = hormone replacement therapy; Peri.M. = peri-
menopausal females.
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Isometric hand grip strength
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Fig. 4.1.18. Percent change (± SE) inforce (Ft lbs) from baseline (1'/ ) to 9 (1'4) and 12 (1'5) months
for grip strength measured during an isometric contraction. SE = standard error; Post.M. = post-
menopausal women; HRT c: hormone replacement therapy,' Peri.M. = peri-menopausal females.
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4.1.3.5. Force-angular velocity relationship
The force-velocity curves were examined between treatment groups at baseline and at
12 months. The relationship between absolute strength and angular velocity at both
time points are shown in Fig. 4.1.19 and 4.1.20. The log transformation of strength
was calculated statistically with the log of height and weight as covariates to correct
for body stature (Fig. 4.1.23 and 4.1.24). A two-way ANOVA with repeated measures
of velocity (x4) and visit (x2) showed that there was no affect of group on force by
visit (F2,22 =0.68; p>O.OS)or by velocity (F6,66 = 1.93; p>O.OS). Further, there was no
interaction between group by velocity or visit (F6,66 = 1.80; p>O.OS).
The force produced isometrically at 90° of flexion was lower than at slower angular
velocities of LOS rad/s. This is not typical of the force-velocity curve in which force
declines with increasing angular velocity. This trend was not affected when strength
was normalised for body size. Force was greatest isometrically at 60° of flexion when
measured on the final visit. Further measurements at a faster angular velocity of S.22
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rad/s resulted in lower force production. This pattern occurred for all treatment groups
and when scaled for body size (Fig. 4.1.20 to 4.1.22).
4.1.3.6. Standardised force-velocity relationship
The relative rate of force loss with angular velocity was examined by expressing force
as a percentage of isometric force. Force is relative to maximal isometric force,
although in this study maximal force was attained at 1.05 rad/s. Since relative force is
presented, scaled results were not used.
A comparison of standardised force between baseline and 9 months are shown for the
HRT group (Fig. 4.1.23) and post-menopausal females (Fig. 4.1.24). There was no
significant affect of forces over time and across velocities for either group (p>0.05).
This is evident in the HRT group (Fig. 4.1.23), although higher relative force with
increasing velocities in the post-menopausal group indicate that greater relative force is
generated at 9 months. This is probably due to a significant decline in isometric force at
9 months and the maintenance of forces at higher angular velocities. Forces at 1.05
rad/s had decreased in proportion to isometric force.
A comparison between groups at baseline (Fig. 4.1.25) and at 9 months (Fig. 4.1.26)
shows that the HRT group generates higher forces as a percentage of their isometric
force. There were no significant differences between groups x velocity (F3,57 = 2.11;
p>0.05) or by visit (F 1,19 = 0.51; p>0.05).
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Force- Velocity Curve for at Baseline
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Fig. 4.1.19. Force (Nm) - angular velocity relationship for absolute strength at baseline between the
three treatment groups. HRT =hormone replacement therapy; Post.M. =Post-menopausal group;
Peri.M.=Peri-menopausal group.
Force - Angular Velocity Curve at 12 Months-~ 160 -+-HRT
-; 140 -o-Post.M.
t 120 -X-PeriM.
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Fig. 4.1.20. Force (Nm) - angular velocity relationship for absolute strength at 12 months between
the three treatment groups. HRT =hormone replacement therapy; Post.M. =Post-menopausal group;
Peri.M. »Peri-menopausal group.
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Force - Angular Velocity Curve at Baseline
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Fig. 4.1.21. Log of force (Nm) - angular velocity relationship for strength at baseline between the
three treatment groups. Mean values adjusted from the log of strength and covariates height and
weight. HRT =hormone replacement therapy; Post.M. =Post-menopausal group; Peri.M. =Peri-
menopausal group.
Force - Angular Velocity Curve at 12 Months
5,..---..::----------,
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Fig. 4.1.22. Log of force (Nm) - angular velocity relationship for strength at 12 months between the
three treatment groups. Mean values adjusted from the log of strength and covariates height and
weight. HRT =hormone replacement therapy; Post.M. =Post-menopausal group; Peri.M.=Peri-
menopausal group.
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Standardised PT at increasing angular
velocities in the HRT group
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Fig. 4.1.2J. Mean standardised peak torque against angular velocity of knee extension of females in
the HRT group at baseline and 9 months (1"4). Concentric force is expressed as a percentage of
isometricforce measured at 90° of knee flexion.
Standardised PT at increasing velocities in
postmenopausal women
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Fig. 4.1.14. Mean standardised peak torque against angular velocity of knee extension of post-
menopausal females at baseline and 9 months (1"4). Concentric force is expressed as a percentage of
isometric force measured at 90° of knee flexion.
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Standardised PT between HRT and
postmenopausal women at baseline
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Fig. 4.1.25. A comparison of standardised peak torque against angular velocity betweenfemales in
the HRT and post-menopausal groups at baseline. HRT =Hormone replacement therapy; Post.M. =
Post-menopausal group.
Standardised PT between HRT and
postmenopausal women at 9 months
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Fig. 4.1.26. A comparison of standardised peak torque against angular velocity between females in
the HRT and post-menopausal groups at 9 months. HRT = Hormone replacement therapy; Post.M. =
Post-menopausal group.
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4.1.4. Discussion
.
The force per cross-sectional area of the adductor pollicis (AP) muscle is significantly
weaker in peri-post-menopausal women compared with age-matched females taking
hormone replacement therapy (HRT) (Phillips et al., 1993b). These findings have
provoked much interest, particularly with the clinical implications of an increased risk
of falling associated with muscle weakness (Wickham et al., 1989). Muscle groups of
significant functional capacities, the quadriceps and handgrip, were assessed over 12
months in post-menopausal women, peri-menopausal women experiencing eratic
changes in the menstrual cycle, and a group of females taking HRT.
Maximal strength between the three groups did not significantly change over 12
months for any muscle group tested or at any angular velocity. However, a reduction
in mean strength at both zero and slow angular velocities was observed in the post-
menopausal group when all three groups were compared (Fig. 4.1.1 and 4.1.2). These
strength changes were not manifest in the peri-menopausal or the HRT groups where
strength remained relatively constant over the duration of testing. Mean strength was~
higher in the peri-menopausal group than the females of the post-menopausal and HRT
groups. Differences in bodyweight may contribute to this, although it is possible that a
strength deficit resulting from oestrogen deficiency had not yet affected this group of
women who, despite elevated gonadotropin levels, still menstruated. The lower
strength scores found during isometric contractions cannot be explained, although
differences in strength were scaled in the statistical analysis.
The peri-menopausal females represent a group with unstable hormonal patterns and
consequently irregular cycles. Given the reported changes in strength during the
menstual cycle (Phillips et al., 1996; Sarwar et al., 1995), these subjects should be
tested at standardised times for reliable assessment of muscle function. This group
were therefore excluded, and subsequent analyses undertaken between the
hypoestrogenicl hypoprogestogenic post-menopausal women and the age-matched
HRT group. Since 3/10 post-menopausal subjects dropped out between 9 and 12
months, the final test session was not analysed. A significant loss of force of the
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quadriceps (knee extensors) for isometric and concentric contractions at slow angular
velocities (1.05 rad/s) (10.0 and 9.1% respectively) was reported in the
postmenopausal group. There were no differences at higher angular velocities (2.09 or
3.13 rad/s), or for the knee flexors and handgrip strength. Maximal strength was stable
in the HRT group for all parameters measured.
These findings demonstrate a hormonally-related loss of strength of the quadriceps, at
a rate of 9-10% per annum, for zero or slow shortening contractions in women within
1-3 years post-menopause. Recent longitudinal studies assessing muscular performance
and hormone status have failed to corroborate these results. In a randomised controlled
study, leg strength was measured at 0 and 1.05 rad/s over 11 months in post-
menopausal women aged 60 to 72 years. There were no changes in peak torque for
either the control group or a HRT group taking the same preparation from the onset of
the study (Kohrt et al., 1995). Leg strength was measured at velocities employed in the
current study but the age range differed. The subjects in Kohrt's study were
considerably older, whereas the target age of females in this study was 51 to 55 years,
depending on the age at menopause. The subjects were recruited 1 to 3 years post-
menopause since this is the vulnerable age of rapid bone loss which attain a plateau
after 5 years (KroIner and Nielson, 1982). The rate of force loss observed in this study
is hypothesised to follow the same pattern as the response of bone loss (KroIner and
Nielson, 1982). Strength deficits related to the loss of reproductive hormones may
have already taken place in 60 to 72 year old subjects. At this age, age-related atrophy
would be responsible for further reductions in strength (Grimby and Saltin, 1983).
In a study examining the effects of HRT on muscular performance and balance,
Armstrong et al. (1996) failed to detect a loss of leg and handgrip strength over 24 and
48 weeks respectively in post-menopausal women not taking HRT. This age group of
45 to 70 years ranged from middle-aged menopausal women to elderly females. These
results were consistent for women taking HRT. 'Whilst the current findings indicates
the time course and rate of strength loss associated with the menopause, supporting
the cross-sectional observations, other longitudinal studies do not support these
suggestions. The changes in strength following the menopause may be attributable to
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muscle atrophy. Armstrong et al. (1996) suggested that declining activity levels are
more accountable for strength losses at the menopause rather than hormonal
deficiency. If this is the case, there would have been a significant loss of force at
higher velocities, particularly since type II fibres are lost more quickly in disuse
atrophy. Furthermore, this weakness was not manifest in the HRT or perimenopausal
women.
The time-course for muscle weakness has been reported in cross-sectional studies in
which a dramatic decline in force/CSA of the AP muscle occurred following the
menopause (Phillips et al., 1993b). These findings are supported by Calmels et al.
(1995), who demonstrated an accelerated loss in muscle strength of the elbow flexors
measured isokinetically at 0.52 and 3.13 radls between the 5th and 6th decades. This
weakness was associated with a reduction in bone mineral density of the lumbar and
femoral regions. The authors also proposed that the strength deficit of the lower limb
was not manifest until the 7th and 8th decade conflicting the current findings.
Rutherford and Jones (1992) reported a significant decrease in the force/CSA of the
quadriceps, where CSA was measured using computed tomography, between the 5th
and 6th decades which concur with the results from the longitudinal data.
Consistent findings of an effect of reproductive hormones on muscle strength are
mainly derived from studies measuring upper limb, distal muscles. Measurements from
lower limb proximal muscles are more conflicting. Bassey et al. (1996) compared
muscular performance of the quadriceps and handgrip strength between four
representative age-matched group of females with different hormonal status. In this
cross-sectional study, strength corrected for covariates age and fat-free mass did not
differ between any group. Taafe et al. (1995) used conventional isotonic exercises (e.g.
1 repetition maximum) to assess muscle strength in post-menopausal women and
females taking oestrogen replacement therapy (ORT). There were no differences in
performance when corrected for body mass between the ORT and non-ORT groups.
These subjects were older (7th decade) than those reported previously.
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Handgrip is often measured to assess muscle function in upper limbs. The time course
of changes in grip strength of males and females over a wide age range has been
demonstrated to peak in the third decade, declining linearly thereafter (Kallman et al.,
1990). A marked reduction in grip strength has been reported in women after 50 years,
around the time of the menopause (Petrofsky et al., 1975; Cauley et al., 1987). Cauley
et al, (1987) proposed that exogenous oestrogens delay the age-related loss of grip
strength. However, multiple linear regression revealed that height, age and activity
levels independently predict handgrip strength. There were no significant differences in
handgrip normalised for differences in body size when either two or three groups were
considered (p>0.05). The inability to standardise hand position may account for the
variation in strength over the 12 months (Fig. 4.1.8), although the results from section
3.3 found good day-to-day repeatability in maximal strength of this muscle group.
The mechanism by which reproductive hormones exert their effect is still uncertain,
although increasing evidence suggests an inotropic effect through increased force at
the cross-bridge. This is supported from work where a rapid stretch is applied to
muscle during an isometric contraction. In muscle from aged (Phillips et al., 1991) and
ovariectomised mice exlubiting weakness (Phillips et al., 1993b), an increase in the
ratio of stretch to isometric force occurs. This has also been demonstrated in the
human adductor pollicis muscle of post-menopausal women (phillips et at, 1993b).
During eccentric actions weakness in the elderly was less pronounced than in
concentric contractions (Vandervoort et al., 1990). Stretching the muscle is proposed
to force all the cross-bridges into a high force state (Lombardi and Piazzesi, 1990).
Reproductive hormones are thought to alter the equilibrium of the cross-bridges to the
low force state, similarly to the effects of an increase in inorganic phosphate (Pi)
(Phillips et al., 1992).
Muscle weakness is absent during lengthening, although force/CSA during isometric
and shortening contractions of the soleus and extensor digitorum in aged mice are
reduced at the same proportion, independent of shortening velocity (Brooks and
Faulkner, 1988). If the effects of ageing and hormonal are of the same aetiology, then
strength loss should be manifest in post-menopausal women irrespective of angular
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velocity. Concentric contractions of the quadriceps were measured isokinetically at
increasing angular velocities of 0, 1.05, 2.09 and 3.13 rad/s. The only significant
changes in maximal strength were found for isometric and concentric contractions at
1.05 rad/s. Force declines with increasing angular velocity as a feature of the force-
velocity curve. At faster velocities, power is important which is additionally affected by
fibre composition. Bassey et al. (1996) compared leg power in women of varying
hormonal status and did not report any difference between regularly menstruating,
females, those with irregular cycles, women taking HRT and post-menopausal women
not taking hormonal supplementation. The authors also failed to detect a difference in
absolute strength of the quadriceps and handgrip. Leg extensor power did not change
over 24 weeks in hypo estrogenic or hormonally replenished females (Armstrong et al.,
1996).
The force-velocity curves were analysed further between treatment groups at baseline
and at the last test session. With the exception of isometric contraction, strength
declined with increasing velocities for all treatment groups, characteristic of the
hyperbolic curve of force-velocity relations described by Hill (Gulch, 1994). There
were no significant differences between groups across angular velocity at baseline or at
12 months for absolute or log transformation of strength corrected for body size
(p>0.05). Isometric strength was measured at 90° of knee flexion. This is not the
optimal angle for generating maximal force which is affected by muscle length
(Osternig, 1986). Murray et al. (1985) reported peak torque at 60° knee flexion. At the
final test, the force-velocity curve was investigated further with the additional variables
of isometric (600 of knee flexion) and concentric contractions at 5.22 rad/s. This
modified angle for isometric tests generated a greater force than at slower angular
velocities. There were no significant differences however, between the three groups
across velocities for absolute or normalised srength (Fig. 4.1.20 and 4.1.22).
Angle of peak torque was not measured in this study, although the decreasing strength
with higher angular velocities has been postulated to be the result of a larger
I
acceleration period at faster velocities in which it is necessary for the limb to 'catch up'
to the predetermined speed of the dynamometer (Osternig, 1986). At high velocities of
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muscle shortening, the joint passes the optimal angle for maximal force before
contractile component attain maximal tension. The proportion of fast twitch fibres also
accounts for ability to develop maximal force at faster velocities (Thortensson et al.,
1976). Mean force across velocities decreases for post-menopausal women and
increases for HRT females when strength is corrected for differences in body size at
baseline and at 12 months (Fig. 4.1.20 and 4.1.22). These differences are not
significant,but are marked at the end of the study in concert with the loss of strength
across all angular velocities.
Standardised force-velocity relations were calculated to compare the relative rate of
force loss with angular velocity across time and between groups. Force was expressed
as a percentage of isometric force. Speed-dependent loss of force is reported to
accelerate in elderly women (Harries and Bassey, 1990) and in both sexes (Aniansson
et aI., 1983; Laforest et al., 1990) across increasing angular velocities. There were no
significanteffects of hormonal changes on the standardised force-velocity relationship.
However, in post-menopausal women (Fig 4.1.24) the relative force at 9 months was
greater than at baseline at higher angular velocities probably because force was
maintained at higher angular velocities while isometric force and concentric force at
1.05 rad/s decreased over time.
There were no significant differences in standardised force-velocity relations between
the HRT and post-menopausal group, although it appears that the HRT group were
able to generate greater force at increasing angular velocities relative to isometric
force. This suggests that force was reduced at a greater rate with speed in the post·
menopausal groups at both time points. Since this did not reach statistical significance,
it appears that forces at higher angular velocities were not affected by changes in
hormonal status.
Maximal strength of the quadriceps at slow angular velocities reduced significantly
over 12 months in hypoestrogenic post-menopausal women. The deficiency in
reproductive hormones at the menopause is associated with this strength loss. The
stability of force production in females taking hormone replacement therapy
146
demonstrated the efficacy of this treatment as a prophylaxis to muscle weakness. Thus,
in women where HRT is contraindicated consideration should be given to alternative
treatment, such as the implementation of exercise protocols.
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4.2. THE RELATIONSHIP BETWEEN REPRODUCTIVE HORMONES AND
MUSCLE FUNCTION OF THE QUADRICEPS AND FIRST DORSAL
INTEROSSEUS (FDI) DURING THE MENSTRUAL CYCLE IN YOUNG,
HEALTHY FEMALES
4.2.1. Introduction
The results from study 4.1 revealed a significant loss in force of the quadriceps over 1
year in hypoestrogenic post-menopausal women_.The reduction in maximal strength for
isometric and slow velocities of shortening (1.05 rad/s) at 9 to 10% per annum was not
evident at faster angular velocities. These findings suggest that hormonal losses
resulting in the menopause are implicated in this reduction in force, supported by the
observations that females taking HRT do not exhibit this weakness.
It is apparent therefore that the quadriceps are responsive to the chronic reduction in
endogenous oestrogen and/or progesterone. The loss of reproductive hormones at the
menopause does not occur rapidly, but can take up to 10 years from the onset of the
climacteric to attain baseline post-menopausal hormonal levels. It is unknown if this
response to oestrogen and progesterone deficiency is rapid, or is a prolonged
adjustment. The -10% loss in force production was found within 3 years
postmenopause. To assess the sensitivity of muscle to changes in oestrogen and the
loss of progesterone, acute changes in these hormones across the menstrual cycle will
be examined in young females. Subjects will be monitored repeatedly across the cycle
thus controlling for differences in muscle size.
The menstrual cycle is a ciracmensal rhythm characterised by fluctuations in
reproductive hormones, regulated by pituitary gonadotropins luteinizing hormone (LH)
and follicle stimulating hormone (FSH). A comparison of the sensitivity of a large
muscle group, the quadriceps to a small muscle, the first dorsal interosseus will be
undertaken. The hormonally-related force loss found in study 4.1 was not evident at
increasing velocities of shortening in post-menopausal women. Previous studies
examining strength across the menstrual cycle have failed to detect changes in dynamic
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contractions at 2.09 and 3.13 radls (Dibrezzo et a1., 1991; Richardson and George,
1993). Muscle function - maximal voluntary contraction (MVC), contractility of the
quadriceps through delivery of increasing frequencies of electrically stimulated
contractions, and fatigue resistance will therefore be examined isometrically.
The changes in maximal voluntary contraction (MVC) during the menstrual cycle has
been investigated in the adductor polllcis (AP) (Phillips et a1., 1996) and the quadriceps
muscle group (Sarwar et al., 1995). Sarwar et a1. (1995) reported peak strength of the
quadriceps at mid-cycle which was attributed to the high oestrogen levels prior to the
LH surge. Without hormone samples and frequent strength measurements, these
conclusions are based on conjecture. Phillips et al. (1996) fulfilled these
reconunendations and found that the peak in force of the AP muscle was followed by a
rapid loss observed around mid-cycle. These strength changes were not correlated with
circulating oestrogen levels. although this hormone was attributed to the loss of force
observed. In this study, oestrogen, progesterone, FSH and LH levels will be measured
and related to muscle function. These hormones will also be used as a marker for
accurate comparisons in muscle strength between subjects. The assessment of muscle
function of the leg will be performed over seven separate measurements, and ten
measures ofmaximal strength of the FDI will be made.
The aims of the study were to:
1] Examine changes in maximal voluntary contraction of the quadriceps and FDI
across the cycle where frequent measurements were made.
2] Investigate contractile properties of the quadriceps during the menstrual cycle.
3] Assess the fatiguability of the quadriceps across different phases.
These aims will be fulfilled through the following hypotheses:
Hypothesis 4: Maximal strength of the quadriceps and FDI is greater when
oestrogen concentrations are at their highest.
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Hypothesis 5: Changes in hormone levels result in a shift of the force-frequency
curve.
Hypothesis 6: The quadriceps are least fatiguable when progesterone levels
are high.
4.2.2 Methods
(i) Subjects
Young, healthy active females were recruited for the study. They were subdivided into
two groups often subjects; the first group consisted of 10 women (age - 26.6 [5.48]
range 19-34 years: weight - 59.9 [9.13] kgs; height - 1.62 [0.07] metres) (mean ±
standard deviation) who were not taking any form of hormonal treatment. This non-
oral contraceptive (non-OC) group had cycle lengths of28-35 days as determined from
self-report and temperature charts recorded from the preceding cycle (see Appendix
3.0). The control group (n=10) (age - 26.5 [4.77]; weight - 61.1 [9.94] kgs; height -
1.66 [0.06] metres) (mean ± sd) were taking combined oral contraceptive (n=7) or
triphasic preparations (n=3). Details of the oral contraceptive (OC) preparations are
given below (Table 4.2.1). Subjects gave written informed consent and were excluded
if they experienced pain or injury to the lower limb or hand.
Table 4.2.1: Oral contraceptive preparations of the control (OC) group.
Preparation Oestrogen (m~ Progestogen (mg)
Combined
Loestrin Ethinyloestradiol 20 Noresthisterone acetate" 1
Cilest (x2) Ethinyloestradiol 35 Norgestimate 0.25
Femodene (x2) Ethinyloestradiol 30 Gestodene 0.075
Marvelon Ethinyloestradiol 30 Desogestel 0.15
Brevinor Ethinyloestradiol 35 Norethisterone 0.5
Trlphasict
Trinordiol Ethinyloestradiol 30 (6 days) Levonorgestrel (6 days) 0.05
Logynon (x2) 40 (5 days) (5 days) 0.075
30 (10 days) (10 days) 0.125
• Converted (> 90%) 10 norethisterone as the active metabolite
t Both triphasic pills have the same formulation
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(ii) Procedure
4.2.2.1. Blood measurements
Blood samples from the antecubital vein were taken on five visits and sampled for
progesterone, oestrogen, follicle stimulating hormone (FSln, luteinizing hormone
(LH). These hormones were assayed at The Royal Liverpool Hospital. These results
were used to confirm cycle phase. All samples were taken at the same time of day for
each subjects. According to a 28 day cycle, the phases were divided into: menses (days
1-3); mid-follicular (MF-days 7-9); pre-Lll peak (PreLH-day 12, or 3 hours prior to
ovulation); LII peak (LfI-day 14); post LH peak (PoLH-days 16-17); mid-luteal (ML-
days 21-23) and late-luteal (LL-days 25-28). Blood samples were taken at menses,
preLH, LH peak, post-LH peak and mid-luteal. The oral contraceptive (OC) users
were tested on corresponding days throughout their cycle. A blood sample was taken
at midfollicular instead of menses which represented the seventh pill-free day. Menses
corresponded to the first day off the pill, and mid-follicular as day 7, the last pill-free
day.
Leg measurements - Seven strength measurements were made across the cycle. Cycle
phases were estimated from the midcycle LH peak, assisted with oral temperature
charts recorded from the preceding cycle, and estimated from ovulation - 14 days prior
to menstruation.
First dorsal interosseus - Strength measurements of the FDI were undertaken at the
same time as the quadriceps. An extra four sessions were also performed on day 4
(between menses and mid-follicular), day 10 (before pre-ovulation), day 19/20 (prior
to mid-luteal) and day 26.
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4.2.2.2. Maximal voluntary contraction
Maximal voluntary contractions (MVC) of the quadriceps and FDI were measured
using a strain gauge. A 5 min warm-up on a cycle ergometer (Monark) at 55 rev/min
preceded strength measurements of the leg, and 10 minutes immersion in hot water
increased blood flow to the FDI. The best of three MVCs were recorded. The protocol
for the leg and FDI are detailed in Chapter 3.3 and 3.4 respectively.
4.2.2.3. Contractile properties
The contractile properties of the leg in fresh and fatigued muscle were measured from
electrically stimulated contractions delivered at 1, 10, 20, 50 and 100 Hz. The ratio
between 20 and 50 Hz were used as an index of the force-frequency curve.
4.2.2.4. Fatigue resistance
Fatiguability of the quadriceps was assessed using the protocol, adapted from Burke
(1973), described in Chapter 3.3. The muscle was stimulated with 40 Hz impulses for
1s intervals over 3 min. This method proved more effective inducing fatigue compared
with the protocol of 3 s stimulation.
(iii) Data analysis
A repeated measures ANOVA (repeated factor of visit) was employed to detect
differences between phases of all varaiables for the experimental non-OC and oral
contraceptive (OC) users. Missing data post-LH peak were interpolated when analysis
was undertaken across all phases. Analysis was also performed across six phases
(minus postovulation). A post-hoc test (Tukey's) was used to identify differences
found from the ANOV A. Measurements of the OC group were also analysed in this
way, with combined and triphasic pill users pooled. They were also analysed separately
to compare the different preparations on muscle function.
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4.2.3 Results
4.2.3.1. Hormone levels across the menstrual cycle
The reproductive hormones oestrogen and progesterone, and gonadotropins LH and
FSH were measured at 5 time points across the menstrual cycle. The characteristics of
these hormones are described below.
4.2.3.1.1. Reproductive hormones
Oestrogen (17~-oestradiol) and progesterone levels in non-OC users are shown in Fig.
4.2.1. Values are missing at phases where samples were not taken. Oestrogen
increased during the follicular phase and peaked mid-cycle (marked as the LH peak)
which is consistent with high oestrogen concentrations inducing the LH surge.
Subsequently, oestrogen decreased rapidly (within 1-2 days) in concert with ovulation.
Oestrogen then increased mid-luteal but does not return to the same levels of the
follicular phase. Progesterone levels were low during the early and late follicular phase.
A gradual increase was then observed with the LH peak which sharply increased
thereafter. The peak in progesterone occurred mid-luteal, which is consistent with
ovulation (levels >35 nmol/l).
In the OC group, hormone levels were measured on the seventh pill-free day rather
than day 1 as with the non-OC group. Oestrogen and progesterone levels remained low
due to the suppression of the hypothalamic-pituitary-ovarian axis. Oestrogen levels
were slightly higher in the first phase in response to the relief of the inhibitory effects of
the exogenous hormones and subsequent increases in FSH. (Fig. 4.2.1). The ratios of
oestrogen to progesterone were calculated for individual values and are plotted in Fig.
4.2.3.
153
800~----------~-----'r-~
700
600
• S 500
Ii ~ 400
f ~ 300
~ 200
100
O+-~r-~---.--.---.-~---+
0 • 50 ~
40:: .Pg
0 0 30 .-. -a 1:
I 20 .§ =
0 • 10• • 0
Men MF Pre LH Po ML LL
peak.
Mens trual Phas e
Oestrogen and Progesterone in
Non-OC's During the Menstrual Cycle
Oestrogen and Progesterone in OC users
During the Menstrual Cycle
800 50 b]700
40 "C:I : Pg.~: 30~ ::s:!! E 400 1:1 ~
a: ~ 300 20 ~ ~
~200 a
100 0 0 0 10• • • ~ ~0 0
Men MF Pre LH Po ML LL
peak.
Menstrual Phase
Fig. 4.2.1: Relationship between oestrogen and progesterone during the reproductive cycle,
comparing non-DC and DC-users. Men = menses; MF = mid-follicular; Pre = pre-luteinizing
hormone (LII) peak; LHpeak; Po = post-Lll peak; ML = mid-luteal; LL = late-luteal.
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4.2.3.1.2. Gonadotropins
The gonadotropin concentrations in non-OC and OC users are shown in Fig. 4.2.2.
The cyclical changes in FSH and LH in ovulating females are indicated by the rise in
these hormones midcycle. Follicle stimulating hormone increases steadily during the
follicular phase, with a modest peak in concert with the surge in LH. This LH surge
induces ovulation. Both gonadotropins decreased thereafter.
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Fig. 4.2.2: Relationship betweenfollicle stimulating hormone (FSH) and luteinizing hormone (LH) in
non oral contraceptive (non-DC) and DC-users during the menstrual cycle. Men = menses; MF =
mid-follicular; Pre = pre-luteinizing hormone (LH) peak; LH peak; Po = post-LH peak; ML = mid-
luteal; LL = late-luteal.
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Fig. 4.2.3. The ratio of oestrogen to progesterone in non-OC and OC users. Men = menses; MF =
mid-follicular; Pre = pre-luteinizing hormone (LlI) peak; LH peak; Po = post-LH peak; ML = mid-
luteal; U = late-luteal.
4.2.3.2. Maximal voluntary strength of the quadriceps
4.2.3.2.1. Absoluteforce
In the non-DC group, significant changes inmaximal voluntary force of the quadriceps
were found across the cycle for all phases (x7) (F6•4S=3.48: p<0.05) and across 6
phases (FS.40= 4.20: p<0.05); the post-LH peak phase was excluded due to a greater
number of missing values which were interpolated. Muscle strength was lowest pre-LH
peak and increased by 12% at midluteal (Fig.4.2.4). The post-hoc test revealed that
menses, mid-follicular, mid-luteal and late-luteal phases were significantly different
from pre-LH peak (p<0.01). There were also significant changes in strength measured
at the LH peak from mid-follicular, late-luteal (p<0.05), and mid-luteal (p<O.OI).
Force production of the quadriceps did not change significantly across the cycle for the
DC group (p>O.05). Results of the DC group were also analysed separately according
to contraceptive preparation (Fig. 4.2.5). There were no significant changes in strength
of the combined DC group (F9•S4=0.6: p>0.05). In the triphasic group there was a low
number of subjects (n=J), hence too few degrees of freedom in the residual error
calculation. The results from both groups were therefore pooled for each variable
analysed.
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Fig. 4.2.4: Comparison of mean (±SE) maximal leg strength across the menstrual cycle of non-OC
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Fig. 4.2.5: Comparison of maximal leg strength between combined and triphasic OC-users. The two
first data points represent pill free days (PF). Pre = Pre-LH peak; LH peak; Po =post-LH peak; ML
= mid-luteal; LL = late-luteal - phases which correspond to the reproductive events in non-OC
subjects. • = low oestrogen/progestogen; •• = high oestrogen/medium progestogen; ••• = low dose
oestrogen/high progestogen components of triphasic preparations (Table 4.2. J).
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4.2.3.2.2. Relative force
Muscle force was expressed relative to the mean of all measurements for each subject
so that proportional changes in strength could be examined (Phillips et at, 1996) (Fig.
4.2.6). The changes in relative force were significantly different over the 7 time points
in the non-C group (F6,48 = 2.06; p<0.05), but not in the OC subjects (FS,54 = 1.35;
p>o.05).
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Fig. 4.2.6: Mean (±SE) relative muscle strength of the quadriceps in non-OC and OC users across
the menstrual cycle. Force is expressed relative to the mean of all measurements (dashed line) for
that subject.
4.2.3.3. The relationship between relative muscle force and hormonal patterns
The relationship between the relative force of the quadriceps and hormones governing
the menstrual cycle were explored to determine if hormonal concentrations are related
to the changes in strength. Correlations were performed between strength and
hormone levels measured on the same occasion for individual subjects across the cycle.
There were no significant correlations between force and oestrogen (r = -0.264) (Fig.
4.2.7), LH (r = -0.255) or FSH (r = -0.125). There was a significant positive
correlation between relative force and progesterone (r = 0.330; p<0.05) (Fig. 4.2.8)
and a negative correlation with the ratio of oestrogen:progesterone (r = -0.416;
p<0.05) (Fig. 4.2.9).
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Fig. 4.2.7: The relation between relative muscle force and oestrogen concentrations for individual
subjects across the menstrual cycle when measured at the same time. The solid black line represents
the regression line.
Relationship between Relative Muscle Force and
Proges te rooe
120 x
x
1.10 x)( XX X
u
~
X X x
t 1.00 x.s! x~x")( Xl( X X
u .,,: )(x x x~ 0.90 x- xGIl X... 0.80
" 0.70
0.60
o 10 20 30 40 50 60
Plasma progesterone (nmolll)
70
Fig. 4.2. B: The relation between relative muscle force and progesterone concentration for individual
subjects across the menstrual cycle when measured at the same time. The solid black line represents
the regression line.
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Fig. 4.2.9: The relation between relative muscle force and the oestrogen.progesterone ratio (E2:Pg)
for individual subjects across the menstrual cycle when measured at the same time. The solid black
line represents the regression line.
4.2.3.4. Maximal voluntary strength of the first dorsal interosseus (FDI)
4.2.3.4.1. Absolute force
The pattern of force production for the FDI differed from that of the quadriceps across
the menstrual cycle in both groups (Fig. 4.2.10). Further, there were no significant
changes in maximal strength of the non-OC group over 10 measurements (F9•72=1.15:
p>0.05) or between the 7 main phases (F6•48=1.37: p>0.05). The strength of the FDI
was greater in the non-OC group although there were no significant differences
between groups for all measurements made (F1•17=0.28: p>0.05). Maximal force of the
FDI in the OC group did not change significantly across the cycle (p>0.05).
Differences in mean maximal strength between combined and triphasic subjects are
shown in Fig. 4.2.11.
4.2.3.4.2. Relativeforce of/he FDI
The relative force ofthe FDI in non-OC and OC users is plotted in Fig. 4.2.12. There
were no significant differences when proportional changes in strength were considered
, for the non-OC (F9•72 = 1.25) and OC (F9•81 = 0.31) groups (p>0.05) across 10
sessions. The relative force of the OC group, subdivided into combined and triphasic
groups, is shown in Fig. 4.2.13.
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Fig. 4.2.10: Comparison of mean (±SE) maximal strength of the first dorsal interosseus muscle (FDI)
across the menstrual cycle of non-DC and DC-users. men = menses; MF = mid-follicular; Pre = pre-
LHpeak; LH peak; Po = post-LH peak; ML = mid-luteal; U = late-luteal.
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Fig. 4.2.11: Comparison of maximal strength of the first dorsal interosseus muscle (FDI) between
combined and triphasic {X-users. The two first data points represent pill free days (PF). men =
menses; MF = mid-follicular; Pre = pre-Lll peak; LH peak; Po = post-LH peak; ML = mid-luteal;
LL = late luteal. • = low oestrogen/progestogen; •• = high oestrogen/medium progestogen,' ••• =
low dose oestrogen/high progestogen components of triphasic preparations (fable 4.2.1).
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Fig. 4.1.12: Mean (iSE) relative muscle strength of the FDI in non-OC and OC users across the
menstrual cycle. Force is expressed relative to the mean of all measurements (dashed line) for that
subject.
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Fig. 4.1.13: Comparison of maximal strength of the first dorsal interosseus muscle (FDI) between
combined and triphasic OC-users. The two first data points represent pill-free days (PF).
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4.2.3.5. Contractile properties of the quadriceps
4.2.3.5.1.20150% - Fresh muscle
The ANOVA did not reveal any trend in the 20/50% ratio across the menstrual cycle in
the non-OC group (F6.4s=2.l5: p>0.05). There were no changes between phases for the
OC group (F6.s4=1.32:p>0.05). The mean (±SE) ratio across the cycle between the
two groups is shown inFig 4.2.14.
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Fig. 4.1.14: A comparison of the mean (±SE) 20-50% ratio between non-OC and OC-users measured
in fresh muscle across the menstrual cycle. The forces generated at 20 Hz was expressed as a
percentage of force at 50 Hz, calculated from a train of increasing frequencies of electrical
stimulation.
4.2.3.5.2.20-50% - Fatigued muscle
The 20-50% ratio in fatigued muscle did not change significantly across all phases
tested for the non-OC (F6.4s=1.15: p>0.05) and OC groups (F6•s4=1.33: p>0.05). The
20-50% ratio in non-OC and OC users is shown in Fig 4.2.15. A comparison of this
ratio between fresh and fatigued muscle is illustrated in Fig 4.2.16 and 4.2.17 for the
non-OC and OC groups respectively. In non-OC's, the ratio was higher in fresh muscle
across all phases compared with fatigued muscle. There was greater variability in the
OC-users, with a mid-cycle decrease inmean 20-50% ratio.
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Fig. 4.1.15: A comparison of the mean (±SE) 20-500/6ratio between non-DC and OC-users measured
in fatigued muscle across the menstrual cycle. The forces generated at 20 Hz was expressed as a
percentage of force at 50 Hz. calculated from a train of increasing frequencies of electrical
stimulation.
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Fig. 4.2.16: A comparison of the mean (±SE) 20-50% ratio in fresh and fatigued muscle of the non-
oc group. The forces generated at 20 Hz was expressed as a percentage of force at 50 Hz, calculated
from a train of increasingfrequencies of electrical stimulation.
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Fig. 4.2.17: A comparison of the mean (±SE) 20-50% ratio in fresh and fatigued muscle of the DC
group. The forces gen rated at 20 Hz was expressed as a percentage of force at 50 Hz, calculated
from a train of increasingfrequencies of electrical stimulation.
4.2.3.6. Fatigue Index (%)
There were no significant differences in peak tension of the non-OC (F6,48=1.13:
p>O.05) or OC (F6•54=O.57: p>O.05) groups across seven phases ofthe menstrual cycle.
Mean values of peak tension in relation to oestrogen is shown in Fig. 4.2.13. Changes
in mean tension of th non-OC and OC groups are shown in Fig. 4.2.19.
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Fig. 4.2.18: Fatigue index (0/0) of peak tension (PT) in non-OC and DC across the menstrual cycle.
Plasma oestradiol (E2) level values of each group are superimposed to compared the pattern of
fatigue between phase with circulating oestrogen.
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Fig. 4.2.19: Fatigue index ('/0) of mean tension (M1) in non-OC and OC across the menstrual cycle.
Mean tension represents the meanforce of the tetanic contraction.
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4.2.4. Discussion
Maximal force of the quadriceps in females not taking oral contraceptive preparations
clearly showed cyclical changes when measured across the menstrual cycle. Strength
was analysed a] across 6 time points of the cycle with all absolute scores and b] at 7
time points with values interpolated at one phase due to missing data. These time
points were ascertained according to predicted changes in hormones which were
retrospectively confirmed with plasma hormonal levels taken at the time of strength
measurements. The mid-cycle LH peak was used as a reference point for a
physiological marker to synchronise cycles. Maximal force was also correlated with
hormones for individual data when both strength and hormone samples were obtained.
When each time point was considered, significant changes in force of the quadriceps
were detected across the cycle. Force was stable during early-mid follicular, but
droped dramatically 1 to 3 days prior to the LH peak. The speed of this force loss was
not realised here since 5 to 6 days elapsed between mid-follicular and pre-LH peak
measurements. A steady increase in strength occurred thereafter, reaching its peak
mid-luteal. Maximal force mid-luteal was greater than the force at the mid-follicular
phase. Significant differences were confirmed between the force generated pre-LH
peak and menses, mid-follicular, mid-luteal and late-luteal phases. There were also
significant changes with strength measured at the LH peak the mid-follicular, mid-
luteal and late-luteal phases.
In the OC group, there were no significant changes in the strength of the quadriceps.
There was a notable decrease from menses to mid-follicular, during the pill-free week
although this did not influence the overall performance in strength. The results from
the non-OC group, however, do not agree with the strength changes reported in past
studies when measurements were made 2 to 3 times during the cycle for handgrip
(Wirth and Lohman, 1982; Davies et al., 1991) or le,g strength (Dibrezzo et al., 1991;
Richardson and George, 1993) or when more detailed measurements were undertaken
(Sarwar et al., 1995; Phillips et al., 1996).
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The concept that hormones influence physical performance has received much
attention over the past decades. However, the variability in protocols of testing and
definitions of cycle phases have precluded the comparison of results between studies
with consequential inconclusive findings. For example, greatest strength has been
reported for handgrip during the follicular compared with the luteal phase (Wirth and
Lohman, 1982), and at menses compared with the follicularand luteal phase (Davies et
aI., 1991). No differences in grip strength were reported when measured at the
premenstrual, menses, postmenses and mid-cycle phases (Allen and Bailey, 1982) or
between pre-ovulatory and luteal phases (petrofsky et al., 1976). Sarwar et al. (1995)
tested isometric leg strength and handgrip five times across the cycle in regularly
menstruating females. Measurements were taken early follicular (days 1-7), mid-
follicular, mid-cycle (days 7-12), mid-luteal and late-luteal. Maximal strength,
confirmed in the quadriceps using superimposed electrical impulses, was highest mid-
cycle compared with the other phases measured. The greatest difference of 11%
occurred with the late luteal phase. Mid-cycle in their study corresponded with
ovulation, estimated from temperature charts and counting back 14 days from onset of
next menses. These findings support the preliminary results of Phillips et al. (1993a)
who reported a 20% increase in force of the adductor pollicis (AP) muscle from day 1
to day 14 of the cycle. There were no significant differences between day 1 and 21.
Oestrogen, a predominant hormone during the follicularphase, undergoes rapid short-
term changes in production mid-cycle as a result of the feedback effects of the
gonadotropins secreted at this time. Oestrogen peaks prior to the LH surge (Ojeda,
1992) and declines to its lowest 2 to 3 days later in concert with ovulation. These
changes in oestrogen can therefore be easily miscalculated. Recently Phillips et al.
(1996) reported a marked reduction in force to its lowest level, 1-2 days after the
preovulatory peak in strength, coinciding with ovulation. These results support the
strengthening role of oestrogen.
In the present study the time course of strength changes were also examined in greater
detail, focusing on the mid-cycle hormonal fluctuations. However, in contrast to
Phillips et al. (1996), weakest strength measures of the quadriceps were found 1 to.2
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days prior to the LII peak, with peak MVC observed mid-luteal (days 20-22). The
higher force values at this point were not significantly different to the follicular phase.
Unless hormonal measures are undertaken, any endocrine effect on the changes in
strength are based on conjecture. To examine the role of the cyclical hormones further,
relative force values (to mean measurements across cycle) of the quadriceps were
correlated with plasma oestrogen (17-(3 oestradiol), progesterone, FSH and LH
concentrations measured on the same occasion. There was no significant relationship
between strength and circulating oestrogen levels, although a negative tendency was
observed (Fig. 4.2.7). A significant negative correlation between oestrogen and
isometric handgrip strength has been reported recently (Bassey et al., 1995) and has
been implicated in previous studies (Davies et aI., 1991; Wirth and Lohman, 1982).
Strength of the biceps brachii, triceps surae and handgrip were measured in nine
eumenorrheic females 8 times over 4 weeks. A 5% fall in handgrip strength for a 200
pmol/l increase in oestrogen was documented (Bassey et al., 1995). Rice et al, (1988)
undertook a battery of strength tests and correlated performances during days 1 to 5
with oestradiol levels. No significant relationship was found, although measurements
were made at only one phase.
Although Phillips et al. (1996) outlined the role of oestrogen in enhancing force
production they were unable to detect a significant association between relative force
of the adductor pollicis muscle and plasma oestradiol when measured around
ovulation. They attributed this to a time lag between the rapid changes in force and the
effects of oestrogen. The results from the present study do not support these
indications. A significant relationship was detected between relative strength of the
quadriceps and progesterone levels and it is believed that this hormone is linked with
the increase in force production. There was an increase in strength from the pre-LH
peak to the mid-luteal phase which corresponded to rising progesterone levels.
Previous studies investigating strength across the menstrual cycle have not measured
progesterone levels. A further noteworthy observation was a significant negative
relationship between relative force and the ratio of oestrogen:progesterone. There was
no relationship between strength and FSH or LH.
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The possibility of progesterone influencing force production of skeletal muscle is not
implausible. There is increasing evidence that progesterone is actively involved in bone
metabolism (Prior, 1990) and has been associated with ovulatory disturbances in young
active females (Prior et al., 1990a). Spinal bone loss of 2% per annum was reported in
healthy young women with progesterone deprived, but normal endogenous oestradiol
production (Prior et al., 1990a). Given the relationship between bone and muscle
strength in postmenopausal women (Rutherford and Jones, 1992), it is possible that
muscle weakness postmenopause, and during the menstrual cycle is caused through
progesterone deficient/reduced states.
The possible mechanisms by which progesterone exerts its effects on skeletal muscle
are indicated in studies examining its actions on other tissues. Progesterone has been
associated with calcium mobilisation from intracellular stores of the pituitary in rats
(Ortmann et al., 1995), which has significant ramaifications on the availability of
calcium for contraction in skeletal muscle. Further, progesterone exposure to excised
myometrial strips of pregnant women increases the frequency and tonus of this smooth
muscle (Fu et al., 1994). It has been proposed that hormones (oestrogen) may
influence the sensitivity of the cross-bridges to phosphorus metabolites i.e. inorganic
phosphate (Pi) (Phillips et al., 1993), an increase of which has been reported to alter
the equilibrium of low and high force states of the cross-bridge (Pate and Cooke,
1989). During the oestrus cycle of hamsters, Shivaji et al. (1995) did not find any
significant difference in Pi or pH using 31P NMR. An increase in phospho creatinine
(PCr) and ATP in the uteri of oestrus animals was found with increasing levels of
oestradiol, although progesterone per se did not cause an increase in the concentration
ofPCr and ATP.
The mechanisms of actions of progesterone are still highly speculative and
progesterone receptors have not been identified on skeletal muscle. Given the above
discussion it is still important to state that oestrogen is still implicated in force
production since a negative relationship was found between strength and the ratio of
oestrogen to progesterone. When oestrogen was unopposed (pre-LH peak), strength
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was at its lowest. With high progesterone and increasing oestrogen levels, strength was
greatest. Whether progesterone and oestrogen combined or progesterone alone
enhances force production is not known, since under no physiological conditions is
progesterone secreted in isolation. It is apparent, however, that muscle weakness
occurs under an "oestrogen-only milieu".
The force patterns produced by the quadriceps in this study are not consistent with
those of Sarwar et al. (1995) who also tested the quadriceps. It does not seem likely
therefore that the changes in strength are dependent on the muscle group tested ..
Phillips et al. (1996) measured force production of the adductor pollicis muscle, a small
parallel fibred muscle of the hand. Whereas the pattern of force is similar to that
obtained with the quadriceps in this study, the onset and magnitude of change are not.
However, maximal strength of the first dorsal interosseus (FDI) was also assessed on
the same occasion as the quadriceps, with extra measurements undertaken between the
main phases. There were no significant changes in force of the FDI for the non-DC
group. These results were surprising given the effects of hormonal changes on the AP.
This contradict the suggestion that smaller muscles are more sensitive to changes in the
hormonal milieu compared with a complex, multi-pennated muscle group such as the
quadriceps.
Maximal strength is one method of assessing muscle function. The measurement of
force production in response to electrically .stimulated contractions at increasing
frequencies determines the contractile properties of muscle. When expressed
numerically, the forces generated at 20 Hz are calculated as a percentage of 50 Hz.
The effects of hormonal status on the contractility ofmusc1e was assessed.There were
no significant changes in the 20/50 % across the cycle for the non-DC group (or DC
users). The fluctuations that were observed were therefore not attributable to hormonal
changes. Even though the electrical stimulation technique is a common method for
. identifying muscular dysfunction in patients with myopathic disorders (Edwards,
1978), it has only been employed in one study to assess the effects of reproductive
hormones on muscle function. Sarwar et al. (1995) reported a left-shift in the force-
frequency curve from mid-luteal to mid-cycle. This was attributed to the slowing of
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relaxation mid-cycle. Whether mid-cycle in their study is representative of the peak or
the trough of this hormone is not known, although they assumed that this measurement
was undertaken at ovulation. If so, oestrogen is at its lowest at this time, which does
not uphold their proposal of an effect of oestrogen. Relaxation time was not assessed
in this study, although the changes observed by Sarwar et al. (1995) are more likely to
be due to the secondary effects of hormones via changes in core temperature rather
than directly.
Muscle fatigue of the quadriceps was induced through electrically stimulated
contractions" over 3 min. The end force as a percentage of the initial force was
expressed as the fatigue index. There were no significant differences in the fatigue
index measured for the quadriceps across the cycle. Both volitional respiratory fatigue
(Chen and Tang, 1989) and electrically elicited fatigue of the quadriceps (Sarwar et al.,
1995) have been reported to be lowest at mid-luteal phase, probably due to the higher
circulating progesterone levels as a result of the increase in core temperature (Prior et
al., 1990b). The modified fatigue protocol used in this study (stimulating for 1 s with a
1 s rest) would be expected to be induce ischaemia similarly to the protocol used by
Sarwar et al. in which the muscle was stimulated for 0.25 s every second for 3 min.
The greater proportion of stimulated muscle (20-30 % ofMVC) elicited by Sarwar and
co-workers, compared with -20 % in this study, may account for greater variability in
force production and as a consequence fatiguability.
These results support a hormonal influence on force production of the quadriceps.
Further, they demonstate that force loss can be acute and unless frequent
measurements are made across the cycle, these changes can be missed. There were no
corresponding changes in strength of the first dorsal interosseus muscle or in the
contractility or fatiguability of the quadriceps. Despite the relationship between
strength and progesterone, the menstrual cycle does not render itself a good method
for examining hormones. The changes in oestrogen are particularly acute and
temporary, with accompanying changes in the gonadotropins and progesterone. A
clearer model for isolating the effects of reproductive hormones is needed to
investigate fully these phenomena.
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4.4. THE EFFECT OF HORMONE REPLACEMENT THERAPY (HRT) ON
MUSCLE FUNCTION OF THE FIRST DORSAL INTEROSSEUS MUSCLE (FDI)
4.4.1. Introduction
It has been established that maximal voluntary contraction (MVC) of the quadriceps is reduced
in post-menopausal women. The strength loss, at a rate of 9-10% per annum, is manifest
within 1 to 3 years of the menopause in association with the reduction in reproductive
hormones. Females taking hormone replacement therapy do not experience this weakness. The
mechanisms of action are not known, although under hypo- and hyperoestrogenic conditions
no change in strength of the FDI is observed (study 4.3). This indicates that oestrogen is not
the sole mediator for influencing force production. During the menstrual cycle, MVC was
greatest during the mid-luteal phase corresponding with high progesterone levels (study 4.2).
The objective of this study was to investigate the effect of HRT on muscle function
administered from an oestrogen and progesterone deficient state, with a focus on the
differences in oestrogen alone, and the oestrogen/progestogen component. Oestrogen was
administered during the first 14 days of HRT and a progestogen component is added during
last 7 days in attempts to mimic the normal menstrual cycle, allowing for a more controlled
method of examining cyclical changes. Whether these synthetic hormones act as a substitute to
endogenous reproductive hormones is not known. The following hypotheses were devised to
undertake this study:
Hypothesis 9: Force production of the FDI increases from baseline levels during HRT
Hypothesis 10: The oestrogen and progestogen phase ofHRT results in greater
force production of the FDI compared with the oestrogen-only phase.
Hypothesis 11: Contractile properties of the FDI differ with the administration ofHRT.
Hypothesis 12: Adrninstration ofHRT induces greater fatigue resistance compared with
baseline values.
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The aims of this study were to:
1) Examine the changes in strength at baseline and during HRT.
2) Investigate fatiguability of muscle.
3) Monitor changes in contractile properties.
4) Compare the difference in muscle function between oestrogen alone, and oestrogen
and progestogen components ofHRT.
4.4.2. Methods
(i) Subjects
Nine healthy post-menopausal women (age: 55.78±6.74; mass: 64.8±10.2: height: 1.59±O.05
(mean±SD» gave informed written consent to participate in the study. Subjects were recruited
from the Menopause Clinic at Liverpool Women's Hospital, where blood samples were taken
to confirm their hormonal status (mean bloods are shown in Table 4.4.1). Following
consultation with the doctor, subjects were referred for a baseline measurement, prior to taking
hormone replacement therapy (HRT). All subjects were prescribed oestrogen and oestrogen-
progestogen treatment (preparations are shown in Table 4.4.2). The dominant hand was
selected for assessment, except in one subject inwhom the PDI of the non-dominant hand was
tested due to rheumatism of the fingers of the dominant hand. All other subjects were free of
pain or disease of the hand.
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Table 4.4.1. Mean (±SD) oestradiol, luteinizing hormone (LH) andfollic1e stimulating hormone (FSH) in post-
menopausal women (n=9).
VALUES Oestrogen (pmolll) FSH (VII) LH (uJl)
MEAN 68.33 70.5 53.5
±SD 46.45 29.2 18.9
RANGE <37-190 26.2-113.7 30.6-88
Normal values t <150 >20 >20
t Normal post-menopausal values
Table 4.4.1. Hormone replacement therapy preparations administered to subjects
ROUTE OF PREPARA nON OESTROGEN PROGESTOGEN
ADMlNISTRA TION
ORAL FEMOSTON (X3) Oestradiol Dydrogesterone P
ORAL TRlDESTRA (X2) Oestradiol valerate Medroxyprogesterone
acetate P
ORAL PREMIQUE (Xl) Conjugated oestrogens Medroxyprogesterone
ESTRACOMBI (X2) Oestradiol
acetate P
PATCH Norethisterone T
TRANS DERMAL PRO-GEST (XI) Oestradiolloestrone Progesterone P
CREAM
P = progesterone derivative
T= testosterone derivative
(iiJ Procedure
Maximal voluntary contraction (MVC), contractile properties and fatiguability of the FDI were
assessed on three occasions. The first measurement was taken on the same day HRT was
prescribed to establish baseline strength. Subjects were requested back to the laboratory four
months following the start of HRT. Two measurements were undertaken during treatment a)
during the oestrogen phase and b) during the oestrogen/progestogen phase of treatment. The
order of testing for measurements during HRT was counterbalanced.
Following the warm-up of the muscle in heated water, the electrodes were positioned on the
hand and stimulated at 1 Hz, with increments of voltage to the highest, but tolerable, level of
stimulation. An isolated lateral movement of the index finger was achieved prior to recording.
A programmed stimulation of electrical impulses, from unfused to fused tetanic contractions
was delivered to the muscle to ensure adjacent muscles were not recruited at higher
frequencies of stimulation. Clear visible recordings of the myogram was also required. The
data of 2/9 subjects for electrically stimulated contractions were excluded from analysis due to
their intolerance of the sensation of the electrical stimulation. Details of the procedure for
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assessment of MVC, contractility and fatigue resistance of the FDI are described in Chapter
3.5.
(iii) Data analysis
A repeated measures analysis of variance (ANOVA), with visit as the repeated factor, was
employed to calculate trends over the three test sessions for all variables. Post-hoc analysis
(Tukey's test) was used to localise differences between trials.
4.4.3. Results
4.4.3.1. Maximal voluntary contraction
The results of the ANOVA shows that there was no significant difference between baseline
measurements of strength and phases of treatment (F2•16=3.03: p<O.1). A t test undertaken
between baseline measurements and the oestrogen/progestogen phase of treatment induced a
significant difference (ts = -2.S1;p<O.OS). Mean (±SE) ofmaximal strength across test sessions
are shown in Fig. 4.4.1.
Maximal Voluntary Contraction
~.--------------------------------
••
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Baseline Oestrogen Progestogen!
Oestrogen
Trials
Fig. 4.4.1: Mean (±SE) maximal voluntary contraction (N) of the first dorsal interosseus muscle (FDl) in post-
menopausal women at baseline, and during the oestrogen and progestogen phases of hormone replacement
treatment. The • indicate significant difference (difference between • and ··al p<O.05)
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4.3.3.2. Contractile properties
The 20/50% ratio was calculated as the force generated from 20 Hz as percentage of 50 Hz.
Whilst there were no significant difference in this ratio between treatments (F2,12=0.1:p>0.05)~
the mean (±SD) was higher for the oestrogen phase (70.5 9±19.5% compared with 67.D±12.8
and 67.4±18.8% for baseline and progestogen, respectively). The comparison between
conditions in the force-frequency curve as an indicator of the contractile properties of muscle,
is shown in Fig. 4.4.2. At lower frequencies (up to 20 Hz) greater force as a percentage of
100Hz was generated during HRT phases. This was maintained in the progestogen phase at
high frequencies, although force for oestrogen-only declined. There were no significant
differences in forces between phases at each frequency (p>0.05).
Force-Frequency Curve of the FDI before and
duringHRT
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Fig. 4.4.2: The force-frequency curve across increasing frequencies of electrical stimulation between baseline
and the oestrogen and progestogen phases of hormone replacement therapy (HR1). Forces at lower
frequencies is expressed as a percentage offorce at J00 Hz.
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4.4.3.3. Fatigue Index (0/0)
There were no significant differences in fatigue index for peak tension (F2.12=2.43; p>O.05) or
mean tension (F2.12=1.10; p>O.05) across the three treatment trials. Fig. 4.4.3 illustrates mean
(±SE) FI% for baseline, oestrogen and progestogen phases ofHRT.
Fatigue Index (%) Across Various Hormonal Milieu
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'8'
ii 80;.
ii 60:
]... 400
~• 20'-'c:
0
Baseline Oestrogen Progestogen!
Oestrogen
Trials
Fig. 4.4.3: A comparison of mean (±SE) fatigue index for peak tension (PI) and mean tension (MIJ between
baseline measurements and subsequently at the oestrogen and progestogen phase of hormone replacement
therapy (HRI).
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4.4.4. Discussion
The influence of reproductive hormones on force generation in skeletal muscle is becoming
more apparent. Under hypo-oestrogenic/hypo-progestogenic conditions, muscle strength is
compromised. In this study, muscle strength was measured prior to hormonal treatment and
monitored during two phases of HRT following 4 months of administration. There was no
significant increase in strength between baseline and the two phases of HRT. When the
oestrogen-only phase was excluded, a significant increase in strength between baseline and the
oestrogen/progestogen phase was observed.
The prevention of muscle weakness of the adductor pollicis (AP) has been reported in post-
menopausal women taking hormone replacement therapy compared to a hypoestrogenic post-
menopausal group (Phillips et al., 1993b). It is not clear if HRT maintains strength, or
enhances the force-generating capacity as no studies have monitored performance before and
after the administrationofHRT. In this study, the results revealed that during the progestogen
phase, muscle strength was higher than during the oestrogen-only phase of treatment. These
findings have important implications in the administration of HRT, since hysterectomised
women do not require progestogen, and are routinely administered unopposed oestrogen.
Progestogens is only added to preparations for women with an intact uterus to prevent
endometrial hyperplasia and reduce the occurrence of carcinoma (Whitehead and Godfree,
1992).
Since the mechanismsofhonnonal action on muscle function are still speculative, it is not clear
if endogenous reproductive hormones act in the same way on skeletal muscle as exogenous
synthetic hormones. Due to the rapid hepat~cmetabolism of oral (micronised) progesterone
(Whitehead et al., 1990), progestogens are administered inHRT preparations. They can either
be of C-19 nortestosterone derivatives (e.g. norgestrel, norethindrone) which are androgenic
or of the C-21 derivatives of progesterone (eg. medroxyprogesterone). The undesirable side
effects of progestogens - breast tenderness, bloatedness, oedema, abdominal cramps,
irritability and anxiety - implicate their effects on electrolyte imbalance and on the central
nervous system. It is also believed that progestogens antagonize the beneficial effects of
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oestrogen on the arterial system by decreasing HDL and increasing LDL. Even though this was
initially attributed to androgenic progestogens, medroxyprogesterone, a progesterone
derivative, has also been shown to reduce HDL-cholesterol (Ottosson et at, 1985). The
antagonistic effects are not class-specific and dydrogesterone does not have the same effect as
medroxyprogesterone, despite being a progesterone derivative.
It is therefore difficult to suggest what mechanisms are operating for progestogens to enhance
strength. The difference in source of derivatives, and inter-class variability of progestogens
makes it difficult to isolate its effects. Phillips et al. (1993b), whose work supports the role of
oestrogen for influencing specific force, suggested that oestrogen exerts its effects through
altering the sensitivity of the cross-bridges to inorganic phosphate (Pi) and pH. High Pi (and
low pH) switches the equilibrium of cross-bridge attachment between low and high force states
but when a rapid stretch is applied to the muscle, this weakness is absent. Stretching forces the
cross-bridges into the high-force state regardless of the force state at the onset of the stretch
(Lombardi and Piazzesi, 1990). The influence of progesterone on these metabolites warrants
examination.
It may be construed that a systematic increase in strength occurred as a result of
familiarisation, particularly since no practice session was undertaken. Given that the IVF
patients were subject to the same protocol and no change in force production was found, and
that the oestrogen and progestogen phases were counterbalanced, it is reasonable to speculate
that reproductive hormones influenced muscle function.
The 20/50% is an indicator of the force-frequency curve, and any changes in force at these
frequencies will be reflected in this ratio. The mean ratio across phases was higher for the
oestrogen phase due to the reduction in force at 50 Hz (Fig 4.4.2). These differences were not
significantly different, probably due to too few subjects and great inter-individual variation.
The cause for a drop in force at this higher frequency for the oestrogen phase is not known.
However, there is a clear left-shift in the force-frequency curve in the progestogen phase from
baseline. This shows that greater force is generated across all frequencies as a percentage of
100 Hz compared to the hypo-hormonal state. A left-shift in the force-frequency curve has also
been demonstrated during the menstrual cycle for the quadriceps at mid-cycle (corresponding
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to high oestrogen, low progesterone) from mid-luteal (corresponding to high oestrogen, high
progesterone) (Sarwar et al., 1995). These results do not concur with those obtained with
exogenous hormones in post-menopausal women. Furthermore, it may be erroneous to
compare responses from the quadriceps, a large multi-pennated muscle group with the FDI, a
single-fibred muscle, despite the similar fibre composition (Johnson et al., 1973).
If the lack of hormonal influences at the level of the cross-bridge was responsible for muscle
weakness, forces generated at low-frequencies would be expected to be affected, via
excitation-contraction coupling. The observation that forces are also lower at higher
frequencies of stimulation at baseline may indicate also that progestogen affects neuromuscular
transmission, maybe mediated through acetlycholine (ACh) release, or propagation of the
neurotransmitter signal. The role of oestrogen and progesterone on muscle function need to be
established before their mechanisms of action can be investigated.
Fatigue of the FDI was induced through electrical impulses delivered over 3 min. There were
no significant differences in the fatigue index (%) across phases of treatment, for peak tension
(PT) or mean tension (Mf). The lack of changes in fatigue resistance with hormonal
manipulation has been found with each study using this measure (study 4.2 and 4.3). However,
Sarwar et at. (1996) reported a pattern of change in fatiguability across the menstual cycle. The
quadriceps were least fatiguable at the mid-luteal phase, when progesterone levels are at their
highest. The authors attributed the fatigue resistance at this phase to progesterone, which in
addition to its thermogenic properties, preserves glycogen stores during the luteal phase. The
muscle would be expected to be reliant on glycogen due to the ischaemic conditions induced
by the fatigue protocol. Whether progestogens have the same effect on glycogen storage as
'natural' progesterone is not known. However, the lack of trend in the fatigue index could be
more easily explained by the some factor such as using percutaneous stimulation of the muscle
rather than supramaxima1 stimulation via the motor nerve, where greater force output would be
attained. This did not occur during the menstrual cycle examined in study 4.2.
In conclusion, there was a significant difference in strength before and during HRT, in which
progestogen and oestrogen combined resulted in an increase in the force-generating capacity of
the muscle. There were no other changes in either contractility or fatigue resistance of the
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muscle as a result oflIRT, and thus the question of the mechanism of action of hormones on
muscle function is still unresolved. The positive role of progestogens on muscle strength is
paradoxical to the many side effects of this synthetic hormone which can reduce the quality of
life of affected post-menopausal women. However, without this component added to HRT
preparations to prevent endometrial hyperplasia, carcinoma is highly likely.
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4.5. Sununary
1) Maximal force of the quadriceps declined over 9 months in hypo estrogenic post-menopausal
females at 9 to 10%, measured isometrically and at 1.05 rad/s. There was no evidence of a
reduction in strength at higher angular velocities, or for handgrip.
2) Muscle weakness was not observed in menopausaVpost-menopausal females taking
hormone replacement therapy (HRT). This implicates reproductive hormones in strength
losses.
3) Isometric strength in young females declines during the menstrual cycle, corresponding with
pre-Lll peak. Strength peaked at the mid-luteal phase when progesterone was highest. The
relationship between these parameters suggests that progesterone is involved in force
generation.
4) The fluctuations in strength of the quadriceps are not manifest in the FDI. There were also
no changes in contractility or fatigue resistance in the quadriceps related to changes in
endogenous hormones.
5) Strength meas~ements across the cycle in oral contraceptive users were not unaltered,
indicating that continuous administration of exogenous steroid sex hormones do not
influence force production.
6) Acute changes in oestrogen were not accompanied by changes in strength or fatiguability of
the FDI. Unopposed oestrogen does not therefore appear to be involved in force changes.
7) Following four months of oestrogen/progestogen replacement therapy, strength did not
increase from baseline to different phases of hormone replacement therapy (HRT) in post-
menopausal females. Strength of the FDI increased from baseline to the
oestrogen/progestogen phase by lS.2±20.6% which may further implicate progesterone-
related component in force production.
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S)(NTHESIS OF FINDIN6S
5.0. SYNTHESIS OF FINDINGS
Thepurpose of this chapter is to collate the findings from the studies undertaken in
this thesis and determine the extent to which the hypotheses and aims have been
realised The outcome of the findings will be discussed in reference to the
consequences and clinical application of the results.
5.1. REALISATION OF AIMS
The rate of strength Joss in hypoestrogenic post-menopausal women was ascertained in
the longitudinal study, fulfilling aim 1. Maximal strength of the quadriceps declined
markedly at a rate of 10 and 9 % for 0 and 1.05 rad/s respectively, but was not evident
at higher angular velocities or in grip strength.
In the menstrua1 cycle model peak strength of the quadriceps occurred at the mid-luteal
phase in concert with greatest progesterone concentration (aim 2a), demonstrating
changes in strength of the quadriceps but not for the first dorsal intersseus (FDI). In
the IVF model, despite large acute changes in oestrogen, no changes in strength wree
reported. These data suggest that oestrogen does not promote an independent effect
on muscle strength (aim 3). The efficacy of hormone replacement therapy (HRT) in
preventing post-mcnopausalloss in muscle strength was established in study 4.0. This
indicated that combined oestrogen and progesterone had an effect (aim 4.0).
Other indices of muscle function i.e. contractile properties and fatigue resistance, were
investigated during acute changes in endogenous hormones (aim 2b and 3b) and with
the administration of honnone replacement therapy (HRT) (aim 4b). There were no
changes in fatiguability or contractile properties under these conditions.
The secondary aims of the methodology section (Chapter 3) were also realised,
establishing the reliability of the equipment, techniques and protocols employed in the
experimental studies.
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5.2. REVIEW OF HYPOTHESES
The hypotheses proposed throughout the experimental studies will be reviewed, and
accepted or disproved according to the findings,
Hypothesis 1. Maximal strength decline over 12months in women
within 1 to 3years post-menopause.
This hypothesis is accepted, a reduction in strength in post-menopausal women was
reported for isometric and dynamic leg strength at 1.05 rad/s. This was only significant
however, when the post-menopausal group was compared with the HRT group only.
The peri-menopausal group had no effect.
IIypothesis 2. There is no change in maximal strength in females
laking hormone replacement therapy (HRT).
Maximal strength remained stable for each strength parameter measured. This
hypothesis was accepted.
Hypothesis 3. Strength loss in hypoestrogenic post-menopausal
women is of the same proportion with increasing
angular velocities.
This hypothesis was rejected. Strength loss in post-menopausal women was only
significant at zero or slow angular velocities (1.05 rad/s).
Hypothesis 4. Maximal strength of the quadriceps and FDI is greater
when oestrogen concentrations are at their highest.
Maximal strength of the quadriceps did not peak with high oestrogen levels. There was
no significant relationship between muscle and circulating oestrogen. This hypothesis
was rejected. Maximal force of the FDI did not change.
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Hypothesis 5. Changes in hormone levels result in a shift of the force-
frequency curve.
This hypothesis was rejected since there was no change in the 20150 Hz ratio during
the menstrual cycle.
Hypothesis 6. The quadriceps are least fatiguable when progesterone
levels are high.
There were no changes in the fatigue resistance of the quadriceps during the menstrual
cycle, and therefore progesterone did not exert the effect as previously postulated. This
hypothesis was rejected.
Hypothesis 7. Maximal force production increases from hypo- to
hyperoestogenic conditions during in vitro fertilisation
treatment.
This hypothesis was rejected. The hypo- and hyperoestrogenic conditions experienced
during in vitro fertilisation treatment did not have an effect on maximal force generated
in the FDI.
Hypothesis 8. The fatigue resistance of the FDI changes during
hypo- and hyperoestrogenic conditions.
The fatigue resistance of the FDI also remained stable across treatment and this
hypothesis was therefore rejected.
Hypothesis 9. Force production of the FDI increases from baseline
levels during HRT.
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This hypothesis was rejected since force did not increase when both phases of
treatment (oestrogen and oestrogen/progestogen) were considered. Exclusion of the
oestrogen-only phase resulted in an increase in force between baseline and the
oestrogen/progestogen phase.
Hypothesis 10. The oestrogen - progestogen phase of HRT results in
greater force production of the FDI compared with
oestrogen-only.
This hypothesis was rejected. There was no difference in maximal strength of the FDI
between the two phases ofHRT.
Hypothesis 11. Contractile properties of the FDI differ with
the adminstration of HRT.
This hypothesis was rejected. The 20/50 Hz ratio was no different before or after the
administration ofHRT.
Hypothesis 12. Administration of HRT induces greater fatigue
resistance compared with baseline values.
The fatiguability of the FDI during electrically stimulated contractions did not alter
with hormonal replacement. This hypothesis was subsequently rejected.
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5.2. GENERAL DISCUSSION
The longitudinal study has revealed that a significant loss of strength occurred in post-
menopausal women of 9 and 10% per annum for dynamic (1.05 rad/s) and isometric
contractions respectively. This rapid weakening of the quadriceps corresponds with the
accelerated loss of bone mass reported at the menopause in response to the reduction
in reproductive sex hormones. Whether this rate of force loss continued was not
examined in this study, although it is predicted that it would reach a plateau similarly to
that shown for menopausal bone loss. The group of peri/post-menopausal women who
were undergoing hormone replacement therapy (HRT) did not experience any strength
deficits, further implicating the involvement of reproductive hormones in regulating
force production. These data suggest that HRT may confer protection against muscle
weakness of the quadriceps, an important muscle group for ambulation and balance.
and thereby reducing the risk of falling and sustaining an osteoporotic fracture.
The findings from this study corroborate cross-sectional data of Phillips et al. (1993b),
who reported a significant reduction in specific force i.e. force per cross-sectional area
(force/CSA) of the adductor pollicis (AP) in women at -50 years. Furthermore,
specific force was greater in post-menopausal women taking HRT compared with
hypoestrogenic age-matched controls. Whilst both studies demonstrated an
hormonally-related strength loss, the hormone responsible cannot be elucidated in the
menopause/post-menopausal model. Phillips et at. (1993b) advocated oestrogen as the
hormone affecting muscle strength. They verified this supposition from observations of
strength changes during the menstrual cycle (Phillips et al., 1996). A pre-ovulatory
peak in strength of the AP, followed by a rapid decline 1 to 2 days later was reported
to parallel the acute changes in oestrogen characteristic of the ovulatory phase.
However. they failed to find significant correlations in relative strength with circulating
oestrogen levels (Phillips et al., 1996).
The changes in force production of the quadriceps during the menstrual cycle in this
thesis did not support those reported by Phillips et al. (1996). A gradual increase in
strength was observed during the follicular phase of the cycle, which was followed by a
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rapid drop prior to the LH surge. A secondary, greater rise in force production reached
its peak mid-luteal These force changes were not coincident with fluctuations in
oestrogen, and there was no relationship between relative strength and circulating
oestradiol,
The menstrual cycle does not lend itself as a good model to isolate any independent
effect of oestrogen. The in vitro fertilisation (IVF) model was therefore employed to
assess muscle function of the first dorsal interosseus (FDI) during 1] down-regulation
of the hypothalamic-pituitary-ovarian axis with suppression of pituitary and
reproductive hormones and 2] during up-regulation with consequently
supraphysiological oestrogen levels. No changes in strength were found during this
treatment. The IVF model provides a unique method of assessing the independent
effects of oestrogen. The massive, acute changes in this hormone, which exceed those
of the menopause, are not observed during normal physiological events. These findings
demonstrate unequivocally that oestrogen alone does not affect the force generating
capacity of muscle.
Finally, there were also Indications from the study assessing the effects and
components ofHRT on strength of the FDI, that oestrogen is not the sole regulator of
force production. From baseline measurements in post-menopausal women, strength
did not increase significantly after four months of treatment when assessed during the
oestrogen-only phase. These findings are preliminary since few subjects were test~d
(n=9), and they only provide tenuous suggestions against oestrogen as the effects of
exogenous hormones on muscle strength, particularly the role in restoring strength, are
not fully understood.
There are reports of oestrogen receptors on skeletal muscle in animal (Dahlberg, 1982)
and humans (Smith et al., 1990). If oestrogen is not the sole regulator of changes in
strength, then some other hormone must be involved. Gonadotropins are important in
the regulation of the reproductive cycle and the synthesis of oestrogen and
progesterone, exerting their effects on reproductive tissues, principally the ovaries.
Both luteinizing hormone (LII) and follicle stimulating hormone (FSH) are elevated in
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post-menopausal women, increasing 18 fold pre-menopausal values. This is
considerably higher for LH. The loss of strength in post-menopausal women could
possibly be associated with the rapid, and very high increases in the gonadotropins.
The trends in strength changes during the menstrual cycle do not contradict this, as
strength peaked mid-lutealwhen gonadotropin levels were low. However, correlations
between relative force and circulating LH and FSH were not significant, suggesting
that gonadotropins were not responsible for changes in strength. This is further
substantiated in the IVF study. Down-regulation suppressed the pituitary release ofLH
and FSH, as well as the reproductive hormones, and subsequent administration of
exogenous pituitary hormones did not result in any reduction in strength.
Progesterone is the only other major hormone involved in reproductive functioning
which could be involved in the strength changes observed so far. Progesterone is
actually the hormone that first becomes deficient at the climacteric. Even though
oestradiol declines at the menopause, a small amount is still produced from the
peripheral conversion of androstenedione to oestrone whereas progesterone is very
low. The findings from this thesis strongly implicatethe involvementof progesterone in
the changes of force production. This was initially observed in the menstrual cycle
study, in which maximal strength of the quadriceps peaked mid-luteal when
progesterone was at its highest. A significant correlation between strength and
circulating progesterone confirmed this pattern of strength change with progesterone
levels.
The IVF model also provided useful evidence supporting the role of progesterone.
During IVF treatment, progesterone does not increase markedly from the baseline
measurements until human chorionic gonadotropic (hCG) hormone is administered. In
this study, the strength measurements were taken prior to hCG administration, and
therefore at a time when progesterone concentration remains constant, as did the
strength of the FDI.
The mechanismby which progesterone may affect muscle strength is conjectural at this
time. There is no known evidence of the presence of progesterone receptors on
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skeletal muscle, although given the recent proposals of a hormally-mediated effect on
muscle function, this may not yet have been investigated. Progesterone and its
metabolites e.g. 3a, Sa - tetrahydroprogesterone, exert diverse effects on various
tissues such as the brain, uterus, smooth muscle and the oocyte. Their effects, which
may be mediated via the classical intracellular receptor, membrane receptors or via the
GAB~ receptor system, depend upon the tissue involved, the dose of progesterone
and time of administration. Ifprogesterone is found to act rapidly, then the latter two
mechanisms are probably involved. Prolonged effects would involve the intracelluar
receptor through which progesterone inhibitsuterine contractility.
The studies within this thesis do not favour the responsibility of oestrogen for
regulating changes in force production. However, the involvementof oestrogen should
not be ignored. Oestrogen may act together with progesterone to exert its effect on
muscle. A significantrelationship between the ratio of oestrogen to progesterone with
leg strength during the present menstrual cycle study implicates the involvement of
both hormones. It was observed that strength peaked mid-luteal when progesterone
and oestrogen were both present. However, force production was also high during the
follicular phase when oestrogen concentrations were greater than progesterone.
Therefore, it may be that progesterone exerts its effects on an oestrogen-primed
muscle. Indeed, this has been demonstrated in reproductive tissue such as the uterus;
the presence of oestrogen is necessary to up-regulate progesterone receptors in the
uterus in preparation for the proliferative luteal phase. Furthermore, the facilitative
effect of progesterone is required for gonadotropin secretion. Oestradiol alone does
not initiate the preovulatory gonadrotropin surge in the ovariectomized rat. Oestradiol
priming is essential for progesterone to exert its action on gonadotropin secretion since
oestrogens are required for the induction of hypothalamic and anterior pituitary
progesterone receptors. Given the pattern of strength changes during the menstrual
cycle it is plausible to suggest an effect upon skeletal muscle. This can be examined
further using the IVF model, and measuring strength at hypo- and hyper oestrogenic
conditions, and following heG administration (when progesterone levels have
increased). Itwould also be of use to examine the effects of progesterone derivatives in
the form of the progestogen only pill on strength.
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The change in strength across the menstrual cycle was not prolonged and appeared to
fluctuate in concert with reproductive hormones. The temporal reduction in force
observed mid-cycle was followed by an increase in strength which shortly attained its
optimal point. This indicates that this is a temporary, but reversible effect. If the same
mechanism operates in hormally-deficient muscle of post-menopausal women, this has
important clinical implications for preventing or treating muscle weakness within this
age-group. The most efficacious treatment for preventing bone loss is HRT, which has
been reported to maintain muscle strength in post-menopausal women This was
confirmed in the longitudinal study since post-menopausal women taking HRT did not
exhibit a reduction in strength.
The recovery of the loss of the force generating capacity of the quadriceps with
fluctuations in endogenous hormones appears to occur with administation of
exogenous hormones. An increase in strength of the FDI was observed m
hypo estrogenic post-menopausal women following hormone replacement therapy from
26.6N at baseline to 30.0N of the oestrogen/progestogen phase, a difference of
+IS.2±20.6%. This further supports the role of oestrogen/progesterone as previously
proposed, corroborated by the lower force values obtained during the oestrogen only
phase. It therefore appears that HRT may restore strength rather than just preventing
further weakening. An adjustment period greater than 4 months for taking HRT may
be necessary for the complete restoration of strength. There is current evidence which
indicates that an increase in strength of the adductor pollicis does occur over 12
months following HRT administration (Woledge, 1997. Unpublished findings,
University College London).
The mean strength of the FDI before (26.6N) and after (30.0N) HRT are comparable
with the differences in strength in young hypoestrogenic IVF patients (-27.0N) and
young females during the menstrual cycle (32-34.0N). The low strength values
observed in the IVF patients may therefore be the result of a decrease in strength in
response to pituitary down regulation, and consequently low reproductive hormones.
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An initial measurement prior to treatment, i.e. during the preceding cycle, would clarify
this and is therefore a recommendation for future research.
If the preservation of muscle strength is conferred by HR.T, then administration of
exogenous hormones would reduce the muscle weakness which impairs performance
and induces vulnerability to falling. The main benefits of this treatment would be two-
fold including the reduction of the accelerated bone loss associated with the
menopause. Unfortunately, this solution would only assist a small proportion of the
female population. Hormone replacement therapy opposed with a progestin is
accompanied by side-effects related to the progestogen component. Hence, this is not
always a favourable treatment in progestogen sensitive females. Under these
circumstances, the promotion of exercise regimens is important, and would not only
increase muscle strength, but would provide a protective mechanism in bone and on
the cardiovascular system.
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CHAPT£RSIX
RECOMMENDATIONS FOR
FUTURE \\fORK
6.0. RECOMMENDATIONS FOR FUTURE WORK
The role of reproductive hormones in regulating muscle strength is a very new
concept, and has important implications in both a clinical environment and in a sporting
context. The findings from the experimental work has therefore lead to many
unanswered questions, and has also generated many more. The recommendations for
future work will focus on in vivo studies, although it is recognised that data from in
vitro research is needed to fully understand the role of oestrogen and progesterone on
skeletal muscle.
(1) A longitudinal study undertaken over a longer duration, from 5 to 10 years, is
needed, to reveal in greater detail the time course of the strength changes associated
with the menopause. This would also determine whether the rapid loss in strength
observed over 1 year plateau as the post-menopausal era is prolonged. The beneficial
effects of exercise and/or HRT assessed over this time period would determine the
most effective prophylaxis in preventing hormonally-related muscle weakness.
(2) There is still speculation of whether reproductive hormones are involved in
regulating muscle function. Assessment of strength before IVF treatment ie. during the
preceding cycle, and during IVF treatment would demonstrate if a loss of strength
occurred as a result of pituitary down-regulation. While this may further implicate the
role of reproductive hormones, it would also justify the low strength values of the FDI
attained in IVF patients.
(3) The outcome of this thesis is that reproductive hormones exert an effect on muscle
strength, and that progestrone is likely to be involved. This needs to be investigated
further. It is impossible to isolate the effects of progesterone in vivo, although the
proposed synergistic effects of oestrogen and progesterone can be tested using the
following models:
a) Utilising the IVF model, assessing strength during treatment when oestrogen levels
are manipulated, and following the administration of heG would allow the
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comparison of strength when oestrogen and progesterone (and LHlFSH) are very
low, when oestrogen is high but progesterone is low, and when oestrogen and
progesterone are high. Strength can be measured confidently under these controlled
conditions, unlike the endogenous fluctuations during the menstrual cycle.
b) Assessment of strength before and during the administration of the progestogen-
only pill in young women would allow the effects of this progesterone-derivative to
be examined. The progestogen-only pill suppresses ouvlation is some women and
thus careful monitoring of hormone levels would be necessary.
c) Oestrogen and progesterone are elevated during pregnancy. Monitoring strength
before and during pregnancy would elucidate the effects of a rise in hormones levels
on muscle function. The rapid decline in these hormones on strength could be tested
postpartum.
(4) Preliminary findings suggest that HRT may restore strength. This needs to be
examined further using larger subject numbers, and controlling for the HRT
preparation. In a large randomised study, baseline levels of strength in post-
menopausal women should be compared with measurements taken after the
stabilisation on HRT, using combined preparations (i.e. in women with an intact
uterus).
(5) The reversible effects of hormonally-related strength deficits applicable to post-
menopausal women can be measured with endogenous hormonal changes. Medically-
induced amenorrhoea is used to relieve disorders such as endometriosis with the same
methods as the IVF treatment, but for a longer duration (up to 6 months). Using these
patients, strength before, during hypoestrogeniaJprogesteronia, and in a follow-up trial
will allow the changes in strength to be characterised. This will also establish if any
strength deficits are reversed with resumption of menses, which will have important
applications for menopausal and amenorrhoeic sedentary and athletic women.
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APPENDICES
APPENDIX ONE
LEISURE TIME ACTIVITY
QUESTIONNAIRE
5. Physical activity
5.1 Have the last two weeks been typical of your normal levels of leisure time
physical activity? yes/no
5.2 Ifno, inwhat ways were they not typical?
---------------------------------------------------------------------------------
---------------------------------------------------------------------------------
5.3 On a scale of 1-5, rate the level of your present fitness compared to other people
your age?
very poor poor average good excellent
1 2 3 4 5
Date of activity recall•••••••••••••••.•••
Activity List
ACTIVITIES (1) FREQUENCY DURATION SWEAT
-----------------------------------------------------------
Aerobic dancing (intense) yes/no
Boxing:
In ring
Sparring
Soccer
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/ no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
---- yes/no
yes/no
yes/no
yes/no
Basketball
Circuit training
Hill climbing:
With 5 kg load
With 10 kg load
With 20 kg load
Cycling (race)
Gardening (digging)
Hockey
Jogging
Judo
Running
11.5 min/mile
9 min/mile
7.5 min/mile
6 min/mile
5.5 min/mile
cross country
Squash
Swimming:
Back stroke
Breast stroke
Crawl (slow)
Please indicate how often (frequency) tbe activity was performed, for how long (duration) and
whether you sweated. For example: If you performed the activity once a day for 20 minutes but
did not sweat then:
1 20 mins yes/no
ACTIVITIES (2) FREQUENCY DURATION SWEAT
Aerobic dancing (moderate) yes/no
Badminton yes/no
Ballet
Crieketr-
Batting
Bowling
Cycling (leisurely: 9.4mpb.)
Dancing
Hill climbing (no load)
Ice skating (less than 9 mph.)
Karate
Roller skating
Tennis:
Singles
Doubles
Walking (4.5 mpb. level)
Weight lifting/training
yes/no
yes/no
yes/no
yes/no
--- yes/no
------ yes/no
--- yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
ACTIVITIES (3) FREQUENCY DURATION SWEAT
---- yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
Bowls
Cricket (fielding)
Cycling (leisurely: 5.5 mph.)
Drumming
Gardening
Hedging
Raking
Golf
Horse riding
Lawn mowing (push-type)
Table Tennis
Sailing
Volleyball
Walking
J.Omph
4.0 mph
Window cleaning
ACTIVITIES (4) FREQUENCY DURATION SWEAT
yes/no
yes/no
yes/no
---- yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
yes/no
Althetics (track and field)
Bowling (ten pin)
Canoeing
Caving/potholing
Fencing
Five-a-side soccer
Gymnastics
Lacrosse
Mountain climbing
Netball
Recreational swimming
Trampolining
APPENDIX TWo
MEAN ±SD OF FORCE FOR DIFFERENT MUSCLE
GROUPS ACROSS ALL ANGULAR VELOCITIES.
Al=HRT
A2=PERI-MENOPAUSAL WOMEN
A3=POST-MENOPAUSAL WOMEN
Table A.I. Mean values (± SD) of force across a range of angular velocities for the Hormone
Replacement Therapy (HR1) group. All subjects completed the five testing sessions for leg (Nm) and
grip (ft Ibs) strength.
HRTGroup
N=l1 EXTENSORS (NM) FLEXORS (NM)
Angular velocity (rad/s) T1 T2 T3 T4 T5 T1 T2 T3 T4 T5
o (900 of flexion) 114.7 114.0 113.8 112.4 111.8 * * * * *
(28.2) (24.0) (22.4) (23.4) (24.4)
1.04 127.1 125.9 125.8 128.8 122.0 67.4 69.9 66.7 68.8 64.8
(25.2) (25.6) (31.8) (26.0) (29.9) (16.5) (20.6) (19.5) (19.8) (19.3)
2.09 93.6 94.8 94.4 93.7 93.4 54.1 55.7 54.8 54.0 52.4
(14.0) (19.3) (19.2) (16.2) (20.9) (13.9) (15.4) (15.7) (15.4) (15.3)
3.13 80.5 80.4 79.4 79.9 80.6 46.6 47.2 45.8 46.6 45.1
(14.9) (16.6) (14.4) (14.9) (16.8) (11.4) (14.4) (11.6) (12.7) (13.0)
5.22 * * * * 74.1 * * * * 48.1
(16.3) (12.6)
0(600 flexion) • • • * 141.4 * * * * *
(28.5)
Grip Strength (Ft lbs) 27.2 26.2 27.4 26.2 25.6
(4.6) (4.6) (3.7) (5.2) (4.2)
Table A.2. Mean values (± SD) of force across a range of angular velocities for the Perimenopausal
group. All subjects completed the five testing sessions for leg (Nm) and grip (ft Ibs) strength.
PerLM. Group
N=9 EXTENSORS (NM) FLEXORS (NM)
Angular velocity (rad/s) T1 T2 T3 T4 T5 T1 T2 T3 T4 T5
o (900 of flexion) 117.7 115.9 112.3 111.3 112.1 • • • • •
(28.4) (29.0) (30.9) (31.5) (29.0)
1.04 136.8 134.3 131.3 133.0 133.9 68.3 70.1 69.1 72.2 64.3
(29.5) (27.7) (19.3) (30.0) (20.3) (22.1) (20.5) (15.6) (21.4) (15.0)
2.09 100.9 100.9 101.4 98.6 103.1 59.2 58.7 56.3 58.7 59.2
(24.1) (18.9) (21.2) (16.7) (17.2) (15.8) (16.5) (14.8) (11.8) (10.4)
3.13 87.4 87.6 88.6 85.3 89.7 50.4 51.1 48.4 50.6 50.3
(19.6) (16.7) (18.6) (16.4) (17.4) (11.9) (12.8) (14.2) (13.2) (10.8)
5.22 • • • • 79.3 • • • • 55.4
(22.1) (17.0)
• • • • 145.8 • • • • •0(600 flexion)
(34.2)
Grip Strength (Ft lbs) 29.3 27.7 29.0 28.4 27.1
(3.0) (3.2) (3.0) (2.9) (3.4)
Table A.3: Mean values (± SD) offorce across a range of angular velocities for the Post-menopausal
group. All subjects completed the first four testing sessions for leg (Nm) and grip (ft Ibs) strength.
Only 7 subjects completed every session (>12 months).
Post.M. Group
N=lO EXTENSORS (NM) FLEXORS (NM)
Angular velocity (radls) T1 T2 T3 T4 T5 T1 T2 T3 T4 T5
o (900 of flexion) 122.3 123.8 113.5 109.7 109.4 * * * * *
(19.9) (20.8) (22.7) (20.4) (27.7)
1.04 127.5 131.0 122.8 116.5 124.1 68.2 70.4 67.2 66.7 69.0
(17.8) (27.4) (27.6) (26.5) (20.1) (16.5) (20.6) (19.5) (19.8) (19.3)
2.09 90.9 90.5 89.7 86.7 89.4 54.1 55.7 54.8 54.0 52.4
(16.6) (22.1) (20.4) (20.3) (13.6) (13.4) (15.4) (15.7) (15.4) (15.3)
3.13 76.8 77.4 78.0 75.3 80.1 44.8 44.5 44.9 44.7 47.3
(15.9) (13.8) (17.7) (20.0) (12.4) (12.1)(7.32) (11.5)(11.3) (9.7)
5.22 * • * * 72.0 • • * * 50.S
(11.5) (10.7)
0(600 flexion) * • * * 146.7 * * * * *
(28.4)
Grip Strength (Ft lbs) 28.S 27.2 27.6 27.0 27.4
(7.1) (6.8) (7.0) (6.6) (5.5)
Values in italics for the last test represents N=7.
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Effects of acute changes in oestrogen on muscle function of the
first dorsal interosseus muscle in humans
J. P. Greeves , N. T. Cable *, M. J. M. Luckas t,T. Reilly and M. M. Biljan t
Centre for Sport and Exercise Sciences, Liverpool John Moore8 University, Byrom Street,
Liverpool L3 3AF and t Reproductive Medicine Unit, Liverpool Women8 Hospital,
Crown Street, Liverpool L8 7S8, UK
1. To investigate the effect of the female reproductive hormones on muscle function, patients
undergoing in vitro fertilization were tested during two phases of treatment. The first was
following the down regulation of pituitary gonadotrophin releasing hormone (GnRH)
receptors and the second after 9 days of gonadotrophin injections.
2. Maximal strength and fatiguability of the first dorsal interosseus muscle were assessed when
oestrogen and progesterone were low, and less than 2 weeks later when oestrogen production
reached supraphysiologicaJ levels.
3. There were no significant changes in either strength or fatigue resistance during acute,
massive fluctuations in oestrogen. These results occurred at a time when progesterone levels
remained relatively low.
4. Contrary to previous work, the present results suggest that oestrogen does not affect muscle
strength.
The menopause is defined as a loss of ovarian function,
characterized by very low concentrations of oestrogen and
progesterone (Whitehead &; Godfree, 1994). This hormonal
change has been aseooieted with a significant reduction in
maximal voluntary contraction per cross-sectional area.
. (MVC/CSA) in postmenopa.usa.l women for the adductor
pollicis muscle (Phillips, Rook, Siddle, Bruce & Woledge,
19936; Phillips, Rowbury, Bruce & Woledge, 1993c) and
the quadriceps (Rutherford &; Jones, 1992). Administration
of hormone replacement therapy prevents the loss of specific
~or~ ~iated with the menopause (Phillips et al. 1993b),
indicating that this muscle weakness is related to changes in
reproducti~e hormone status, rather than an age-related
decrement 10 the force-generating capacity of muscle (Bruce,
Newton &; Woledge, 1989).
Both oestrogen and progesterone levels diminish at the
meno~ause and thus the hormone responsible for the
reduction Of. force-generating capacity is uncertain. In
eumenorrhoeio younger females there are cyclical changes in
strength of the adductor pollicis (Phillips, Gopinathan,
Meehan, Bruce &; Woledge, 1993a) and the quadriceps
(Sarwar, Beltran Niclos & Rutherford, 1996) during the
menstrual cycle. Maximum strength is reported to coincide
with the mid-cycle peak of oestrogen and lowest force
production occurs at the post-ovulatory trough of oestrogen
concentrations (Phillips, Rutherford, Birch, Bruce &;
Woledge, 1995). Current evidence therefore supports the
positive rol~of oestrogen for enhancing strength.
In the present study, the independent effect of oestrogen on
muscle function was examined in young females undergoing
in vitro fertilization (IVF). In this model, oestrogen levels
are significantly reduced after 3weeks of administration of
gonadotrophin releasing hormone (GnRH) analogues, which
downregulate pituitary GnRH receptors. Secretion of
gonadotrophin and ovarian steroid hormones is subsequently
suppressed. This is followed by 9-10 days of injected
exogenous gonadotrophins, which hyperstimulate the ovaries
to produce multiple follicles and consequently very high
oestrogen levels.
Maximal voluntary contraction (MVC) and fatigue
characteristics of a small muscle, the first dorsal interosseus
(FDI), were measured following downregulation and during
hyperstimulation of the ovary.
METHODS
Subjects
Fourteen volunteers undergoing in vitro fertilization treatment,
with a mean ± S.D. age of 34'7 ± 4'2 years, height of 162'2 ± 4'5 cm
and body mass of 61'1 ± 6'2 kg were recruited from the
Reproductive Medicine Unit of the Liverpool Women's Hospital.
Informed consent was obtained by the medical staff and the
patients were referred to the laboratory. The cause of infertility in
• To whom correspondence should he addressed.
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Table 1. Oestradiol concentrations and endometrial thicltnet18
of patients ... determinants of adequate downreguJa.tion and
hyperstimuJa.tion of in llitro fertilization treatment
Condition Oestradiol
(pmol T']
Endometrial lining
(mm)
Hypoestrogenia
Hyperoestrogen ia
10-100
1551-9935
all the ubjects recruited in this study was damaged fallopian tubes.
Their follicle stimulating hormone (FSH) levels at day 2 or 3 of the
menstrual cycle were 2 to 6 U 1--1indicating normal ovarian fUl'lOtion
and reserve (Toner, 1993). Patiente with abnormal fotl'
stimu1&ting hormone (FSH): luteinizing hormone (LII) rat· ,
oligom norrhoe& or ultrasonic evidence 8ugge&ting polyoyatio
ova.ria.n syndrome were excluded from the study. Pati nte taking
medica.tioo likely to affect mu.acle strength did not pactioip&te.
8ubjecta gave their written informed oonaent to p&rtioipate in tbe
BtIldy. whi<il WIllI approved by the Etbial ChnmiIitAl(l8 of Livotpool
John Moores Univemty and The Royal LiVerpool Uni~ty'
Hospital.
Experimental protocol
Maximal voluntary oontraction and fatigue resiatance of the FDI
were measured on two occasions, aepuated by 9 day •. All
were performed in the morning. The first measurem t wu
Fi ure 1
Uyn mom
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experiment a reading lamp was positioned at a standard distance
over the muscle. Whilst muscle temperature was not measured, this
procedure was repeated on both occasions in an attempt to
standardize muscle temperature.
The FDI was stimulated percutaneously with self-adhesive surface
electrodes (3M Hea.lthcare, St Paul, MN, USA). The cathode was
positioned on the belly of the FDI and the anode placed near the
carpometacarpal joint of the thumb. The muscle was stimulated
with 1 and 40 Hz tetani to confirm accurate location of the
electrodes. Electrical impulses were applied at 150 V at a pulse
width of 100 p.s duration with a computer-driven Digitimer
stimulator (ModelDS7, Digitimer Ltd, Welwyn Garden City, UK).
The force output was amplified and visually displayed on an Apple
Maointosh computer, interfaced with a data acquisition system
(BiopaoMPl00WS, Santa Barbara, CA, USA).
Maximal voluntary oontraction
Maximal volunatary contraction of the FDI was measured whilst
fully abducting the index finger. This is the only muscle involved in
producing this movement. Superimposed percutaneous electrical
stimulation was employed to ensure maximal activation of the FDI.
Disappearance of the 1 Hz impulses confirmed maximal volitional
force. Eaoh trial was preceded by a 60 s rest interval. The highest
of three trials was recorded. The coefficient of variation (c.v.)from
repeated tests using this technique in our laboratory is 9'6% with
limits of agreement ranging from -8'54 to 8'43 N.
Fatigue charaoteristics
Fatigue resistance of the FDI was assessed using a modified Burke
protocol (Burke, Levine, Tsairis & Zajao, 1973). This involved
repeatedly stimulating the muscle for 3 min at 40 Hz with a 1 s
interval between each tetanic contraction. Patients were not able to
A --n
t.../-------
1 S
c
tolerate voltages that were sufficient to elicit maximal stimulation
of the muscle, although the current was constant for individual
subjects between tests. Forces of up to 20% of maximal voluntary
contraction (MVC)were recorded. Figure 2A and B displays typical
myograms of a tetanic contraction in a fresh and fatigued state. The
fatigue index (FI) was calculated as the percentage loss of force over
the 3 min (Fig. 2C). Speed of relaxation was measured as the time
taken for peak force to reach half-peak force. A 2 min rest was
allowed between the MVC and before commencing the fatigue test.
Fatigue results are presented for seven subjects; the remaining
patients did not tolerate the 40 Hz electrical impulse.
Statistical analysis
Differences in MVC and fatigue characteristics (force loss, mean
time to peak tension and relaxation rate expressed as percentage of
initial force) between the two test conditions were assessed using
Student's paired I tests. The significance levelwas set at 5%.
RESULTS
Maximal voluntary contra.ction
There were no significant differences in maximal voluntary
contraction of the FDI between the low (27'9 ± 1'6 N) and
high (27'5 ± 1'5 N) oestrogen conditions (means ± S.E.M.)
(P> 0'05). This is seen in Fig. 3.
Fatigue test
A typical myogram of the fatigue test is shown in Fig. 2C.
There were no statistically significant differences in any of
the fatigue parameters measured during the fatigue test
between the two trials (P> 0'05). There was a loss of peak
B
/~.
~ -------j~-
1 s
Figure 2. Typical myograms from the fatigue test
A, tetani in fresh muscle showin.g half-relaxation time (t",). B, tetani in fatigued muscle illustrating slowing
of relaxation. C, trace from a fatigue test (I s, 40 Hz twitch for 3 min).
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tension over the 3 min of 36'4 ± 6'8 % in the hypoestrogenic
and 42'5 ± 15'6% in the hyperoestrogenic condition. Mean
twitch tension also diminished to 58'9 ± 7'6 and
57'5 ± 9'2% of its initial value following the low and high
oestrogen concentrations, respectively. Half-relaxation time
increased by 52'9 ± 16'4 and 81'4 ± 20'1 % during the
fatigue test in hypo- and hyperoestrogenic conditions,
respectively.
DISCUSSION
Muscle function wa.s measured in IVF patients following (1)
downregulation of pituitary GnRH receptors and (2)
administration of exogenous gonadotrophins. The hormonal
consequences of this treatment are low oestrogen levels due
to a. lack of pituitary stimulation and subsequently massive
inereasss in oestrogen concentrations due to development of
multiple follicles. Under these conditions, we did not observe
any change in maximal strength or fatigue resistance of the
FDI.
These results suggest that oestrogen does not influence force.
However, muscle weakness reported in postmenopausal
250
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Figure 3
Maximal voluntary contraction (MVC; me&118± S.R.M.) of the first
dorsal interosseus (FDI) muscle in hypoestrogenic (II) and hyper-
oestrogenic females (0). There was no significant difference
between treatments.
women is prevented in females taking hormone replacement
therapy (Philllips et al. 1993b) implicating the role of
reproductive hormones in this loss of strength. Evidence
from studies undertaken during the menstrual cycle also
indicates oestrogen is responsible for these changes in
strength, as maximal strength is greatest around midcycle,
at the peak of oestrogen production (Phillips et al. 1993a;
Sarwar et al. 1996).
In the above models, oestrogen is accompanied by
fluctuations in the other main reproductive hormone,
progesterone, and peptide gonadotrophins follicle stimulating
hormone (FSH) and luteinizing hormone (LH), this makes
it impossible to isolate the hormone responsible for a.
strengthening effect. In IVF patients, pituitary down-
regulation suppresses both oestrogen and progesterone.
Oestrogen increases with subsequent gonadotrophin
administration while progesterone remains low. Although
progesterone concentrations were not measured in the
present study, progesterone values during this procedure
remain low until buman chorionic gonadotrophin (hCG) is
given prior to egg collection (Harada et al.1995). Patients in
this study were-tested before hCG was given. Consequently,
Figure 4. Fatigue characteristics of the FDI
muscle in hypoestrogenic and hyperoestrogenio
females
•• hypoestrogenia; D. hyperoestrogenia. Values at the
end of the fatigue test for peak tension (fYf). mean
tension (MT)and half-relaxation time (/1<,) are reported
as a percentage of initial value. There were no
significant differences between treatments for any
variable.
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muscle strength Was examined when both oestrogen and
progesterone concentrations were very low and again with
high oestrogen and low progesterone concentrations.
To our knowledge, this is the first study to assess the
strength-related effects of oestrogen independently from
other reproductive hormones. Furthermore, down regulation
of GnRH receptors at the stage of IVF treatment inhibits
gonadotrophin secretion. The subsequent administration of
these peptide hormones, initiating follicular growth, results
in high concentrations of the gonadotrophins concurrent
with the increasing levels of oestrogen. These results
therefore also suggest that muscle strength is not influenced
by fluctuations in LH and FSH which occur at this time.
Since the present study argues against an independent role
of oestrogen on muscle strength, the alterations in force
production cited in previous work (Phillips el al.1993a, b, c;
Sarwar et al. 1996) may be influenced by progesterone, or
may be a consequence of an interaction between oestrogen
and progesterone. This possibility is supported by the
observation that the force-generating capacity of the FDI in
the IVF patients was much lower than age-matched females
at the same stage of the menstrual cycle in our laboratory
(J. Greeves, unpublished observations). Due to the nature of
subject recruitment in the present study, it was not possible
to establish baseline values of MVC prior to pituitary
down regulation. The possibility therefore exists that the
MVCs measured after down regulation may be reduced in
response to a decline in progesterone concentrations. The
fact that MVC values remained constant following hyper-
stimulation of the ovary (producing large increases in
oestrogen but little change in progesterone] further
implicates progesterone as a moderator of muscle strength.
This hypothesis warrants further investigation:
Our findings against a positive effect of oestrogen have
been demonstrated in previous work. Bassey, Coates,
Culpan, Littlewood, Owen & Wilson (1995) reported that
oestrogen h~ a negative influence on strength. In young,
eumenorrhoelC females, oestrogen concentration was
inversely related to handgrip strength, which declined by
5% with ~ 200 pmol T' rise in oestrogen. Furthermore, in
olJer subjects (aged 45-54 years) of varying menstrual
status, no differences in strength of the quadriceps or in
handgrip strength have been observed (Bassey, Mockett &
Fentem, 1996).
Few studies have used fatiguability as a parameter for
assessing muscle function in relation to hormonal changes.
Electrical stimulation was employed to determine the
fatigue resistance of the FDI via electrically evoked
impulses. There were no significant differences in fatigue
characteristics between the hypo- and hyperoestrogenic
conditions. These observations are contrary to those
reported previously. Sarwar et al. (1996) measured the
quadriceps during five stages of the menstrual cycle, early
and mid-follicular, ovulatory and mid- and late luteal. The
muscle was slower and more fatiguable at ovulation,
compared with the late-luteal phase. No changes were
observed in women on the combined oral contraceptive pill
as a control group.
The fatigue protocol used in the present study differed from
that employed by Sarwar et al. (1996). The frequency of
stimulation was the same although contraction time and
relaxation were longer in duration. AIl a consequence, the
FDI did not fatigue to the same extent as the quadriceps.
This difference was not the result of stimulating a larger
muscle, since the fatigue index of the adductor pollicis and
the FDI are also higher using a similar protocol to previous
studies (Tanaka McDonagh & Davies, 1984; Rutherford &
Jones, 1988; Sarwar et al. 1996). Since the FDI muscle in
the present study was less fatigued, it is possible that any
hormonally induced strength changes were less apparent.
However, given the precise manipulation in the hormonal
milieu, it is far more likely that the lack of change in FI
reflects minimal change in concentration of progesterone.
This hypothesis is supported by the t0bservation that
fatiguability relates to changes in basal body temperature
secondary to increases in progesterone concentration during
the luteal phase (Sarwar et al. 1996).
In conclusion we have failed to detect an independent effect
of oestrogen on muscle function. Given that muscle strength
remained constant when both LH and FSH also changed
markedly, the present results suggest that changes in
progesterone alone, or in combination with other reproductive
hormones, may be responsible for the changes in strength
previously reported, both postmenopausally and during the
menstrual cycle.
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APPENDIX FIVE·
INFORMED CONSENT FORMS
INFORMED CONSENT FORM
Title: The reliability of day-to-day testing of isokinetic leg strength
Researcher: Julie Greeves
The study aims to evaluate test-retest variation of leg strength using the isokinetic
dynamometer at 3 different velocities. You will be required to attend the laboratory on
4 different occasions separated by at least 2-3 days. The first session will familiarise
you with the equipment and procedures involved.
You will initially complete a 5 minute warm-up on the cycle ergometer (65 rpm) and 3
minutes of static stretching of the relevant muscle groups (quadriceps and hamstrings),
Leg strength will be measured on the computerised isokinetic dynamometer and peak
torque of the left and right knee extensors and flexors will be recorded. You will
perform two submaximal and four reciprocal maximal voluntary contractions (MVC)
at angular velocities of 60, 180 and 3000/s. Each trial will be conducted at the same
time of day (l0:00±1 hour) for each session.
All information will remain confidential. Feedback on performance will be given after
the completion of the experiment.
I.••••••••••••••••••••••.•••••••••••••.••••.••••••understand the experimental protocol and have no
objection to participating in this study. I also reserve the right to withdraw from
testing at any time.
SIGNED . DATE .
SUBJECT INFORMED CONSENT
Title: The reliability of day-to-day testing of leg and grip strength in post-
menopausal women with and without hormone replacement therapy
Researcher: Julie Greeves
Experimental protocol
The aim of the study is to assess the test-retest variation of leg and grip strength in
post-menopausal women. One group will be receiving hormone replacement therapy
(HRT) and the other group will be oestrogen deficient ie. not receiving HRT.
Initially a questionnaire will be distnbuted to determine your present health and
gynaecological details. You will then be required to visit the laboratory on 3 different
occasions each lasting 25-30 minutes, separated by 3-4 days. The first session will
familiarise you with the equipment and procedures involved.
You will undertake a 5 minute warm-up on a cycle ergometer at a low resistance,
followed by 3 minutes of static stretching of the upper leg muscles. Leg strength will
be measured at 3 different speeds of the preferred leg of the knee extensors and flexors
for 4 maximal contractions. This will be preceded by 2 submaximal contractions as a
practice run. Each trial will be separated by one minute of passive recovery.
Following a 5 minute rest period, you will be required to contract your muscles
maximally against a non-movable resistance. To ensure you are working maximally (as
hard as possible), electrodes will be positioned on the involved muscle group. This will
cause nQ discomfort or pain. The final test will measure your maximal hand grip
strength and the best of 3 trials will be recorded.
Yo~ will be fre~.ofinjwy to thelower body and dominant ann, or ofpainldiscomfort
which may debilitate performance. Also, you must refrain from strenuous activity 24
hours prior to testing. It is important that constant exercise levels are maintained
throughout the experimental period. Testing will be conducted at the same time of day
for each session
All infonnation will remain confidential. If you would like a fitness assessment ie.
Blood pressure, skinfolds (fat measurements) and lung function, this can be arranged
(this is not obligatory).
1 am willing to participate in this study having
read and understood the experimental protocol. I reserve the right to withdraw
my consent at any time.
SIGNED . DATE .
INFORMED CONSENT FORM
Title: Day-to-day variation inmuscle function of the quadriceps determined
by programmed stimulation electromyography (PSEM) and fatiguability
Researcher: Julie Greeves
This study aims to evaluate the variability in muscle function of the quadriceps assessed
using programmed stimulation electromyogram (PSEM) and fatiguability tests. The
PSEM test involves delivering electrical impulses of two second duration at
frequencies of 1, 10, 20, 50 and 100 Hz. Fatiguability will be measured with 40 Hz
impulsed per second for 3 minutes. You will be required to visit the laboratory on three
occasions. The first sesstion will be a familiarisation trial with the electrical stimulation
techniques. This will be followed one week later by two visits, separated by 3-4 days.
It is important that exercise is not undertaken on the day of testing as this will affect
performance. Exercise should also be controlled the day preceding the trial.
The test protocol will involve:-
• 5 minutes warm-up on the cycle ergometer at 60 rpm
• PSEM
• 5 minute rest
• Fatigue test of 40 Hz/s with one second rest intervals
• PSEM
The PSEM test will cause some discomfort. If this is not tolerated, the experiment will
be terminated. There may be some muscle soreness the following day and thus tests
will be scheduled carefully.
SUBJECT DECLARATION
I············ understand the experimental protocol and have no
objection to partiCipating in the study. I also reserve the right to withdraw from
testing at any time.
SIGNED . DATE .
EXPERIMENTERS SIGNATURE .
SUBJECT INFORMED CONSENT FORM
Title: The Reliability of the hand dynamometer for measuring Strength and
Contractile Properties of the First Dorsal Interosseus Muscle (Index
Finger)
Researcher: Julie Greeves
The aim of this study is to determine the reliability of repeated measurements of
maximal strength and contractile properties of the first dorsal interosseus (FDI)
muscle. The FDI functions to move the index finger away from the middle finger. You
will be required to visit the laboratory on three occasions at 2 to 3 day intervals.
The following tests will be undertaken on each visit:-
• The hand will be immersed in hot water for 10 minutes to stabilise the temperature
of the finger
• Three maximal voluntary contractions with the index finger - (pushing as hard as
you can away from the middle finger)
• Five minute rest
• Electrical stimulation test, whereby the finger is stimulated at increasing frequencies.
Each frequency will last 2 seconds, with a 5 second rest interval.
• Five minute rest
• Three minute fatigue test. The muscle will be fatigued for 3 minutes with one
second interval impulses.
Each test session will last approximately 30-35 minutes. If the electrical stimulation is
not tolerated, the experiment will be terminated. All information will be confidential.
SUBJECt DECLARATION
I···············..••••••••••••••••••••••••••••••••.AM WILLING TO PARTICIPATE IN THIS STUDY,
HAVING READ AND UNDERSTOOD THE EXPERIMENTAL PROTOCOL. HOWEVER, I
RESERVE THE RIGHT TO WITHDRAW FRO~ TESTING AT ANY TIME WITHOUT
FURTHER EXPLANATION.
SIGNATURES:-
Subject: . Date: .
Experimenter: .
LIVERPOOL JOHN MOORES UNIVERSITY
INFORMED CONSENT FORM
Researcher: Julie Greeves
Title: The Effect of Hormone Replacement Therapy on Muscle Strength in
Postmenopausal Women
Experimental Protocol
The aim of this project is to determine whether a decline in the reproductive hormone
oestrogen associated with the menopause, causes a reduction in the strength of the quadriceps
(thigh) muscle. Differences in strength will be compared in two groups of postmenopausal
women: One group will be receiving hormone replacement therapy (HR T) and the other group
will be oestrogen deficient ie. not receiving, or have not received any form of HR T.
Initially, a questionnaire will be distributed to determine your present health, family medical
history and gynaecological details. Following this, you will be asked to attend the laboratories
at John Moores University, The Royal Liverpool University Hospital and The Liverpool
University, prior to HRT and once every three months over a 12 month period.
Body composition will be assessed at John Moores University. This will involve height and
weight, and skinfold measurements taken at four sites of the body ie. front and back of the arm,
above the hipbone and under the shoulder blade. Blood pressure, grip and leg strength and
venous blood samples will also be taken. Grip strength will be measured using a hand-held
device, and leg strength will be determined whilst performing a kicking action and contracting
against a non-movable resistance. To ensure you are working maximally (as hard as possible),
electrodes will be positioned on the involved muscle group. This will cause !1Q discomfort or
pain. Blood will be drawn from the antecubital vein (of the forearm) to determine hormonal
levels. For subjects receiving HRT, blood samples may possibly be taken at the gynaecology
clinic.
All information will be kept strictly confidential and your identity will not be revealed in any
way. If you would like a fitness test then this will be arranged.
SUBJECT DECLARATION
1 am willing to participate in the study having read and
understood the experimental protocol. I am aware of the length of time the experiment will
last and reserve the right to withdraw my consent at any lime,
SIGNATURES: SUBJECT. . DATE .
UNBIASED WITNESS .
EXPERIMENTER .
INFORMED CONSENT FORM
Researcher: Julie Greeves
Title: The effects of the menstrual cycle on strength and contractile
properties of a distal and proximal muscle group
Experimental protocol
1. Each stage of the menstrual cycle will be determined by monitoring oral
temperature. This will be taken on awakening each morning (± 2 hours) for two
complete cycles using a digital thermometer provided. Instructions will be given
separately. The data will be recorded on the sheet provided, and temperature readings
will be plotted on the attached temperature chart starting from day 1 of menses. A
questionnaire will also be completed prior to testing.
2. You will be required to attend the research laboratory at John Moores University for
8 visits. These include:
i] A familiarisation session with the electrical stimulation procedure and finger strength
technique.
ii]Once during menses (between day 1-5)
iii]Mid-follicular (day 12)
iv] Pre-ovulation (day 14)
v] Ovulation
vi] Post-ovulation
vii] Mid-luteal
vi] Late-luteal
On each visit you will be monitored as follows:-
Strength measurements
Index finger: Maximal strength of the index finger will be measured during a pushing
movement away from the middle finger. To ensure maximal effort is employed, the
muscle will be stimulated percutaneously using electrodes attached to the hand. This
will cause minimum discomfort.
Quadriceps: You will be secured in a chair with the leg suspended at 90°. The
quadriceps will be electrically stimulated during a maximal effort of pushing against a
non-movable resistance. The muscle group will then be stimulated whilst relaxed at
increasing frequencies (1, 10, 20, 50 and 100 Hz) for 2 seconds at each frequency.
You will be rested for 5 minutes and the procedure will be repeated 6 times in 30
minutes. This test will cause some discomfort and may affect results if a familiarisation
session is not performed.
All information will be confidential;
I ' agree to participate in this study having read and
understood the experimental protocol as described above. I do, however, reserve the
right to withdraw from testing at any time without further explanation.
SIGNED DATE .
mFORMEDCONSENTFORM
Title: The Effect of Oestrogen Changes on Strength and Contractile Properties of the
First Dorsal Interosseus Muscle (Index Finger)
Researcher: Julie Greeves (BSc Hons)
The aim of this study is to determine whether a decline in the reproductive hormone
oestrogen causes a change in strength and contractile properties of the first dorsal
interosseus (FDI) muscle. This muscle functions to move the index finger away from
the middle finger. Differences in performance will be monitored before, during and
after treatment. Maximal voluntary effort and electrical impulses of increasing
frequencies to the muscle (called programmed stimulation electromyogram (PSEM)),
will be perfonned.
The test protocol will involver-
i] Immersion of the hand and forearm in water for 10 minutes at 45° to stabilize
muscle temperature
ti] One Hz twitches (electrical impulses) delivered to the finger muscle via
electrodes to ensure correct stimulation of the muscle
iii] Maximal voluntary contraction superimposed with 1 Hz twitches
iv] A PSEM (increasing frequencies of electrical impulses of 1, 10, 20, 50, 100 Hz
and 1Hz for 2 seconds each)
v] Fatigue test offrequent stimulation for 3 minutes
vi] APSEM
A rest period of3 minutes will be given between each phase of testing. The PSEM test
will cause some discomfort. If this is not tolerated, the experiment will be terminated,
All information will remain confidential. The test will last approximately 20-30
minutes.
SUBJECT DECLARATION
I understand the experimental protocol and have no
objection to participating in this study. I also reserve the right to withdraw from
testing at any time.
SIGNATURES
SUBJECT .
DATE .
EXPERIMENTER .
UNBIASED
WITNESS .
SUBJECT INFORMED CONSENT FORM
TITLE: The effects of hormone replacement therapy on muscle function of the
first dorsal interosseus muscle (FDI) in post-menopausal women before
and during treatment. ~.
The aim of this study is to assess the effect of hormone replacement therapy on muscle
function of the index finger (first dorsal interosseus). You will be required to visit the
laboratory on 3 occasions over 4 months. The first visit will follow your appointment
at the menopause clinic. You will then be asked to attend the laboratory for two visits
four months later, following a routine visit to the menopause clinic. The following tests
will be undertaken on each visit:-
• The hand will be immersed in hot water for 10minutes to stabilise the temperature
of the finger
• Three maximal voluntary contractions with the index finger - (pushing as hard as
you can away from the middle finger)
• Five minute rest
• Electrical stimulation test, whereby the finger is stimulated at increasing frequencies.
Each frequency will last 2 seconds, with a 5 second rest interval.
• Five minute rest .
• Three minute fatigue test. The muscle will be fatigued for 3 minutes with one
second interval impulses.
• Skinfolds, estimating your percentage body fat, will also be assessed at four sites:-
the front and back of the arm, shoulder blade and hip bone.
Each test session will last approximately 30-35 minutes. If the electrical stimulation is
not tolerated, the experiment will be terminated. All information will be confidential.
SUBJECT DECLARATION
I AM WILLING TO PARTICIPATE IN THIS STUDY,
HAVING READ AND UNDERSTOOD THE EXPERIMENTAL PROTOCOL. HOWEVER, I
RESERVE THE RIGHT TO WITHDRAW FROM TESTING AT ANY TIME WITHOUT
, FURTHER EXPLANATION.
SIGNATURES:-
Subject: . Date: .
Experimenter: .
Unbiased witness: .
